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ABSTRACT
 Macrophages are cells of the innate immune system that exhibit a huge phenotypic and functional 
heterogeneity, what gives macrophages the ability to sense and respond accurately to the needs of their 
microenvironment. Thus, macrophage differentiation and functions are dependent on the integration 
of cues provided by their ontogeny, surrounding tissue, microbiota, metabolism and pathogens. In line 
with their functional plasticity, macrophages are able to both initiate and resolve inflammation. Besides, 
macrophages have essential roles in development, homeostasis and inflammation and, consequently, 
deregulation of macrophage functions leads to the onset and maintenance of numerous chronic 
inflammatory pathologies. Therefore, determination of the molecular basis of the macrophage functional 
heterogeneity should pave the way for the development of tissue-specific anti-inflammatory therapies.
 Macrophage activation relies on the recognition of pathogen- and danger-associated molecular 
patterns from exogenous and endogenous factors by a variety of receptors, like TLRs. Depending on the 
nature of previous cues received by macrophages, the response to activating stimuli may be pro- or anti-
inflammatory. The former is characteristic of macrophages exposed to GM-CSF or IFNγ  and results in 
the production of TNF-α, IL-12, IL-6 and IL-23. The latter is specific for macrophages exposed to M-CSF, 
IL-4 or glucocorticoids and leads to the secretion of IL-10. Unlike the macrophage pro-inflammatory 
response, which has been extensively studied, scarce knowledge is currently available on the activation 
of anti-inflammatory macrophages, especially in humans. To address this issue, we have thoroughly 
analyzed the transcriptome of TLR-activated, human M-CSF-polarized anti-inflammatory macrophages 
(M-MØ). Microarray analysis of M-MØ after a short exposure to LPS revealed the existence of a gene 
set that includes chemokines (e.g., CCL19), signaling molecules (e.g., SOCS2) and growth factors (e.g., 
BMP6, PDGFA), that is exclusively induced in M-MØ in vitro and whose expression is dependent on the 
activation of the MAPKs ERK, p38 and JNK. Representative examples of this gene set, including CCL19, 
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SOCS2, BMP6 and PDGFA, are co-expressed in humans in gut and skin-resident macrophages and 
tumor-associated macrophages in nevi and melanoma. Thus, we have identified a novel gene set whose 
expression is specific for human activated homeostatic/anti-inflammatory macrophages. This finding 
sheds light on the mechanisms underlying the regulatory and trophic functions of this macrophage 
subtype. 
 The differentiation and functional polarization of steady state tissue-resident macrophages is 
controlled by M-CSF, as well as by GM-CSF, RANKL, heme or retinoic acid, whose effects induce 
transcription factors like PPARγ, NFATc1, SPI-C or GATA6, which then shape the appropriate 
transcriptomic profile needed for macrophages to accommodate to the functional demands of each 
specific tissue. MAFB, a bZIP transcription factor that performs essential functions during development 
and control organ homeostasis in the adult, is an important factor in the control of monocyte/macrophage 
differentiation. However, this notion primarily relies on studies performed on avian cell lines and mice 
macrophages, whereas the MAFB contribution to the macrophage differentiation program in human is 
mostly unknown. Interestingly, MAFB is greatly expressed by human anti-inflammatory M-MØ, in contrast 
to its very low expression found in GM-CSF-polarized pro-inflammatory macrophages. Therefore, we 
have addressed the determination of the whole range of MAFB-dependent genes in human M-MØ. 
Microarray analysis of MAFB-knocked-down macrophages revealed that MAFB positively controls the 
acquisition of the homeostatic/anti-inflammatory profile of M-MØ (including genes like IL10, CCL2, 
CD163L1, HTR2B and CXCL12), and impairs the expression of pro-inflammatory factors (like CLEC5A). 
Importantly, MAFB-dependent genes are  co-expressed with MAFB in vivo in macrophages from the gut, 
dermis and melanoma samples. The control of the anti-inflammatory profile of human macrophages by 
MAFB is further supported by results obtained from macrophages derived from patients with Multicentric 
carpotarsal osteolysis (MCTO), a rare disease caused by heterozygous mutation in the MAFB gene. 
Our results indicate that MCTO MAFB mutations increase the MAFB protein stability, lead to an 
exacerbated anti-inflammatory macrophage phenotype, and impair the monocyte ability to differentiate 
in vitro into functional osteoclasts. Therefore, our results show, for the first time, that MAFB controls the 
differentiation and function of human anti-inflammatory macrophages. 
 In summary, this PhD thesis describes the acquisition and regulation of the transcriptional profile 
of human M-CSF-dependent macrophages in homeostatic, activating and pathological conditions. 
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RESUMEN
Los macrófagos son células del sistema inmune innato que exhiben una gran heterogeneidad fenotípica 
y funcional, lo que les confiere la capacidad de detectar y responder con precisión a las necesidades de 
su microambiente. La diferenciación y funciones de los macrófagos dependen de la integración de las 
señales proporcionadas por su ontogenia, el tejido donde se encuentren, la microbiota, el metabolismo 
y la potencial presencia de estímulos patógenicos. Los macrófagos juegan un papel esencial en 
desarrollo, homeostasis e inflamación y, por ello, la desregulación de funciones de los macrófagos lleva 
a la aparición y mantenimiento de numerosas patologías de base inflamatoria. En consecuencia, la 
determinación de la base molecular de la heterogeneidad funcional de macrófagos debería allanar el 
camino para el desarrollo de terapias anti-inflamatorias específicas de tejido.
 Los macrófagos son capaces de iniciar y resolver la inflamación. La activación de macrófagos 
se basa en el reconocimiento de patrones moleculares asociados a patógenos (PAMP) y de peligro 
(DAMP) que llevan a cabo receptores como los miembros de la familia de TLR,. Dependiendo de la 
ontogenia, el entorno y naturaleza de las señales previas recibidas por los macrófagos, la respuesta a 
un estímulo puede ser pro- o anti-inflamatoria. La primera es característica de macrófagos expuestos a 
GM-CSF o IFNγ  y resulta en la producción de TNF-α, IL-12, IL-6 e IL-23. La respuesta anti-inflamatoria, 
en cambio, es específica de macrófagos expuestos a M-CSF, IL-4 o glucocorticoides y conlleva la 
secreción de IL-10. La respuesta pro-inflamatoria de macrófagos ha sido ampliamente estudiada, en 
contraposición al escaso conocimiento disponible sobre la activación de macrófagos anti-inflamatorios, 
especialmente en humanos. Por este motivo hemos llevado a cabo la determinación del transcriptoma 
de macrófagos polarizados con M-CSF (M-MØ) y activados con ligandos de TLRs. Dicho análisis ha 
revelado la existencia de un conjunto de genes inducido por LPS exclusivamente en M-MØ, que incluye 
genes que codifian quimiocinas (CCL19), moléculas de señalización (SOCS2) y factores de crecimiento 
(BMP6, PDGFA), y cuya expressión es dependiente de la activación de las MAPKs ERK, p38 y JNK. 
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Además, CCL19, SOCS2, BMP6 y PDGFA se co-expresan  en macrófagos humanos residentes en 
intestino y piel y en macrófagos asociados a nevus y melanoma. La identificación de este nuevo conjunto 
de genes dependiente de activación que es exclusivo de macrófagos antiinflamatorios/homeostáticos 
humanos contribuye de manera significativa al conocimiento de los mecanismos que subyacen a las 
funciones regulatorias y tróficas de este subtipo de macrófagos.
 La diferenciación y polarización funcional de la mayoría de macrófagos de tejido en homeostasis 
depende de M-CSF, así como de GM-CSF, RANKL, el grupo hemo o el ácido retinoico. Estos factores 
conducen a la inducción de factores de transcripción (como PPARγ, NFATc1, SPI-C o GATA6) que 
regulan el perfil transcriptómico tejido-específico de macrófagos. MAFB es un factor de transcripción 
bZIP que realiza funciones esenciales durante el desarrollo y el control de la homeostasis de tejidos, y 
es crítico en el control de la diferenciación de monocitos/macrófagos. Sin embargo, este conocimiento 
deriva de estudios realizados sobre líneas celulares aviares y macrófagos de ratón. Por lo tanto, la 
contribución de MAFB en el programa de diferenciación de macrófagos en humanos es aún bastante 
limitada. MAFB se expresa en niveles muy elevados en macrófagos anti-inflamatorios humanos (M-
MØ), en contraste con su muy baja expresión en macrófagos pro-inflamatorios polarizados por GM-CSF. 
Por esta razón hemos abordado el estudio del rango de genes dependientes de MAFB en macrófagos 
anti-inflamatorios humanos. El análisis mediante microarrays de macrófagos humanos en los que se 
silenció la expression de MAFB reveló que MAFB controla la adquisición del perfil homeostático/anti-
inflamatorio de M-MØ (incluyendo genes como IL10, CCL2, CD163L1, HTR2B y CXCL12), e impide 
la expresión de genes asociados a la polarización pro-inflamatoria (CLEC5A). Por otra parte, los 
genes MAFB-dependientes son co-expresados con MAFB in vivo en macrófagos de intestino, dermis y 
melanoma. Por otra parte, la capacidad de MAFB de controlar el perfil anti-inflamatorio de macrófagos 
humanos se ha puesto también de manifiesto por los resultados obtenidos en macrófagos derivados 
de pacientes de Osteolisis carpotarsal multicéntrica (MCTO), enfermedad rara causada por mutaciones 
en el dominio de transactivación de MAFB. Nuestros resultados han puesto de manifesto que dichas 
mutaciones aumentan la estabilidad de MAFB, promueven la adquisición de un fenotipo antiinflamatorio 
exacerbado en los M-MØ de pacientes MCTO, y limitan la capacidad de monocitos de diferenciarse in 
vitro hacia osteoclastos funcionales. En conjunto, nuestros resultados demuestran por primera vez que 
MAFB controla la diferenciación y función de los macrófagos anti-inflamatorios humanos.
 De forma global, esta tesis doctoral describe la adquisición y la regulación del perfil transcripcional 
de macrófagos humanos dependientes de M-CSF en homeostasis, activación y condiciones patológicas.


Since Metchnikoff’s breakthrough in the late 19th century, macrophages have been 
traditionally known for their critical role in innate immunity as first line responders 
against pathogens and tissue damage. However, the idea of what a macrophage is 
has greatly widened, specially in light of the advances accomplished in recent years. 
Nowadays, macrophages are increasingly considered as essential regulators of 
vertebrate biology and, consequently, as key players in the aetiology and development 
of many pathologies. 
INTRODUCTION
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INTRODUCTION
 MACROPHAGE ONTOGENY
 In recent years, previously stablished paradigms about the origin and maintenance 
of tissue macrophages have been drastically amended. The ‘mononuclear phagocyte 
system’ was described in 1972 by van Furth et al., who stated that hematopoietic stem 
cell-derived peripheral blood monocytes continuously migrate into tissues where they 
become terminally differentiated macrophages without proliferation ability 1. However, 
it is now known that this is true for only a number of murine tissues under homeostasis, 
such as the intestine, dermis, heart, pancreas and peritoneum 2-5 6, whereas resident 
macrophages in other tissues have an embryonic origin. Microglia, brain-resident 
macrophages, are derived from yolk sac progenitors, whereas lung, kidney and liver 
macrophages derive from fetal liver monocytes. Otherwise, Langerhans cells, the 
epidermis macrophages, have a dual yolk sac and fetal liver origin 7-12. Moreover, these 
embryonic-derived macrophage populations are now known to self-maintain by local 
proliferation 9; 13-15, although whether this capacity is unique to a specific population or 
general for all tissue macrophages is still unclear.  In humans, host Langerhans cells 
are not replaced by donor cells in bone marrow transplant patients and monocytopenic 
individuals have a normal number of Langerhans cells 16-18. These observations 
reinforce the studies in mice indicating that there are indeed tissue-resident macrophage 
populations that are independent of replenishment by circulating monocytes. 
 This new paradigm, however, does not apply under inflammatory conditions. 
Massive recruitment of monocytes to tissues occurs upon tissue injury or infection, a 
process that takes place simultaneously with the proliferation of resident macrophages 
in cases like nematode infection 19; 20. Once inflammation has been contained, it is 
still unclear whether resident macrophages reestablish the total macrophage pool or 
the newly recruited cells take up residence by acquiring self-renewal capabilities and 
tissue-resident effector functions. Most likely, this will depend on the nature of the insult 
and the tissue where inflammation takes place 21-24.
MACROPHAGES IN INFLAMMATION
 Macrophages are myeloid cells of the innate immune system that are primarily 
considered as “homeostasis keepers” due to their ability to sense any perturbation and 
to respond with a smorgasbord of activities (from tissue-dependent tasks to general 
immune effector functions) 25-27. In fact, inflammation caused by either pathogens 
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or injury may be considered as an extreme disruption of homeostasis that calls 
macrophages into action to restore tissue integrity and functionality. 
 Macrophages continuously survey their surroundings to detect anomalies, 
such as foreing invaders or tissue damage, and respond accordingly by initiating 
inflammation and by eliminating the threat by phagocytosis and production of enzymes, 
anti-microbial peptides and reactive oxygen species (Figure 1A,B). Besides, as 
major cytokine and chemokine producers, macrophages orchestrate inflammation 
and regulate the recruitment of other leukocyte populations (Figure 1B). Moreover, 
macrophages participate in the adaptive immune response by presenting antigen via 
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Figure 1. Macrophage functions during inflammation. (A) Macrophages take up apoptotic cells, 
pathogens, immune complexes and debris by phagocytosis. (B) Production of reactive oxygen species 
(ROS), proinflammatory cytokines and chemokines by macrophages leads to the recruitment of 
other leukocytes to the inflammed site and contribute to T cell polarization. (C) Macrophages present 
antigen through MHCI and MHCII complexes to T and B lymphocytes to initiate an adaptive immune 
response. Expression of co-stimulatory molecules (CD40, CD80, CD86) on the macrophage surface is 
essential for correct lymphocyte activation. (D) The reparative phase of inflammation is orchestrated by 
macrophages via production of growth factors to promote fibroblast proliferation as well as remodelling 
and deposition of new extracellular matrix. (E) Production of anti-inflammatory cytokines and chemokynes 
by macrophages dampen inflammation and promotes tolerance to endogenous or commensal antigens. 
TNF-α (Tumor necrosis factor alpha), IL-12 (Interleukin-12), IL-1 (Interleukin-1), Th1 (T helper cell 1), 
Th17 (T helper cell 17), NK (Natural killer cell), PMN (Polymorphonuclear leukocyte), CD8 T (Cytotoxic 
CD8+ T cell), MHC (Major histocompatibility complex), Treg (T regulatory cell), IL-10 (Interleukin-10), 
M-CSF (Macrophage-colony stimulating factor).
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major histocompatibility complexes (MHCI and MCHII) to T and B lymphocytes, and by 
clearing pathogenic agents in the humoral response of B lymphocytes (Figure 1A,C). 
Finally, macrophages regulate the resolution of inflammation and wound healing 
processes by secreting anti-inflammatory mediators, remodelling of extracellular matrix 
and promoting angiogenesis (Figure 1D,E) 28-33. 
 In line with their critical role in tissue homeostasis, deregulation of the macrophage 
effector functions results in numerous pathologies, as best illustrated in the case 
of tumors. A combination of tissue-injury signals (i.e. hypoxia, extracellular matrix 
degradation products and apoptosis) and immune-thwarting instructions from tumour 
cells compell macrophages to restore homeostasis, what ends up favoring tumor 
growth 34-38. As an example, breast carcinoma cells promote macrophage recruitment 
and survival in a M-CSF-dependent manner whereas macrophages, in turn, favour 
angiogenesis and tumor growth by producing epidermal growth factor (EGF) 39; 40. 
Indeed, macrophage depletion results in reduced tumor growth and improved prognosis 
41-44. Other diseases where deregulated macrophage functions contribute to pathology 
are chronic inflammatory diseases and fibrosis. In the former, the inability to restrain 
inflammation by macrophages results in the prolonged production of inflammatory 
mediators and collateral tissue damage that causes pathologies like inflammatory 
bowel disease, rheumatoid arthritis, and neurologic disorders like Alzheimer disease 
45-47. Contrarily, fibrosis is the consequence of an exacerbated macrophage reparative 
response towards a prolonged insult 30. In fibrosis, a sustained inflammatory stimulus 
promotes excessive wound healing and extracellular matrix deposition by macrophages, 
thus disrupting normal tissue architecture and function 48. Therefore, understanding 
the mechanisms that control the immunogenic, immunoregulatory and wound healing 
functions of macrophages will allow for future therapies to develop. 
TISSUE-RESIDENT MACROPHAGES
 The most remarkable feature of macrophages is their impressive functional 
plasticity which reflects their ability to adapt to different environments. Irrespective of 
their origin, macrophages sense external cues (exogenous stimuli, prevailing cytokines 
and metabolites) and rearrange their epigenetic and transcriptional programs to 
acquire the effector functions required by the surrounding tissue. Therefore, migrating 
macrophage progenitors respond to different cues by differentiating into macrophages 
with distinct functional polarization and tissue-specific phenotypes (Table I) 25; 49; 50. 
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 M-CSF and IL-34 are essential for the differentiation of tissue-resident 
macrophages 51. Both cytokines signal through CSF1R, which is highly expressed 
by all macrophages, but exhibit distinct expression patterns. M-CSF is ubiquituously 
expressed by fibroblasts, osteoblasts, macrophages, endothelial and smooth muscle 
cells, among others, and is found in plasma at 10 ng/ml 51. IL-34 expression is restricted 
to the brain and the epidermis, where it is produced by neurons and keratinocytes 51. 
Thus, IL-34 is responsible for microglia and Langerhans cell differentiation, whereas 
M-CSF dependency is widespread for most macrophage populations 51-54. The latter 
is evidenced by the fact that a mice strain with a null mutation in the M-CSF-coding 
gene (Csf1op/op) has a broad reduction in tissue-resident macrophage numbers 54. In 
the presence of M-CSF, monocytes differentiate in vitro into macrophages with potent 
tissue repair and pro-angiogenic functions, and with a strong IL-10-producing ability 
upon stimulation by Toll-like receptor (TLR) ligands 55-58. Together with RANKL, M-CSF 
also promotes the generation of highly specialised bone-resident macrophages or 
osteoclasts. Specifically, osteoblast-derived  RANKL and M-CSF upregulate NFATc1, 
MITF, FOS and NF-κB, all of which activate the transcriptional program needed for 
cell fusion and generation of multi-nucleated mature osteoclasts 59; 60. GM-CSF is 
abundantly produced during inflammation and has a key role in the development and 
maintenance of alveolar macrophages 51; 61. When migrating into the lung, fetal liver 
precursors are exposed to GM-CSF, what leads to induction of PPARγ expression and 
drives alveolar macrophage differentiation 62. Unlike M-CSF, GM-CSF directs the in vitro 
differentiation of monocytes towards macrophages with robust antigen-presenting and 
immunogenic activity, and with preferential production of pro-inflammatory cytokines 
upon TLR stimulation 55-58. 
 Tissue resident macrophage differentiation is not only dependent on cytokines 
produced by neighbouring cells. Factors derived from microbiota’s or tissue’s metabolism 
are as well detected by macrophages and determine their functional specialisation. 
Metabolites such as retinoid acid, heme and oxysterols have been found to be essential, 
together with M-CSF, for the differentiation of peritoneal, splenic red pulp and splenic 
marginal zone macrophages, respectively 63-65. In each case, metabolites are sensed 
by macrophages and the appropriate differentiation program is triggered by induction 
of GATA6 in the peritoneum, SPI-C in the red pulp and LXRα in the marginal zone.
 The extreme functional plasticity of macrophages allow them to exert tissue-
specific activities required for maintenance of homeostasis and the functionality of 
the distinct tissues and organs. In the case of the gut, intestinal muscularis mucosa 
macrophages regulate local tissue and systemic homeostasis through a particular 
interaction with enteric neurons. By a still unknown microbiota-dependent mechanism, 
muscularis mucosa macrophages secrete BMP2, which is bound by enteric neurons 
that secrete M-CSF in return for macrophage survival 66. Interruption of this loop leads to 
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Table I
Macrophage
subset 
Specific 
transcription 
factors
Homeostatic function Pathology
Microglia SMADs? SALL1?MEF2C? IRF8
Synaptic pruning,
learning-dependent 
synapse formation
Neurodegeneration
Alveolar
macrophage PPARγ, BACH2 Surfactant clearance
Pulmonary alveolar 
proteinosis
Cardiac
macrophage ND
Phagocytose dying 
cardiomyocytes
Ischaemic heart
disease
Kupffer cell LXRα? SPIC?
Erythrocyte clearance, 
bilirubin metabolism,
particulate antigen clearance
 from portal circulation
Fibrosis
Red pulp 
macrophage SPIC
Iron recycling, 
erythrocyte clearance Iron overload
Intestinal 
muscularis
macrophage
ND Peristalsis Postoperative ileus
Osteoclast NFATC1, FOS, MITF Bone resorption Osteoporosis, osteopetrosis
Marginal zone
macrophage LXRα
Marginal zone
B cell maintenance Autoimmune disease
Lamina propria
macrophages RUNX3? Gut tolerance
Inflammatory
bowel disease
Bone marrow
macrophage  SPIC, LXRα
Regulation of HSC niche,
erythroblast development,
removal of aged neutrophils
Leukemia
Adapted from Wynn et al, Nature 2013 and Lavin et al, Nat Rev 2015
Table I. Tissue-resident macrophage functions, transcription factors and related pathologies.
abnormal intestinal smooth muscle cell contractions and to defective colonic peristalsis 
and altered transit time. In the spleen, red pulp macrophages are continuously exposed 
to senescent erythrocytes and are specialised in phagocytosing and recycling heme. 
In this context, an improper regulation of macrophage differentiation and function leads 
to splenic iron overload 67. Adipose tissue macrophages are key in regulating insulin 
sensitivity of adipocytes through IL-10 secretion and, thus, regulate physiological 
homeostasis upon nutrient intake. In obesity, metabolically stressed adipocytes 
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secrete inflammatory cytokines that increase macrophage recruitment and build up 
inflammation 68. In the lungs, alveolar macrophages are specialised in pulmonary 
surfactant recycling and an imbalance in this process leads to pulmonary alveolar 
proteinosis 61; 69. Osteoclasts, multinucleated macrophages of the bone, resorb bone 
in a finely tuned equilibrium with bone-forming osteoblasts to maintain bone integrity 
and calcium levels in the organism 70. Failure in osteoclast formation, as seen in the 
osteoclast-deficient Csf1op/op mice strain, leads to aberrant bone architecture, with 
bones lacking the necessary cavities for bone marrow hematopoiesis 71. 
MACROPHAGE ACTIVATION
 Another aspect of macrophage functional specialisation and polarization becomes 
evident upon macrophage encounter with endogenous or exogenous pathogenic insults. 
The features of the macrophage reaction towards the stimulus is critically dependent on 
the surrounding environment at the moment of the insult and on previous instructions 
received during the macrophage’s lifetime 28; 49; 72; 73. Therefore, macrophage activation 
relies on the integration of signals derived from their ontogeny, differentiating factors, 
cytokines, metabolites and ligands for pathogen-/danger-associated molecular patterns 
(PAMPs/DAMPs) (Figure 2). As a consequence, macrophages can acquire an almost 
infinite number of activation (polarization) states, what has led to the hypothesis of 
the “spectrum model” of macrophage activation 28; 74. In this context, macrophages are 
classified according to the factors which they have been primed with and to the type 
of response they carry out upon a pathogenic challenge 75. For the sake of simplicity, 
this classification may be divided in two big groups according to the macrophage’s 
response to the pathogenic insult. Thus, macrophages can either be pro-inflammatory 
or anti-inflammatory. The former secrete TNF-α, IL-12, IL-6 and IL-23 upon activation 
with PAMPs and DAMPs and exhibit high antigen-presenting capabilities, whereas 
the latter produce IL-10 and are highly phagocytic and profibrotic. Macrophages can 
be further classified according to the differentiating and/or activating cytokines and 
factors. So, macrophages exposed to IFNγ or GM-CSF become proinflammatory, 
whereas macrophages treated with IL-10, IL-4, IL-13, glucocorticoids or M-CSF 
preferentially display anti-inflammatory functions 76. Needles to say, these in vitro 
derived macrophage populations reflect only discrete aspects of in vivo macrophages. 
Nevertheless, in vitro-polarized macrophages have proven very useful in the study of 
macrophage biology since many of their specific responses and behaviours have been 
confirmed in vivo 77. Macrophages in the synovium of rheumatoid arthritis patients are 
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typically proinflammatory and transcriptionally similar to in vitro GM-CSF-differentiated 
monocyte-derived macrophages (GM-MØ) 78, whereas lamina propria macrophages 
that sample microbiota antigens in the intestinal lumen are anti-inflammatory and 
resemble IL-10-producing M-CSF-dependent monocyte-derived macrophages (M-
MØ) 79; 80. Tumor-associated macrophages tend to exhibit an ambivalent pro- and anti-
inflammatory phenotype 81, probably due to the concomitant stimulation by tumor cell-
derived immunosuppressive signals and by stimuli from dying cells and hypoxia. 
 Nowadays, however, the vast majority of the current knowledge on macrophage 
activation derives from studies performed on mice. Even though mouse disease models 
have greatly increased our understanding of the molecular basis of many pathologies, 
the existence of relevant differences between the mouse and human immune systems 
calls for more intense study of human macrophage biology 74; 82-86. 
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Figure 2. Multidimensional model of 
macrophage activation. A multidimensional 
model is depicted whereby macrophage 
activation is the result of the integration of the 
information provided by the microenvironment 
(tissue-specific signals and stress signals) and 
the macrophage ontogeny (developmental 
origin). Brain, kidney, liver and lung tissue-
resident macrophages have an embryonic 
origin, whereas macrophages in the intestine, 
peritoneum and heart are continuously 
replenished by monocytes. Macrophage 
progenitors in each tissue receive specific 
instructions from different tissue factors. 
Pathologies or injuries lead to the production of 
stress signals that, in a localization- and kinetic-
dependent manner, are integrated together 
with previous developmental instructions 
and differentially affect the outcome of the 
macrophage response. Adapted from Ginhoux 
et al, Nat. Imm. 2016. 
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 Toll-like receptors
 Macrophages are equipped with a collection of pattern recognition receptors 
(PRRs) that allows them to detect pathogen-associated molecular patterns (PAMPs), 
such as microbial products, and danger-associated molecular patterns (DAMPs) 
produced or released from endogenous injured cells and tissues. Among PRRs, Toll-
like receptors (TLRs) are the best characterised. TLRs are type I single spanning 
transmembrane proteins that are characterised by a PAMP/DAMP-recognizing 
Leucine-rich repeat (LRR) domain, a transmembrane helix and a cytoplasmic TLR-
IL1R (TIR) domain. So far, 10 TLRs have been identified in humans and they are 
classified in two groups according to their cellular location. Plasma membrane TLRs 
(TLR1, TLR2, TLR4, TLR5, TLR6, TLR10) recognise lipids, lipoproteins and proteins, 
while intracellular TLRs (TLR3, TLR7, TLR8 and TLR9) recognise nucleic acids (Table 
II) 87-89. Upon ligand recognition, TLRs dimerise and several adaptor proteins bind 
to their TIR domains. The most well characterised adaptor proteins include MYD88 
(myeloid differentiation factor 88) and TRIF (TIR domain-containing adaptor inducing 
interferon beta), but MAL, TRAM and SARM also mediate TLR signalling 90. Generally, 
ligand recognition by TLRs in macrophages leads to MYD88-dependent production of 
proinflammatory cytokines and TRIF-dependent expression of type I IFNs (Figure 3). 
Table II
PAMP
TLR1/2/6
Lipoproteins 
(Gram+)
TLR5
Flagellin 
(bacteria)
TLR10
ND
DAMP
TLR3
dsRNA 
(virus)
mRNA
TLR7/8
ssRNA 
(virus)
ssRNA
TLR9
DNA
(bacteria,
virus, fungus,
protozoa)
mitochondrial
DNA
TLR2
LTA (Gram+)
β-Glycan 
(fungus)
GPI anchors
(protozoa)
HMGB1
Fibronectin
Hyaluran
Serum  
Amyloid A
TLR4
LPS 
(Gram-) 
GPI anchors
(protozoa)
HMGB1
Fibrinogen
Hyaluran
Serum  
Amyloid A
oxLDL,
saturated 
fatty acids
S100 proteins
Adapted from Bryan et al, Critic Rev Biochem Mol Biol 2015
Table II. Exogenous and endogenous TLR ligands. 
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All TLRs can signal through MYD88- and TRIF-dependent pathways, except TLR3, 
which only signals through TRIF 90. 
 TLR4 signaling is initiated by binding of its co-receptor MD2 to lipopolysaccharide 
(LPS), its prototypical ligand that constitutes an important component of the 
Gram-negative bacterial cell wall (Figure 3). Then, the TLR4-MD2-LPS complex 
homodimerises and, during early signalling, MAL-MYD88 is recruited to the TLR4 TIR 
domains. MYD88 binds IRAK4, which sequentially phosphorylates IRAK1 and IRAK2. 
The MYD88-IRAK complex engages the ubiquitin ligase TRAF6 to make polyubiquitin 
chains that activate the TAK1 kinase. TAK1 activation triggers both the dissociation of 
the NF-κB inhibitor complex, leading to the release of NF-κB and its translocation to 
the nucleus, and also the activation of ERK, p38 and JNK mitogen-activated protein 
kinases (MAPKs) 91; 92. TLR4 is later endocytosed and then signals through recruitment 
of the TRAM-TRIF complex, which triggers NF-κB activation and IRF3 phosphorylation 
91; 92.
 Macrophage activation by TLR4 ligands triggers a potent transcriptional 
response that depends on NF-κB, IRF3, CREB, CEBP-α and AP1 transcription factor 
activation. The ‘classical’ TLR4-mediated macrophage activation, which can be seen 
in macrophages generated under the influence of GM-CSF (GM-MØ), is characterised 
by the release of proinflammatory cytokines and type I interferons and is dependent on 
NF-κB, MAPK and IRF3. Conversely, LPS-TLR4 activation of macrophages generated 
under the influence of M-CSF (M-MØ), primarily leads to the release of IL-10 and is 
dependent on ERK and p38 signalling 87; 93; 94. A myriad of studies have thoroughly 
assessed the molecular mechanisms and transcriptome behind the pro-inflammatory 
activation of murine macrophages 28; 75; 87; 95. However, the molecular basis for the anti-
inflammatory activation of macrophages has been much less studied, especially in the 
case of human macrophages.
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Figure 3. TLR signaling pathways. MYD88-dependent TLR signaling leads to activation of TRAF6, 
which activates the MAPK and NFκB pathways that lead to the expression of proinflammatory 
cytokine and chemokine genes. Signaling from TLR3 and endocytosed TLR4 activates IRF-dependent 
transcription of type-I-IFNs via the TRAM/TRIF pathway. Adapted from Ullah et al, Journal of Leukocyte 
Biology 2016.
33
INTRODUCTION
MAFB
 Structural features and expression
 MAFB is a transcription factor that belongs to the MAF family, which is made up 
of 7 members, namely MAFA, MAFB, MAF and NRL (large MAFs) and MAFG, MAFF 
and MAFK (small MAFs) (Figure 4) 96. The MAF family is part of the AP1 superfamily 
of transcription factors that contain basic and leucine zipper (bZIP) domains for 
DNA-binding and dimerisation 96. AP1 members recognise TRE (12-O-tetradecanoyl 
phorbol 13-acetate (TPA)-responsive element) or CRE (cAMP-responsive element) 
DNA palindromic sequences. MAF members, however, contain an extended homology 
region that also contacts DNA and allows them to recognise TRE or CRE sequences 
flanked by a TGC motif, the so-called MARE (Maf-recognition element) sequences 
(Figure 4A) 96. Interestingly, many MAF family target genes only contain half a MARE 
in their promoters, which highlights the ability of the MAF proteins to heterodimerize 
with other AP1 family members. Particularly, MAFB can heterodimerize with MAF, JUN 
and FOS to induce transcription 96-98, whereas it associates to other transcription factors 
to inhibit their function, i.e. MYB, MITF and NFATc1 98; 99. 
 MAFB expression is regulated by retinoic acid and TNF-α in the monocytic cell 
line THP-1 100, VEGF-C in lymphatic endothelial cells 101, IL-10 and STAT3 signalling in 
macrophages and the vitamin D3/Hox-A10 pathway in CD34+ hematopoietic progenitors 
102; 103. MAFB is also regulated at the post-transcriptional level by phosphorylation and 
sumoylation (Figure 4B). All members of the large MAF family share similar regulatory 
mechanisms via phosphorylation by p38, JNK and GSK3. Like in MAF and MAFA, four 
residues of the MAFB transactivation domain (S66, T62, T58 and S54) are targets for 
GSK3 phosphorylation after a priming phosphorylation at S70 96; 104; 105. In an apparent 
contradiction, GSK3 phosphorylation of MAFs increases both transactivation activity 
and ubiquitylation and subsequent degradation 104; 105. MAFB can also be phosphorylated 
by JNK and p38 at T62 106 and other unspecified residues 107. Phosphorylation by JNK 
also regulates MAFB stability and ubiquitinilation, while sumoylation at K32 and K297 
inhibits MAFB transactivation activity 98. 
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 MAFB functions
 The functions of MAFB range from regulation of organ development and patterning 
during embryogenesis to control of terminal differentiation and function of adult cell 
lineages (Figure 4C). MAFB is required for proper segmentation of rhombomeres 5 and 
6 of the mouse hindbrain and regulates other factors involved in hindbrain patterning 
108. Development of pancreatic α and β cell, as well as glucagon production in the adult 
pancreas, is regulated by MAFB 109; 110. During lymphangiogenesis, a process regulated 
by VEGF-C/VEGFR-3, MAFB is activated by VEGFR-3-initiated signalling and induces 
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Figure 4. MAF family members. (A) The 
AP1 sup rfamily has different DNA recognition 
sequences: TRE (12-O- tetradecanoyl phorbol 
13-acetate (TPA)-responsive element), CRE (cAMP-
responsive element) and MAREs (MAF recognition 
elements). MAF proteins can bind to a T-MARE 
(containing a TRE core), a C-MARE (containing a 
CRE core), a degenerated MARE or a half MARE 
flanked by AT-rich sequences. (B) Representation 
of the structures and residues affected by post-
transcriptional modifications in the human MAF family 
proteins. MAF proteins are phosphorylated by JNK, 
p38 and GSK3 at conserved sites. Sumoylation of 
lysines is another mean of regulation of MAF activity. 
Small MAF proteins are devoid of a transactivation 
domain. Acetylation on indicated residues of MAFG 
has been reported. (C) Illustration of the involvement 
of MAFB in the development of the hindbrain, 
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(left) and in the regulation of differentiation of cells 
of the hematopoietic cells (right). MAFB inhibits the 
differentiation of erythrocytes, promoting monocyte 
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adapted from Eychène et al, Nat Rev 2008. 
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lymphatic endothelial cell-specific transcription factors and markers 101. Moreover, 
MAFB has a role in skin cell differentiation 111, and contributes to chondrocyte matrix 
formation and development through CTGF gene expression control 112 and to podocyte 
generation 113-116.  
 In hematopoietic and immune cells, MAFB shapes responses to viral infections 
through regulation of type I interferon by recruitment of coactivators to IRF3 117. 
However, MAFB is best known for its role in the myeloid lineage (Figure 4C), where 
it induces monocytic differentiation in avian myeloblasts in vitro and represses 
avian erythroid cell differentiation by direct binding to Ets1 118; 119. This observations 
are supported by experiments in primary human hematopoietic progenitors, where 
ectopic expression of MAFB skews differentiation towards the monocytic lineage 120. 
Moreover, an antagonistic equilibrium between Myb and Mafb controls proliferation 
of avian progenitors versus macrophage commitment 98, whereas Mafb ablation in 
murine hematopoietic stem cells leads to enhanced myeloid commitment 121. Besides, 
PU.1 inhibits Mafb in avian myeloblasts to promote dendritic cell at the expense of 
macrophage differentiation 122, while in murine bone marrow-derived cells Mafb binds 
to Fos, Mitf and NFATc1 to inhibit osteoclast differentiation 99. 
 Regarding adult tissue-resident macrophages, the study of the role of Mafb has 
been impaired due to the fact that Mafb-/- mice die twenty-four hours after birth 123. 
Nevertheless, irradiated mice that are reconstituted with fetal liver Mafb-/- hematopoietic 
progenitors do not show deffects in monocyte numbers in blood nor macrophage 
populations in spleen and peritoneum, while in vitro-derived Mafb-/- have an altered 
actin organization 124. This mild phenotype of Mafb-/- macrophages was attributed to 
redundant functions of Mafb and c-Maf, being the latter upregulated after Mafb ablation 
124. However, double deletion of c-Maf and Mafb provides murine macrophages with 
self-renewal ability and adoptively-transferred double knockout monocytes are able 
to contribute long-term to the spleen, liver and peritoneum macrophage pool 125. 
Adult mouse tissue resident macrophage-specific enhancers are enriched in MARE 
sequences and have high expression of Mafb and c-Maf RNA as compared to monocytes 
and neutrophils 21. Altogether, a role for Mafb has been established in the differentiation 
of the monocyte/macrophage lineage in animal models, yet the exact nature of the 
implication of MAFB for human macrophage function remains to be addressed.
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 MAFB-related pathologies
 The deregulated expression/function of MAFB affects cell, tissue and organ 
functions, giving rise to human pathologies. MAFB loss of function mutations have 
been described to cause Duane retraction syndrome, a congenital eye-movement 
disorder caused by defects in abducens nerve development 126. MAFB overexpression 
is a common feature in multiple myeloma 127 and is linked to Dupuytren’s disease 128, 
a fibroblastic proliferation of the palmar fascia. Besides, analysis of animal models 
of disease has revealed that MafB promotes atherosclerosis by inhibiting foam-cell 
apoptosis 129 and that MafB mutations cause kidney-associated diseases that result 
from altered podocyte differentiation 130. Moreover, MafB is upregulated in alveolar 
macrophages in pulmonary emphysema 131 as well as in human adipocytes during 
adipogenesis with adverse metabolic features 132. Finally, MafB knockout mice have 
an aberrant development of the respiratory center of the brain that causes fatal apnea 
immediately after birth 123.
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Figure 5. Multicentric carpotarsal osteolysis. Pictures and radiographs of hands and feet of MCTO 
patients (A) and a control individual (B). Yellow arrow marks the missing carpal (left panel) and tarsal 
(right panel) bones. (C) Reported MAFB mutations causing MCTO. 
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 Multicentric carpotarsal osteolysis (MCTO)
 MCTO is a rare autosomal dominant skeletal disorder (OMIM #166300) that is 
characterized by the gradual disappearance of the carpal and tarsal bones (Figure 
5A,B) causing joint deformities and pain as the syndrome progresses during the first 
decades of life 133-135. Thieffry and Sorrel-Dejerine first reported a complete description 
of multicentric carpotarsal osteolysis (MCTO) in 1958. Since then, only around 70 cases 
have been reported worldwide 134-136, probably due in part to common misdiagnoses as 
juvenile idiopathic arthritis. Some affected individuals may present minor craniofacial 
abnormalities, such as triangular faces, micrognathia and exophthalmos, as well 
as corneal opacity 133-135; 137. Moreover, many patients develop nephropathy, which 
is usually diagnosed at terminal renal insufficiency. The mechanisms underlying 
the onset of nephropathy in MCTO are still unknown, although focal and segmental 
glomerulosclerosis have been diagnosed on rare early stage biopsies 134. Recently, 
heterozygous missense mutations within a very short region (aminoacids 54-71, see 
Figure 4B) of the transactivation domain in MAFB have been reported to cause MCTO 
(Figure 5C) 133. Both familial transmission and simplex cases have been detected, and 
MCTO is believed to be an autosomal dominant disorder. 
 In spite of its wide pathological relevance, the association of MAFB to specific 
macrophage polarization states and the identity of MAFB-regulated genes and functions 
in human macrophages are mostly unknown. 
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1.  To determine the molecular basis for the differential cytokine responsiveness  
 of LPS-activated GM-CSF (GM-MØ) and M-CSF-primed (M-MØ) human   
 macrophages:
 
 1.1.  To identify the signalling pathways differentially triggered by TLR   
  activation in GM-MØ and M-MØ.
 1.2. To define the transcriptomes of GM-MØ and M-MØ upon TLR4    
  activation with LPS.
 1.3. To identify genes co-expressed with IL-10 in anti-inflammatory human   
  macrophages in vitro and in vivo.
2. To determine the role of MAFB in macrophage polarization:
 2.1. To assess the expression of MAFB in M-MØ in vitro and in vivo.
 2.2. To determine the genes and effector functions that are controlled by   
  MAFB in M-MØ.
 2.3. To study the transcriptional and functional consequences of Multicentric  
  carpotarsal osteolysis (MCTO)-causing MAFB mutations.
OBJECTIVES

CHAPTER ONE
RESULTS
A novel set of genes that define the activation 
state of human anti-inflammatory macrophages
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Differential cytokine LPS responsiveness of GM-MØ and M-MØ. 
 GM-CSF and M-CSF contribute to monocyte/macrophage cell survival 
and proliferation, and promote monocyte differentiation into functionally different 
macrophages 56; 138. GM-CSF gives rise to macrophages (hereafter termed GM-MØ) 
that produce pro-inflammatory cytokines upon TLR stimulation, whereas M-CSF 
generates macrophages (M-MØ) with robust IL-10-producing ability in response to 
pathogenic stimuli 56; 57; 95. Accordingly, human GM-MØ and M-MØ are considered as 
pro-inflammatory and anti-inflammatory macrophages. LPS treatment, either alone or 
in combination with IFNγ, is considered as the paradigmatic stimulus for acquisition 
of the classical macrophage polarization/activation state 75. However, this definition 
does not take into account the influence that other macrophage differentiating/priming 
factors might have on the LPS response. To identify the molecular basis for the 
distinct LPS-induced cytokine profiles of GM-MØ and M-MØ we first determined their 
respective kinetics of LPS responsiveness at the cytokine mRNA and protein levels. 
Significantly elevated levels of IL12B, IL6 and IFNB1 mRNA were detected in GM-
MØ after 3-5 hours of LPS exposure, a time at which IL10 mRNA was significantly 
elevated in M-MØ (Figure 6A & Figure 7A). These changes preceded the significantly 
distinct LPS-induced cytokine profiles of both macrophage subsets: higher levels of 
IL-12p40 (after 12 hours), IL-6 and IFN-β (after 3 hours) in GM-MØ and higher levels 
of IL-10 in M-MØ (after 5 hours) (Figure 6B, Figure 7B). The distinct cytokine pattern 
of LPS-activated GM-MØ and M-MØ was also seen when both macrophage subtypes 
were stimulated by the TLR2 ligand PAM3CSK4 (Figure 6C, Figure 7C). Interestingly, 
although LPS-induced TNF mRNA levels were similar in both macrophage subtypes 
(Figure 6A, Figure 7A), high production was exclusively seen in GM-MØ at 12-24 
hours after LPS treatment (Figure 6B, Figure 7B). The lack of TNF-α production in 
M-MØ, confirmed by flow cytometry and Western blot, was not secondary to IL-10 
production, thus indicating that non-transcriptional mechanisms are responsible for the 
differential LPS-induced production expression of TNF-α by GM-MØ and M-MØ (data 
not shown).
 Next, we determined at which stage during differentiation each macrophage 
subtype acquires their specific LPS-induced cytokine profile. In GM-MØ, the 
characteristic high LPS-induced TNF-α production was seen as early as 24 hours along 
the GM-CSF-driven differentiation, whereas high LPS-stimulated IL-10 production 
was detected 48 hours after monocyte exposure to M-CSF (Figure 6D, Figure 7D). 
Therefore, differentiating monocytes acquire the characteristic LPS-induced cytokine 
profile of GM-MØ (TNF-αhigh IL-10low) and M-MØ (TNF-αlow IL-10high) at early stages along 
the monocyte-to-macrophage differentiation promoted by either GM-CSF or M-CSF 
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Figure 6. Differential cytokine profile of activated M-MØ and GM-MØ. (A,B) Kinetics of LPS-induced 
cytokine mRNA (A) and protein (B) expression of M-MØ and GM-MØ. Results are expressed relative 
to the maximal level of cytokine mRNA (A) or protein (B) in GM-MØ (TNF-α, IL-12p40, IL-6, IFN-β) or 
M-MØ (IL-10). Shown are the means and SD of three independent expreriments (n=3; *, p < 0.05; **, 
p < 0.005; ***, p < 0.0005). (C) PAM3CSK4 (PAM)-induced cytokine production of M-MØ and GM-MØ. 
Results are expressed relative to the maximal level of cytokine production in GM-MØ (TNF-α, IL-6) 
or M-MØ (IL-10). Shown are the means and SD of six independent experiments (n=6; *, p < 0.05; **, 
p < 0.005; ***, p < 0.0005). (D) LPS-induced cytokine production along the monocyte-to-macrophage 
differentiation of M-MØ and GM-MØ. Six experiments were done on independent monocyte samples 
and one of them is shown. 
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Figure 7. Differential cytokine profile of activated M-MØ and GM-MØ. (A,B) Kinetics of LPS-induced 
cytokine mRNA (A) and protein (B) expression of M-MØ and GM-MØ. Results indicate the relative 
levels of the indicated mRNA (relative to TBP mRNA levels) (A), and the concentration of the indicated 
cytokines (B). Shown are the means and SD of three independent experiments (n=3; *, p < 0.05; **, p < 
0.005; ***, p < 0.0005). (C) PAM3CSK4-induced cytokine production of M-MØ and GM-MØ. Shown are 
the means and SD of six independent experiments (n=6; *, p < 0.05; **, p < 0.005; ***, p < 0.0005). (D) 
LPS-induced cytokine production along the monocyte-to-macrophage differentiation of M-MØ and GM-
MØ. Shown are the means and SD of six independent experiments (n=6; *, p < 0.05). 
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Figure 8. The differential cytokine profile of activated M-MØ and GM-MØ is cell-intrinsic. (A) 
LPS-induced expression of cytokine mRNA in cells kept in their conditioned media (M-MØ, GM-MØ) 
or whose culture medium was switched (M-MØ>GM-MØ, GM-MØ>GM-MØ) immediately before LPS 
stimulation. Cytokines were determined 3-24 hours after LPS exposure. Results are expressed relative 
to the maximal level of cytokine mRNA in GM-MØ (TNF, IL-12B, IL6, IFN-β) or M-MØ (IL10). Shown are 
the means and SD of four independent experiments (n=4; *, p < 0.05; **, p < 0.005; ***, p < 0.0005). (B) 
LPS-induced IL-10 production in cells kept in their conditioned media (M-MØ, GM-MØ) or whose culture 
medium was switched (M-MØ>GM-MØ, GM-MØ>GM-MØ) immediately before LPS stimulation. Shown 
are the means and SD of four independent experiments (n=4).
(Figure 6D). In contrast, the preferential LPS-stimulated production of IL-12p40 in 
GM-CSF-differentiated macrophages was not acquired until later time points (4 days) 
(Figure 6D, Figure 7D). The delayed acquisition of the IL-12 p40 production ability by 
GM-MØ led us to assess whether autocrine factors contributed to the establishment 
of the LPS-induced cytokine profile of each macrophage subtype. To that end, GM-
MØ and M-MØ were treated with LPS after exchange of their respective conditioned 
media. GM-MØ kept in the presence of M-MØ-conditioned medium also displayed 
a preferential expression of TNF, IL12B, IL6 and IFNB1 mRNA after LPS exposure 
(Figure 8A). Similarly, M-MØ exhibited the preferential expression of LPS-induced 
IL-10 mRNA and protein regardless of whether LPS stimulation took place in their 
own culture medium or in GM-MØ-conditioned medium (Figure 8A,B).  Therefore, 
the ability of GM-MØ and M-MØ to preferentially produce pro-inflammatory (GM-MØ) 
or anti-inflammatory (M-MØ) cytokines in response to activating stimuli is cell-intrinsic 
and is not significantly modulated by the extracellular milieu or by autocrine factors 
accumulated along the differentiation process. 
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Figure 9. Differential LPS-triggered intracellular signaling in M-MØ and GM-MØ. M-MØ and GM-MØ 
were treated with LPS (A-D,F,G) or PAM3CSK4 (E), and cell lysates were obtained at the indicated time 
points and assayed for the expression of IkBα (A), phosphorylated and total STAT1 (B), phosphorylated 
IRF3 (C), phosphorylated and total ERK1/2, p38MAPK and JNK (D,E), phosphorylated and total STAT3 
(F), and phosphorylated CREB (G) by Western blot using specific antibodies. Where indicated, protein 
loading was normalized using a monoclonal antibody against GAPDH or α-tubulin.
Differential LPS-initiated intracellular signaling pathways in GM-MØ and M-MØ.
 The fact that the LPS-induced cytokine profile of GM-MØ and M-MØ was cell-
intrinsic prompted us to evaluate LPS-initiated intracellular signals 139; 140 in both 
macrophage subsets. LPS activated the NF-κB pathway to a similar extent in both 
GM-MØ and M-MØ, as evidenced by the loss of IκBα at early time points after LPS 
treatment (Figure 9A). Similarly, STAT1 became activated to the same extent in both 
subtypes by LPS (Figure 9B). However, IRF3 phosphorylation, which lies below the 
TRAM/TRIF branch of LPS signaling 139; 140 (see Figure 3), was higher in the case 
of GM-MØ (Figure 9C, Figure 10A,B), a result in agreement with their higher LPS-
induced production of IFN-β. Conversely, the LPS-induced phosphorylation of ERK, 
JNK and p38 was significantly higher in LPS-treated M-MØ (Figure 9D, Figure 10C), 
and a similar finding was observed after stimulation with the TLR2 ligand PAM3CSK4 
(Figure 9E). Moreover, LPS-induced phosphorylation of STAT3 (Figure 9F, Figure 
10C) and CREB (Figure 9G, Figure 10C) was exclusively detected in M-MØ. Therefore, 
the response of GM-MØ and M-MØ to LPS and other TLR ligands differs in terms of 
intracellular signaling, with a higher activation of MAPK, STAT3 and CREB in M-MØ, 
and a more robust phosphorylation of IRF3 in GM-MØ. 
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Figure 10. Differential LPS-triggered intracellular signaling in M-MØ and GM-MØ. (A,B) M-MØ 
and GM-MØ were treated with LPS, and cell lysates were obtained after 30 minutes (A) or 60-180 
minutes (B) and assayed for the expression of phosphorylated IRF3 by Western blot. Protein loading 
was normalized using a monoclonal antibody against GAPDH. (C) Densitometric analysis of the set of 
experiments illustrated in Figure 2 and in (A,B). Shown are the means and SD of three independent 
experiments (n=3; *, p < 0.05; **, p < 0.005; ***, p < 0.0005). In the case of IRF3 (lower panels), 
phosphorylation was determined on three independent samples and at the indicated time points in each 
experiment. 
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Definition of the LPS-regulated transcriptional signature of GM-MØ and M-MØ: 
identification of gene sets specifically regulated by TLR agonists in both 
macrophage subtypes. 
 The limited available information on the gene signature of LPS-treated human 
GM-MØ and M-MØ precluded further evaluation of the transcriptional relevance of the 
differences in LPS-initiated signaling pathways between GM-MØ and M-MØ. Thus, 
we undertook the identification of the range of genes whose expression is modulated 
by LPS in both macrophage subsets. Microarray analysis on RNA from macrophages 
exposed to LPS for 4 hours (Figure 11A and Table III included in attached CD) 
reflected the differential regulation of cytokine genes in response to LPS (Figure 11B), 
and revealed the existence of gene sets differentially regulated by LPS in GM-MØ and 
M-MØ. Specifically, 1143 genes were up-regulated and 1545 genes down-regulated by 
LPS in GM-MØ, while 1906 genes were up-regulated and 2463 genes down-regulated 
by LPS in M-MØ (adj p<0.05; log2 LPS-treated/untreated >1 or <1) (Figure 11C,D 
and Table III). A more stringent analysis of the data (adj p<0.05 in one macrophage 
subtype and p>0.1 in the counterpart; log2 LPS-treated/untreated >2 or <-2) identified 62 
genes exclusively upregulated by LPS in GM-MØ (hereafter termed activated-GM-MØ 
gene set), while 195 genes were upregulated by LPS only in M-MØ (hereafter termed 
activated-M-MØ gene set) (Figure 11E and Table IV). Besides, LPS triggered the 
downregulation of 40 genes in GM-MØ and 169 genes in M-MØ (Figure 11E and Table 
IV). A roughly similar number of genes were strongly upregulated or downregulated 
by LPS in both macrophage subtypes (351 and 141 genes, respectively) (adj p<0.05 
and log2 LPS-treated/untreated >2 or <-2) (Figure 11E and Table V). Therefore, 
the differential LPS-responsiveness of GM-MØ and M-MØ is not limited to cytokine 
production, and there is a large set of genes whose expression is regulated by LPS 
in a macrophage subtype-dependent manner (that is, their expression is differentially 
modulated by LPS in GM-MØ and M-MØ). Analysis of independent samples of GM-
MØ+LPS and M-MØ+LPS verified the existence of a gene set whose expression is 
exclusively modulated in M-MØ by LPS (Figure 12A,B) and also after stimulation with 
PAM3CSK4 (Figure 12C). This gene set included CCL19 (Figure 12D), whose LPS-
inducibility in M-MØ was confirmed at the protein level (Figure 12E). Along the same 
line, gene sets were identified whose expression is upregulated by LPS only in GM-
MØ, and others whose expression is downregulated exclusively in either M-MØ or 
GM-MØ (Figure 12B and Table IV). Therefore, the preferential production of IL-10 by 
activated M-MØ, the defining feature of this macrophage subtype, is in line with the 
existence of an M-MØ-specific gene expression program that can be triggered by LPS 
and other TLR ligands. 
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Figure 11. Determination of the gene signature of LPS-activated M-MØ and GM-MØ. (A) 
Experimental design. (B) Normalized fluorescence intensity of the indicated mRNAs in untreated and 
LPS-treated M-MØ and GM-MØ. (C) Number of annotated genes whose expression is upregulated 
(UP) or downregulated (DOWN) in the indicated macrophage subtypes after 4h of LPS treatment 
(adjusted p < 0.05; log2 LPS-treated/untreated >1 or <1). (D) Scatter plot of microarray results, showing 
the LPS-induced gene expression changes in GM-MØ (log2 LPS-treated/untreated GM-MØ, x-axis) 
plotted against the LPS-induced gene expression changes in M-MØ (log2 LPS-treated/untreated GM-
MØ, y-axis). The relative position of some informative genes is indicated, with color code as indicated 
in panel (A). 
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Figure 12
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Figure 12. Validation of the M-MØ-specific LPS-activated gene signature. (A,B) Expression of the 
indicated genes in untreated and LPS-treated M-MØ and GM-MØ as determined by qRT-PCR on three 
additional independent samples. Results are indicated as the mRNA levels of each gene in LPS-treated 
cells relative to the level of the same mRNA in untreated cells, with all depicted changes showing at least 
p < 0.05 (n=4). Only genes whose expression is specifically upregulated by LPS in M-MØ are shown 
in (A). (C) Expression of the indicated genes in untreated and PAM3CSK4(PAM)-treated M-MØ as 
determined by qRT-PCR on three additional independent samples. Results are indicated as the mRNA 
levels of each gene in PAM3CSK4-treated cells relative to the level of the same mRNA in untreated cells, 
with all depicted changes showing at least p < 0.05 (n=3), unless otherwise noted (ns: not statistically 
significant). (D) CCL19 mRNA expression in untreated (-) and LPS-treated M-MØ and GM-MØ. Results 
indicate the level of CCL19 mRNA relative to the TBP mRNA level in each sample (n=3; *, p < 0.05). (E) 
CCL19 protein levels produced by untreated (-) and LPS-treated M-MØ and GM-MØ. Shown are the 
means and SD of five independent expreriments (n=5; *, p < 0.05). 
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Biological function of the genes upregulated by LPS exclusively in anti-
inflammatory M-MØ. 
 As expected from the pro-inflammatory priming of GM-MØ, the activated-GM-MØ 
gene set was significantly enriched in genes known to be positively controlled by LPS 
(adj p = 4.1x10-13), associated with the GO Biological Process “inflammatory response” 
(GO:0006954, adj p = 1.1x10-4), regulated by RelA as determined by ChIP (adj p = 
5.5x10-7), positively regulated by IL-1β (adj p = 5.2x10-10) and negatively regulated by 
IL-4 (adj p = 1.8x10-3), estrogen (adj p = 6.9x10-3) and TGF-β1 (adj p = 7.8x10-3) (Figure 
13A). Conversely, the activated-M-MØ gene set included a significant number of genes 
regulated by EGR1 (adj p = 3.8x10-21) and PPARγ (adj p = 1.8x10-13) as determined 
by ChIP (Figure 13B), and a much lower association to the “inflammatory response” 
GO term (GO:0006954, adj p = 5.4x10-6) (Figure 13B). Interestingly, the expression 
of a significant number of genes in the activated M-MØ gene set has been described 
to be enhanced by B-Raf overexpression (adj p = 1.8x10-8) and impaired by the B-Raf 
inhibitor Vemurafenib (adj p = 6.35x10-6) (Figure 13B), thus suggesting a link between 
B-Raf/MEK/ERK activation and M-MØ-specific LPS responsiveness. This prediction is, 
in fact, in line with the preferential activation of ERK in LPS- and PAM3CSK4-treated 
M-MØ (see Figure 9D,E). Moreover, the activated M-MØ was significantlly enriched 
in genes that are upregulated by IL-10 (adj p = 1.8x10-14), TGF-β1 (adj p = 3.6x10-7) 
and estradiol (adj p = 1.3x10-5) (Figure 13B), thus supporting the existence of a strong 
anti-inflammatory component in the transcriptome of LPS-stimulated M-MØ. 
Contribution of ERK, JNK and p38 activation to the M-MØ-specific LPS-dependent 
transcriptional profile. 
 The higher LPS-induced activation of ERK, JNK and p38MAPK, together with 
the enrichment of B-RAF-regulated genes within the gene set exclusively upregulated 
by LPS in M-MØ, prompted us to analyze the contribution of the three MAPK to 
the acquisition of the characteristic transcriptome of LPS-stimulated M-MØ. To that 
end, M-MØ were exposed to LPS in the presence of inhibitors of MEK (U0126) 141, 
JNK (SP600125) 142 or p38MAPK (BIRB0796) 143. Inhibition of the activation of ERK, 
p38MAPK (Figure 14A) or JNK (Figure 14B) had a major impact on the characteristic 
LPS-induced cytokine mRNA profile of M-MØ. Specifically, simultaneous inhibition of 
ERK and p38 activation significantly enhanced the LPS-induced TNF mRNA levels 
but inhibited the LPS-induced IL10 mRNA levels (Figure 14C). Conversely, inhibition 
of JNK activation resulted in reduced TNF mRNA and IL10 mRNA levels after LPS 
exposure (Figure 14D). By contrast, siRNA-mediated knockdown of STAT3 in M-MØ 
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Figure 13
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Figure 13. Gene ontology analysis of the activated-GM-MØ and activated-M-MØ gene sets. The 
set of genes specifically upregulated by LPS in either GM-MØ (A) or M-MØ (B) were analyzed for 
significant enrichment of functional activities and potential regulators using the ENRICHR tool and the 
indicated databases [combined score = log(p-value) x z-score]. Red and green colors indicate gene-
upregulation or gene-downregulation in the indicated databases. 
(Figure 14E) had no major effect on the LPS-stimulated cytokine mRNA expression 
(Figure 14F). Therefore, ERK, p38MAPK and JNK directly contribute to the M-MØ-
specific LPS-induced cytokine profile, supporting that differences in LPS-triggered 
intracellular signals lie at the basis of the distinct cytokine profile of GM-MØ and M-MØ. 
 Based on this information, we next sought to determine the contribution of the 
three MAPK to the acquisition of the activated M-MØ transcriptional profile. To that end 
we analyzed the effect of the three inhibitors on the expression of genes exclusively 
upregulated (37) or downregulated (26) by LPS in M-MØ and genes upregulated by 
LPS in both M-MØ and GM-MØ (see Table IV, V, VI). As shown in Figure 15A, U0126 
inhibited the LPS-induced increase of 6 genes, while inhibition of JNK or p38 impaired 
the LPS-induced upregulation of 14 and 21 genes, respectively. Moreover, and in line 
with their effect on IL10, the combined presence of U0126 and BIRB0796 significantly 
impaired the LPS-mediated upregulation of 24 genes (Figure 15A). The synergistic 
inhibitory effect of U0126 and BIRB0796 was particularly evident in the case of 
CCL19, SOCS2, BMP6 and PDGFA (Figure 15B), which display the most differential 
LPS-mediated regulation between M-MØ and GM-MØ (Table IV). Conversely, the 
inhibitors impaired the LPS-induced downregulation of 2 (U0126), 5 (BIRB0796) and 6 
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Figure 14. MAPK activation contributes to the specific cytokine profile of activated M-MØ. (A,B) 
ERK, p38MAPK and JNK phosphorylation in untreated and LPS-treated M-MØ and in the absence 
(-) or presence of the MEK inhibitor U0126 (U0), p38MAPK inhibitor BIRB0796 (BIRB) (A), the JNK 
inhibitor SP600125 (SP600) (B) or DMSO as a vehicle control. (C,D) LPS-induced cytokine production 
in M-MØ in the absence (-) or presence of U0126 (U0), BIRB0796 (BIRB) (C), SP600125 (SP600) 
(D) or DMSO as a vehicle control. Results are expressed relative to the level of each cytokine mRNA 
after LPS treatment. Shown are the means and SD of four independent expreriments (n=4; *, p < 0.05; 
***, p < 0.0005). (E) STAT3 protein expression in M-MØ after transfection with either siControl or a 
STAT3-specific siRNA (siSTAT3) for 24, 48 or 72 hours, as determined by western blot. (F) LPS-induced 
cytokine mRNA expression production in M-MØ transfected with either siControl or siSTAT3. Results are 
expressed relative to the level of each cytokine mRNA after LPS treatment. Shown are the means and 
SD of three independent expreriments (n=3; *, p < 0.05; ***, p < 0.0005).
(SP600125) genes (Figure 15A). Interestingly, and in consonance with its regulation 
of TNF-α expression, JNK positively regulates genes that are induced by LPS in both 
GM-MØ and M-MØ (Figure 15A). Therefore, ERK, JNK and p38 significantly contribute 
to the acquisition of the transcriptome of LPS-stimulated M-MØ as well as to their 
characteristic LPS-induced cytokine profile. 
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Figure 15. MAPK activation mediates the expression of the M-MØ-
specific LPS-dependent transcriptional profile. (A) Heat map of 
the expression of the indicated genes in LPS-stimulated M-MØ in the 
presence of UO126 (UO), BIRB0796 (BIRB), UO126 and BIRB0796 
(UO+BIRB) and SP600125 (SP600). Results indicate the expression 
of each gene relative to its expression in LPS-stimulated M-MØ without 
inhibitors. Red (log2 fold > 1; p < 0.05), black (-1 < log2 fold < 1 and/or p > 
0.05), green (log2 fold < -1; p > 0.05) (B) Expression of CCL19, SOCS2, 
BMP6 and PDGFA mRNA in LPS-stimulated M-MØ in the presence of 
UO126 (UO), BIRB0796 (BIRB), UO126 and BIRB0796 (UO+BIRB) 
and SP600125 (SP600). Results indicate the expression of each gene 
relative to its expression in LPS-stimulated M-MØ without inhibitors. 
Shown are the means and SD of three independent expreriments (n=3; 
*, p < 0.05; **, p < 0.005).
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Physiologic and pathologic relevance of the M-MØ-specific LPS-induced 
transcriptional profile. 
 The identification of the LPS-inducible M-MØ-specific gene set, whose expression 
primarily depends on MAPK activation, led us to explore the expression of this gene 
set in macrophages in vivo. As representatives of this set gene we focused on CCL19, 
PDGFA, BMP6 and SOCS2 because they exert potent trophic (PDGFA) 144, anti-
inflammatory (SOCS2) 145-147 and matrix-synthesis stimulatory (BMP6) 148 actions that 
are compatible with the known effector functions of M-MØ. Tissue screening revealed 
the presence of BMP6+/CCL19+/CD163+ macrophages in gut (colon submucosa) and 
skin (data not shown) tissues whose tissue-resident macrophages are monocyte-
derived and replaced by circulating monocytes in homeostasis 4; 149. A percentage of 
CD163+ macrophages in primary melanoma were also found to co-express SOCS2 
Figure 16
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Figure 16. Human macrophages co-express genes within the activated-M-MØ-specific gene set. 
(A) Expression of SOCS2 (left) and BMP6 (right) in CD163+ macrophages from a primary melanoma 
sample, as determined by immunofluorescence and confocal microscopy. (B) Expression of SOCS2, 
BMP6, PDGFA and CCL19 in CD163+ macrophages from human nevi. Bottom panels illustrate a 
magnification of the section indicated in upper panels. Left panels show the staining produced by 
irrelevant non-specific and isotype-matched antibodies. (C) Positive correlation between the expression 
of SOCS2 and BMP6 (left), PDGFA and BMP6 (center), and CCL19 and BMP6 (right) in CD163+ 
macrophages from human nevi (black, red, blue) and normal skin (green). 
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and BMP6 (Figure 16A). The simultaneous expression of PDGFA, SOCS2, BMP6 
and CCL19 in CD163+ macrophages was more evident in nevus (Figure 16B), where 
the expression of the four genes in CD163+ macrophages exhibited a very similar 
distribution pattern and a good correlation (Figure 16C). These results confirm the 
co-expression of CCL19, PDGFA, BMP6 and SOCS2 in LPS-activated M-MØ, and 
reinforce the existence of a co-regulated set of genes that are specifically expressed 
upon activation of human anti-inflammatory/homeostatic macrophages.
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CCL20
CXCL1
IL1A
CXCL3
IL8
CXCL2
EREG
WNT5A
NCF1
HHLA2
CCL15
NR4A2
HEY1
ADC
CXCL6
ACKR3
LOC283485
TLL1
GPC3
TAGAP
CYP3A7
IL19
PDGFB
APOL6
CYP3A5
ASPHD2
IFNL1
DHX58
SECTM1
C5orf56
TMEM88
FOXD3
JAK2
PKIG
ZC3H12C
LOC100506342
TMEM139
PPP1R17
ANXA2R
MXD1
OTUD1
TCF4
SIGLEC1
HOPX
SAT1
TRIL
C7orf60
ANO1
PID1
RASGEF1B
MVB12B
CLIC2
IL18
PDZD2
C14orf182
GPR64
TLR7
SLC25A37
UNC79
THRB
GRASP
JAG1
Genes upregulated in GM-MØ
Table IV. Genes regulated by LPS exclusively in GM-MØ or M-MØ 
Adj p<0.05 in one macrophage subtype and p>0.1 in the counterpart; log2 LPS-treated/untreated >2 or <-2 in one macrophage subtype and ‘not 
expressed or does not change or changes in the opposite manner’ in the counterpart. From top to bottom and left to right, genes are classified from 
more to less fold change.
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CCL19
RGS16
SOCS2
LY6K
BMP6
CSRP2
ARNT2
LIMS2
GCGR
GJB2
CHI3L2
FFAR3
CTHRC1
MMP12
SPINK1
CLEC4D
SBSN
S100A3
PDGFA
VEGFC
APOL4
ADIRF
C1R
DUSP2
ABHD17C
STRIP2
IL3RA
PIM1
NNMT
KIAA1199
SLC8A3
MT1M
EHF
SMARCA1
RET
SLCO5A1
UBD
C10orf10
MAOA
SLC2A1
FZD6
LOC100509445
ADAM19
BOC
CXCL13
AMIGO2
LMNB1
CDKN1A
DLL1
FRMD6
GGT5
TM4SF1
CRLF2
IRGM
IL18RAP
PFKP
DDIT4
FOSL2
FAM115C
LY6E
BCAR1
PLSCR4
CAPSL
SYNPO
GJA4
EMR2
ITGB3
LRG1
LMCD1
FLVCR2
ENTHD1
IL18R1
METTL1
C1orf21
IGF2
SLC26A9
CCR5
MPP6
XLOC_014512
PTP4A3
BAI1
PDCD1LG2
UST
NUPR1
STEAP3
PRR5
NCS1
SYTL4
CHRNA6
HSPA2
LAMA4
WNT1
GZMB
IFNγ 
PRDM8
SLC16A10
IL1RN
FAM60A
FCAMR
NXN
TMEM2
GBP7
GPR31
ZNF462
KCNN4
CHST2
LINC00605
LAMB3
LYPD5
GADD45G
NABP1
OR11A1
EPO
DSTYK
MUCL1
GAREM
CBR3
HES1
UGCG
CGNL1
CISH
STEAP1
SMAD7
TCHH
KIAA0226L
EBF1
HLX
VAV2
ADD2
TUBB6
COL5A3
ANTXR2
VAC14
GCKR
SRFBP1
ABCB5
CD200
LDLRAD3
CSAG4
FAM57A
FKBP5
SH3PXD2B
CDCA4
ITGA1
TNFRSF1B
SH2B2
CEBPB
MYO5C
MPP4
CCR8
AEN
ECE1
LOC154761
LILRA2
RGS20
LAMA3
MYOF
RUNX1-IT1
SLC5A3
CXCR5
TMEM178B
LOC285300
TGM2
TTC39A
FERMT2
FNDC4
EGR4
HRASLS5
TCEA2
KIAA1522
RAB30
IL4R
CTDSP2
RBBP8
ELK1
BACH1
VEGFA
TFRC
MMP19
UBE2S
PLOD2
L2HGDH
TRIM14
TPBG
MYO10
HNRNPLL
GLI3
PUS7
SVIL
SCN9A
LANCL3
VCAN
CDC42EP4
RAB15
MGAT1
Genes upregulated in M-MØ
Table IV. Genes regulated by LPS exclusively in GM-MØ or M-MØ 
Adj p<0.05 in one macrophage subtype and p>0.1 in the counterpart; log2 LPS-treated/untreated >2 or <-2 in one macrophage subtype and ‘not 
expressed or does not change or changes in the opposite manner’ in the counterpart. From top to bottom and left to right, genes are classified from 
more to less fold change.
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NFE2
CCR2
C2orf71
RAB11FIP4
ARHGEF28
FOXO6
TSEN2
ARRDC4
SLC20A1
USP2
MYB
ADRA2B
ITPRIPL1
FAM211A
CBX2
GDF15
FAM95B1
PPP1R13B
RAB36
CLMN
ST6GALNAC6
SAPCD2
STIP1
SLC46A2
KIAA0922
DISP2
CBFA2T3
XLOC_014512
KLHL30
NEURL1B
SPIN4
IL21R
LOC100130938
CECR6
ZNRF3
ALKBH2
RRS1
RPUSD1
AFAP1L1
SLC25A19
Genes downregulated in GM-MØ
Table IV. Genes regulated by LPS exclusively in GM-MØ or M-MØ 
Adj p<0.05 in one macrophage subtype and p>0.1 in the counterpart; log2 LPS-treated/untreated >2 or <-2 in one macrophage subtype and ‘not 
expressed or does not change or changes in the opposite manner’ in the counterpart. From top to bottom and left to right, genes are classified from 
more to less fold change.
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ADORA3
F2RL3
ZFP36L2
TRIB3
HTR7
RHPN2
KLF2
MTSS1
GPR155
DDIT4L
HTR2B
ALK
KCNMB4
FRAT1
CD28
LRRK2
GPRC5B
C10orf105
GAPT
BNC2
MS4A4E
MRVI1
PIK3CG
HTR7P1
ZFP36L1
SRGAP3
RREB1
MEF2C
NHS
CXCR4
LOC340508
FAM174B
ARL4C
SH3PXD2A
FZD2
MGC24103
LINC00294
CLCN4
EVI2A
SLC7A8
FRMD4B
LOC100240735
ARRDC2
CRHBP
PPM1F
MPPED2
CD200R1
C12orf76
PPAPDC2
MS4A7
TMEM117
DEPTOR
MANBA
RAB3IL1
CLEC4GP1
PCED1B
ZNF217
PPARγC1B
CPOX
LYPLAL1
CCDC152
RASAL1
WWP1
ZKSCAN4
ADAT2
MIS18BP1
RAPH1
SCAMP5
DPRXP4
PCDH12
ACVR2B
TRIM45
C5AR2
CACNA2D3
LOC100129550
LACC1
LINC00921
SLC40A1
KAL1
HAVCR2
LYRM9
UBTF
SLC22A15
ARID3B
ARHGAP6
FGD6
HS3ST2
GCNT1
ANKRD50
ITSN1
CKAP2
EGR1
TRIM50
LEPREL4
HIST1H4E
DNMBP-AS1
APBA1
GIMAP8
UNC80
CDK19
IQCD
CIITA
GDPD1
C16orf86
MTL5
SLC16A5
ST3GAL6
LOC100132741
HTR1F
OLFML2B
BDH1
MYOM1
CARD8
ZNF280D
APAF1
SIDT1
TRPS1
NR3C2
AHRR
ZNF581
SGMS1
HMGB2
TPRG1L
PTPN6
ZNF469
MPZL2
ADRB1
XLOC_010709
LYPD1
NR1D2
AKAP13
PINK1
TTLL1
PDGFC
MS4A14
PHF20
CEP120
GPR162
SLC45A3
KLHL41
RFPL1S
MMD
NOTCH4
PDLIM2
C6orf164
MYLK
PPM1M
ISCU
CUX2
ZMYND8
LOC286272
ZNF395
PELI2
ZNF106
ING5
SFMBT2
NECAB3
HVCN1
PCCA
SASH3
COQ10A
KLHL13
RCN3
FARP1
CCDC149
LOC100130219
ZFP14
CAPS2
ADAMTS10
Genes downregulated in M-MØ
Table IV. Genes regulated by LPS exclusively in GM-MØ or M-MØ 
Adj p<0.05 in one macrophage subtype and p>0.1 in the counterpart; log2 LPS-treated/untreated >2 or <-2 in one macrophage subtype and ‘not 
expressed or does not change or changes in the opposite manner’ in the counterpart. From top to bottom and left to right, genes are classified from 
more to less fold change.
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Genes upregulated
Table V. Genes regulated by LPS in both GM-MØ and M-MØ 
CXCL11
IDO1
IRG1
CXCL10
LAMP3
CCR7
SLAMF1
OASL
PTX3
IL27
LOC440896
TNIP3
GREM1
IFIT2
RSAD2
IFIT3
BATF3
CCL5
ISG20
ABTB2
SSTR2
HES4
NIPAL4
G0S2
CXCL9
IL6
CSF3
PDGFRL
CD274
IL7R
ETV7
SOCS1
USP18
NEURL3
GBP1
GBP5
SOCS3
GFPT2
TRAF1
ANGPTL4
INHBA
APOBEC3A
IL12B
SNAI1
MIR155HG
TNF-αIP6
HAPLN3
ZC3HAV1
ISG15
LINC00158
IFITM1
MCOLN2
MMP1
ITGB8
ADORA2A
IFIT1
USP41
HERC5
CYP7B1
ELOVL7
AIM2
GCH1
GBP4
ZBTB32
HELZ2
HCAR3
IFI44L
TNF
IFI27
TMCC2
STAT4
RANBP3L
CD38
IL15RA
PTGS2
CFB
TNFSF9
CMPK2
DDX58
C11orf96
NAMPT
OAS3
CCL8
IL23A
IL2RA
CD80
CKB
MX1
EBI3
ATP10A
SAMD9L
TNFSF10
HERC6
BAALC
CCL3L3
CYP27B1
NR4A3
TMEM217
CCL23
TCF7L1
LRRC32
IL36G
ADAD2
CSRNP1
MX2
HS3ST3B1
AKAP2
SLAMF7
OAS2
TARP
BATF2
PLEKHA4
IDO2
IFIH1
TNFRSF9
HESX1
TANC1
C15orf48
SLC41A2
TTC39A
ADM
ZC3H12A
PVRL3
CDC42EP2
SLC13A3
CSF2
XAF1
CH25H
GRB10
DUSP1
TNF-αIP3
APOBEC3B
SPSB1
APOL3
RNF213
CD40
LAG3
PNPT1
MAMLD1
NT5C3A
TNFSF15
IFIT5
EXT1
KCNA3
PDE4B
CLIC4
LOC400043
PFKFB3
RAB33A
PRDM8
GBP1P1
TFPI2
IRF7
GBP2
BIRC3
RHOH
IFI44
WTAP
C17orf96
MSC
EHD1
FAM26F
GADD45B
EPSTI1
TRIP10
MFSD2A
ARL5B
FERMT2
PPM1K
P2RX7
IL10
NKX3-1
SAMD4A
HAS1
DEFB1
SERPINB9
TAP1
FAM83H-AS1
APOL6
SH2D3A
HSH2D
IRF1
TRAF3IP2
CNKSR3
FAM115C
FFAR2
EIF2AK2
GRAMD1A
CFLAR
CCM2L
RASL11A
STX11
ATF3
CACNA1A
OAS1
SAMD9
ACSL1
CD69
RAPGEF2
SOD2
SP140
PLAT
GPR132
SLC25A28
IFI35
Adj p<0.05 and log2 LPS-treated/untreated >2 or <-2 in both macrophage subtypes. From top to bottom and left to right, genes are classified from 
more to less fold change.
63
CHAPTER ONE
B4GALT5
ICAM1
TDRD7
MSANTD3
ZNFX1
AREG
SDC4
OSR2
CD70
PMAIP1
NFKB2
HILPDA
CLCF1
SRSF12
PML
AKT1S1
TNIP1
CCL1
SLC2A6
SNHG15
FLJ32255
BCL2L14
TMPRSS7
SFT2D2
PIM3
C12orf76
DDX60L
KIAA0040
UPB1
USP30-AS1
MASTL
MST4
NFKB1
BAMBI
SERPINB2
RTP4
RASGRP1
NEXN
NBN
MB21D1
PARP9
KYNU
SRC
CCNA1
TMPRSS13
C5orf56
MAP1LC3A
DCP1A
KMO
SP110
HDX
YJEFN3
STAT1
RND3
N4BP2L1
BAZ1A
TMEM229B
PI4K2B
LSS
USP12
ZHX2
CCL3
TP53INP2
NFKBIA
APOBEC3G
ADRA1B
HIF1A
CCRL2
KCNS3
BLZF1
LINC00346
SLED1
PARP14
GUCY1A3
HCAR2
TOR1B
MAP3K8
PTGIR
RELA
ETV3L
PANX1
TMEM171
RNF19B
NRP2
MAML2
LRRC3
NTN1
SYNE3
ST7-AS1
DDX60
LOC644090
PRPF3
PELI1
FAS
CASP7
NFKBIZ
IL4I1
IL15
NR6A1
MGC12916
RNF144B
CASP10
ANKLE2
GRAMD3
STAT5A
RAP2C
PSTPIP2
FPR2
NDP
STARD5
GTPBP1
TNF-αIP8
KANK1
CCL16
LOC641510
FZD4
PDLIM5
GBP3
VSX1
CD48
PPP4R2
C9orf91
SLCO3A1
IFIT1B
IGFBP4
IER3
SLC39A8
FUT4
LOC285957
PPP3CC
C2CD4B
TRIM36
LYSMD2
KRTAP4-1
ENDOD1
TIAM2
RIPK2
IFITM4P
GTF2B
ASPHD2
IFITM3
STBD1
IRF4
LHFP
SLC1A2
LONRF1
Genes upregulated
Table V. Genes regulated by LPS in both GM-MØ and M-MØ 
Adj p<0.05 and log2 LPS-treated/untreated >2 or <-2 in both macrophage subtypes. From top to bottom and left to right, genes are classified from 
more to less fold change.
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Genes downregulated
Table V. Genes regulated by LPS in both GM-MØ and M-MØ 
HHEX
FAM78A
P2RY8
SOWAHD
KLHDC8B
KCNE3
C15orf52
RNF125
RGS18
RIMBP3
MYCL
HEXIM2
IL16
TMEM170B
MERTK
DAB2
EEPD1
TMEM86A
DBP
RAB42
FAM13A
FAM117B
LRMP
TBC1D14
RHOBTB1
FRAT1
MAF
MXD4
CEBPA
C16orf54
BAIAP2-AS1
OSBPL7
RAP2B
SNHG12
PANK1
TLR5
CAMK2G
DOK3
PGPEP1
NT5DC2
TSHZ1
ZHX3
SH2D3C
SUFU
GPR65
PRR12
TMEM37
C22orf29
ZCCHC24
GIMAP1
PLA2G15
PLCXD1
ABHD6
WDR91
VAV3
C9orf139
NAPEPLD
CABLES1
SNAI3
MBP
MID1IP1
RNF166
WDR81
FRMD4A
ZNF652
TBC1D2
FAM53B
ZNF362
FAM217B
CX3CR1
MYZAP
GPAM
NINL
SMYD4
ABHD8
ARHGEF40
GPATCH11
MUM1
NR2F6
CARD9
SAC3D1
ENC1
ZBTB47
OSGEPL1
PIK3C2B
DOK2
RHOBTB2
TRERF1
TRIM65
PLAU
ASB13
ZNF788
FAM214A
CEBPA-AS1
MBLAC2
PTPN22
GPRIN3
RAB3A
SLC29A3
SCAI
ABHD15
PRAM1
SH3TC1
TIGD2
ZBED3
ZNF589
THEM6
NLRP12
GFOD1
ZNF248
E2F2
OGFOD2
TNRC6C-AS1
CTSC
PSTPIP1
LOC93622
ASB1
KIAA1737
MAPKAPK5-AS1
CSRP2BP
SPRY2
RTN4R
OSBPL11
NFATC3
CAMKK1
RSAD1
CRTC1
TBC1D10C
PELI3
NAIP
FAM50B
SAPCD1
FGD5
PROC
RFXAP
C16orf59
CD180
FAM156A
TMEM223
MKL2
ZNF573
RASSF7
Adj p<0.05 and log2 LPS-treated/untreated >2 or <-2 in both macrophage subtypes. From top to bottom and left to right, genes are classified from 
more to less fold change.
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gene geneset p.value fold.value log2.fold.value p.value fold.value log2.fold.value p.value fold.value log2.fold.value p.value fold.value log2.fold.value
CCR7 0.029 1.994 0.995 -0.005 0.153 -2.709 -0.035 0.150 -2.737 -0.007 0.418 -1.258
CXCL10 0.184 1.427 0.513 0.256 1.558 0.639 0.110 1.741 0.800 -0.002 0.003 -8.406
CXCL11 0.422 1.140 0.189 0.121 1.469 0.555 0.097 1.503 0.588 -0.001 0.002 -9.088
IDO1 0.201 1.171 0.228 -0.068 0.539 -0.892 -0.043 0.364 -1.458 -0.003 0.223 -2.166
IFIT2 0.034 1.304 0.383 -0.096 0.574 -0.801 -0.515 0.918 -0.123 -0.003 0.043 -4.547
IL27 0.026 1.222 0.289 0.592 1.107 0.147 -0.065 0.794 -0.332 -0.001 0.142 -2.820
ISG20 0.003 1.176 0.234 -0.080 0.854 -0.228 -0.080 0.752 -0.410 -0.001 0.129 -2.954
OASL 0.002 2.641 1.401 -0.010 0.405 -1.303 -0.011 0.600 -0.738 -0.011 0.151 -2.732
RSAD2 0.466 1.079 0.110 -0.025 0.439 -1.186 -0.009 0.370 -1.434 -0.005 0.006 -7.498
TNFAIP6 0.030 2.260 1.176 -0.517 0.954 -0.068 0.733 1.116 0.159 -0.443 0.870 -0.201
ABHD17C -0.096 0.620 -0.690 -0.009 0.224 -2.155 -0.082 0.321 -1.638 -0.574 0.966 -0.050
ADIRF 0.057 1.514 0.599 -0.238 0.648 -0.626 -0.029 0.164 -2.607 0.212 1.201 0.264
ANTXR2 -0.455 0.989 -0.016 -0.086 0.888 -0.172 -0.079 0.764 -0.387 0.111 1.123 0.167
ARNT2 0.013 2.347 1.231 -0.009 0.079 -3.669 -0.009 0.160 -2.644 -0.016 0.488 -1.035
BMP6 -0.002 0.489 -1.031 -0.001 0.154 -2.698 -0.009 0.048 -4.382 0.060 2.321 1.214
C1R 0.516 1.140 0.189 -0.059 0.571 -0.809 -0.165 0.521 -0.940 -0.001 0.205 -2.288
CCL19 -0.400 0.806 -0.312 -0.056 0.291 -1.780 -0.013 0.036 -4.808 -0.016 0.517 -0.951
CEBPB 0.077 1.117 0.160 -0.114 0.707 -0.500 -0.021 0.417 -1.261 -0.055 0.854 -0.228
CRLF2 -0.014 0.526 -0.926 -0.012 0.155 -2.690 -0.001 0.054 -4.219 -0.221 0.687 -0.541
CSRP2 0.008 3.088 1.626 -0.006 0.232 -2.106 -0.714 0.962 -0.055 -0.010 0.521 -0.941
DLL1 0.504 1.169 0.225 -0.042 0.510 -0.971 -0.113 0.609 -0.715 -0.003 0.299 -1.743
EMR2 -0.117 0.863 -0.213 -0.049 0.416 -1.265 -0.013 0.249 -2.004 -0.002 0.715 -0.485
GGCT -0.021 0.732 -0.451 -0.001 0.453 -1.143 -0.022 0.506 -0.982 -0.375 0.852 -0.230
GPATCH4 -0.408 0.577 -0.792 -0.447 0.872 -0.197 0.311 1.383 0.467 -0.299 0.401 -1.319
IL1RN -0.003 0.651 -0.619 -0.010 0.387 -1.370 -0.007 0.160 -2.641 -0.001 0.190 -2.393
ITPKB 0.693 1.098 0.135 -0.037 0.553 -0.854 -0.763 0.991 -0.013 -0.090 0.500 -1.000
LAMB3 -0.062 0.565 -0.824 -0.018 0.592 -0.757 -0.026 0.301 -1.731 0.019 2.296 1.199
LMNB1 -0.326 0.860 -0.218 -0.025 0.503 -0.992 -0.032 0.404 -1.306 -0.002 0.290 -1.786
LY6K -0.010 0.130 -2.946 -0.217 0.124 -3.013 -0.103 0.034 -4.898 0.093 1.974 0.981
MAOA 0.330 1.138 0.187 -0.093 0.598 -0.742 -0.029 0.262 -1.931 0.015 1.700 0.766
NABP1 0.067 1.354 0.437 -0.054 0.329 -1.603 -0.004 0.208 -2.265 -0.328 0.908 -0.139
NAT10 -0.710 0.967 -0.048 0.226 1.211 0.276 0.216 1.323 0.403 -0.389 0.838 -0.256
NNMT -0.050 0.494 -1.016 -0.006 0.090 -3.477 -0.143 0.096 -3.381 0.653 1.591 0.670
NOD1 -0.090 0.754 -0.407 -0.031 0.422 -1.245 -0.023 0.536 -0.900 -0.010 0.350 -1.515
PDGFA 0.630 1.271 0.346 -0.078 0.325 -1.620 -0.048 0.176 -2.508 -0.020 0.544 -0.878
PFKP -0.095 0.873 -0.196 -0.065 0.966 -0.050 -0.192 0.819 -0.288 -0.001 0.402 -1.314
PIM1 0.211 1.672 0.741 0.744 1.142 0.192 -0.175 0.723 -0.468 -0.002 0.709 -0.496
PRR5 -0.076 0.692 -0.530 -0.013 0.362 -1.467 -0.008 0.219 -2.189 0.546 1.179 0.237
RASGRP2 -0.371 0.730 -0.454 -0.031 0.199 -2.328 -0.047 0.327 -1.614 0.021 3.008 1.589
RGS16 -0.786 0.979 -0.031 -0.111 0.591 -0.758 -0.003 0.088 -3.512 0.000 0.068 -3.882
SH2B2 -0.101 0.438 -1.193 -0.017 0.256 -1.967 -0.008 0.100 -3.324 -0.040 0.449 -1.154
SOCS2 0.655 1.223 0.290 -0.021 0.230 -2.118 -0.025 0.100 -3.321 -0.564 1.191 0.252
SRFBP1 -0.506 0.902 -0.149 -0.093 0.640 -0.644 -0.550 0.906 -0.143 -0.008 0.416 -1.264
TMEM2 -0.236 0.778 -0.363 -0.014 0.300 -1.739 -0.026 0.257 -1.962 0.697 1.438 0.524
TNFRSF1B -0.022 0.558 -0.843 -0.016 0.348 -1.522 -0.001 0.144 -2.794 -0.909 1.012 0.017
UGCG -0.617 0.961 -0.057 -0.110 0.462 -1.116 -0.031 0.404 -1.309 -0.487 0.961 -0.058
VEGFC -0.019 0.578 -0.792 -0.008 0.368 -1.442 -0.023 0.130 -2.945 -0.010 0.132 -2.923
AHRR 0.009 4.069 2.025 -0.650 0.944 -0.084 0.009 3.213 1.684 0.229 1.226 0.294
AKAP13 0.669 1.052 0.073 0.045 1.173 0.230 0.094 2.234 1.160 -0.009 0.635 -0.654
ARL4C 0.304 1.631 0.706 -0.579 0.921 -0.119 0.185 1.733 0.793 0.008 1.973 0.981
CD28 -0.110 0.707 -0.501 -0.346 0.822 -0.283 -0.734 0.970 -0.044 -0.003 0.633 -0.659
CDKN1B 0.923 1.013 0.019 -0.661 0.966 -0.050 -0.470 0.911 -0.135 0.000 2.034 1.024
CPOX 0.061 1.769 0.823 0.016 2.799 1.485 0.011 3.946 1.980 0.024 2.136 1.095
CREBRF 0.298 1.516 0.600 -0.018 0.477 -1.069 -0.885 1.021 0.030 0.005 1.496 0.581
EGR1 -0.015 0.210 -2.251 0.053 3.703 1.889 -0.265 0.616 -0.700 -0.500 0.913 -0.132
FRMD4B -0.036 0.636 -0.652 0.064 1.629 0.704 0.049 1.474 0.559 -0.936 1.012 0.017
FZD1 0.281 1.533 0.617 0.005 1.474 0.560 0.634 1.168 0.223 0.030 4.363 2.125
HTR2B 0.027 1.352 0.435 0.497 1.118 0.161 0.559 1.293 0.371 -0.042 0.666 -0.586
HTR7 -0.033 0.682 -0.553 0.062 2.103 1.072 0.948 1.058 0.081 0.070 1.235 0.304
KCNMB4 0.269 1.108 0.148 -0.929 1.002 0.003 0.098 1.639 0.713 0.100 1.267 0.341
KLF2 0.205 55.054 5.783 -0.492 0.936 -0.095 0.226 151.575 7.244 0.003 5.392 2.431
LACC1 0.108 1.697 0.763 0.393 1.288 0.365 -0.527 1.741 0.800 -0.098 0.715 -0.484
MMD 0.017 2.293 1.197 0.002 3.171 1.665 0.011 6.543 2.710 0.359 1.326 0.407
MTSS1 -0.727 0.974 -0.039 0.564 1.117 0.159 0.128 1.709 0.773 0.025 2.277 1.187
NLRP3 -0.005 0.327 -1.613 0.028 1.749 0.806 -0.025 0.266 -1.912 -0.774 0.995 -0.007
OLFML2B 0.032 1.264 0.337 0.057 1.615 0.692 0.008 2.183 1.126 -0.610 0.952 -0.071
PID1 -0.117 0.738 -0.438 0.556 1.088 0.121 -0.132 0.630 -0.667 0.347 1.159 0.213
PIK3CG -0.453 0.914 -0.130 0.114 1.360 0.444 0.189 1.742 0.800 0.054 1.401 0.486
RHPN2 0.133 1.784 0.835 -0.390 0.800 -0.322 -0.079 0.548 -0.869 -0.240 0.732 -0.449
SGMS1 0.022 1.497 0.582 -0.267 0.911 -0.135 0.049 1.375 0.460 -0.007 0.521 -0.941
SLC40A1 -0.775 0.973 -0.039 -0.131 0.545 -0.875 0.964 1.041 0.057 0.487 1.116 0.159
TRIB3 -0.063 0.587 -0.769 0.003 19.121 4.257 0.005 9.798 3.292 -0.436 0.878 -0.188
ZFP36L2 -0.364 0.952 -0.071 0.015 2.771 1.470 0.006 7.534 2.913 -0.828 1.021 0.030
UO BIRB UO+BIRB SP600
Table VI. Effect of ERK, p38 and JNK inhibitors on the 
LPS-induced transcriptional profile of M-MØ  
UO (UO126, MEK inhibitor), BIRB (BIR0796, p38 inhibitor), SP600 (JNK inhibitor). Green and red highlight genes that are significantly up- or 
downregulated, respectively, after LPS stimulation by the inhibitor treatment as compared to controls (p<0.05 and log2LPS+inhibitor/LPS+vehicle>1 
or <-1)
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MAFB determines human macrophage 
anti-inflammatory polarization: pathological 
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CHAPTER TWO
MAFB expression in human macrophages under homeostatic and anti-
inflammatory conditions. 
 Transcriptional analysis of M-MØ and GM-MØ identified the transcription 
factor-encoding MAFB gene as preferentially expressed in macrophages with anti-
inflammatory potential (GSE27792) 138, since M-MØ express much higher levels of 
MAFB RNA than GM-MØ (19-times higher, p<0.0005) (Figure 17A). In agreement with 
the transcriptional data, MAFB protein expression was very high in M-MØ but barely 
detectable in GM-MØ (Figure 17B). During M-CSF-driven differentiation, MAFB mRNA 
levels dropped at early time points and peaked 24-48 hours after M-CSF treatment 
(Figure 17C, left panel) while high MAFB protein levels were acquired along M-MØ 
differentiation and reached maximum levels after 24 hours (Figure 17C, right panel). 
IL-34, a cytokine that drives macrophage differentiation through the M-CSF receptor 
52; 53, also led to macrophages exhibiting high levels of MAFB mRNA (Figure 17D). 
Moreover, MAFB protein levels were upregulated in monocytes exposed to M-CSF-
containing tumor cell-conditioned media (ascitic fluid) (Figure 17E). Therefore, M-CSF, 
IL-34 and M-CSF-containing ascitic fluids increase MAFB expression in human 
monocytes and promote the generation of macrophages with an anti-inflammatory 
profile, in line with our previous reports 38. Inmunohistochemistry analysis revealed that 
MAFB expression is readily detected in vivo in tissue-resident CD163+ macrophages 
from colon (submucosa and muscle) and skin, as well as in tumor-associated CD163+ 
macrophages in melanoma samples (Figure 17F), thus confirming the expression 
of MAFB in tissue-resident homeostatic macrophages from certain tissues as well 
as in macrophages with anti-inflammatory potential under pathological conditions. 
Altogether, these results reveal that the expression of MAFB characterizes human 
macrophages with homeostatic/anti-inflammatory functions both in vitro and in vivo. 
MAFB controls the acquisition of the anti-inflammatory transcriptional profile of 
M-MØ.
 Since MAFB is the transcription factor most differentially expressed between anti-
inflammatory M-MØ and pro-inflammatory GM-MØ (GSE27792) 138, its role in human 
anti-inflammatory human macrophage polarization was assessed. To that end, MAFB 
expression was knocked-down in M-MØ using MAFB-specific siRNA (siMAFB, Figure 
18A), and the expression of the genes exhibiting the highest differential expression 
between GM-MØ and M-MØ was determined. The expression of most M-MØ-specific 
genes was found to be dependent on MAFB expression levels (Figure 18B), including 
HTR2B, CCL2, IGF1, STAB1 and CD163L1, whose expression is associated with 
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macrophage homeostatic and anti-inflammatory functions 79; 150-153. A similar result 
was observed in M-CSF-dependent bone marrow-derived mouse macrophages, 
where Mafb knockdown diminished the expression of genes associated to M-CSF-
driven anti-inflammatory polarization like Il10, Gas6 and Ctla2b 95 (Figure 18D,C). 
Therefore, MAFB controls the expression of genes associated to anti-inflammatory 
M-MØ polarization.
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Figure 17. MAFB expression in homeostatic and anti-inflammatory macrophages in vitro and 
in vivo. (A) MAFB mRNA expression in GM-MØ and M-MØ as determined by qRT-PCR. Results 
are indicated as the expression of MAFB mRNA in M-MØ relative to the expression in GM-MØ (n=6, 
p = 0.0055). (B) MAFB protein expression in GM-MØ and M-MØ as determined by western blot. A 
representative experiment of three independent experiments is shown. (C) MAFB mRNA (left panel) 
and MAFB protein (right panel) expression in monocytes differented in the presence of M-CSF. The 
left panel shows the mean ± SD of the MAFB mRNA levels at the indicated time points and relative to 
the levels detected at the 24h time point (n=4; *, p < 0.05). The right panel illustrates the result of one 
of two independent experiments. (D) MAFB mRNA expression in IL34-MØ. Shown is a representative 
experiment run in triplicates by qRT-PCR. Results are indicated as the levels of MAFB mRNA relative 
to the levels of housekeeping HPRT1, TBP and RPLP0 genes. (E) MAFB protein expression levels 
in untreated monocytes (lane -) and monocytes exposed for 48h to ascitic fluids from patients with 
tumors of distinct origin: bladder (lane 1), colon (lanes 2,3,6), stomach (lane 4), ovary (lane 5), bile 
duct (lane 7) and thyroid gland (lane 8). (F) MAFB (green) expression in CD163+ (red) macrophages in 
frozen samples of the indicated homeostatic and pathological tissues. DAPI staining is shown in blue. 
Melanoma #274 refers to a biopsy from a lymph node melanoma metastasis sample.
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Figure 18
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Figure 18. The expression of most M-MØ-specific genes is MAFB-dependent. (A) MAFB protein 
expression in M-MØ after transfection with either siControl or a MAFB-specific siRNA (siMAFB) for 24, 
48 or 72 hours as determined by western blot. (B) Expression of the indicated M-MØ-specific genes in 
siRNA-transfected M-MØ for 24 hours, as determined by qRT-PCR. Results are indicated as the mRNA 
levels of each gene in siMAFB-transfected M-MØ relative to siControl-tranfected cells (n=4; *, p < 0.05; 
**, p < 0.005; ***, p < 0.0005). (C) MAFB protein expression in mouse M-MØ 24 hours after transfection 
with either siControl or a Mafb-specific siRNA (siMafb), as determined by western blot. Two independent 
experiments were performed (#1, #2) and both are shown. (D) Expression of the indicated murine 
M-MØ-specific genes in siRNA-transfected mouse M-MØ, as determined by qRT-PCR. Results are 
indicated as the mRNA levels of each gene in siMafb-transfected M-MØ relative to siControl-tranfected 
M-MØ (n=5; **, p < 0.005; ***, p < 0.0005).
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Figure 19. MAFB controls the global anti-inflammatory transcriptional signature of M-MØ. (A) 
Experimental design. (B) Number of genes whose expression is higher (UP) or lower (DOWN) in 
siMAFB-transfected M-MØ compared to siControl-transfected M-MØ (adjusted p < 0.05). (C) Validation 
of microarray results by qRT-PCR in independent samples of siMAFB-transfected and siControl-
transfected M-MØ (n=4; p < 0.05; **, p < 0.005; ***, p < 0.0005). Results are indicated as the mRNA 
levels of each gene in siMAFB-transfected M-MØ relative to siControl-tranfected cells. (D) CLEC5A 
protein expression in siMAFB-transfected and siControl-tranfected M-MØ, as determined by western 
blot. Shown is one experiment out of three experiments performed on independent M-MØ samples. 
(E) GSEA analysis on the “t statistic-ranked” list of genes obtained from the siMAFB-M-MØ versus 
siControl-M-MØ limma analysis, using the proinflammatory (top) and anti-inflammatory (bottom) gene 
sets previously defined 142. The red arrow indicates the location in the ranked list of those genes whose 
expression is higher in siMAFB-transfected M-MØ, while the blue arrow indicates the location of genes 
with lower expression in siMAFB-transfected M-MØ. (F) Venn diagram analysis of the genes with 
significantly lower expression in siMAFB-transfected M-MØ compared to the genes that best define 
the GM-MØ-specific and M-MØ-specific signatures (genes that are differentially expressed between 
GM-MØ and M-MØ by more than 8-fold, GSE68061) 142. (G, H) CCL2 (G) and IL-10 (H) protein levels in 
culture media from M-MØ transfected with either siControl or siMAFB, as determined by ELISA (n=4 for 
CCL2, n=7 for IL-10; *, p < 0.05). 
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 Notwithstanding the essential role of MAFB in the monocyte/macrophage 
lineage differentiation 119; 120; 125, the gene profile specifically regulated by human MAFB 
remained yet to be unraveled. To identify the whole range of MAFB-dependent genes 
in human macrophages, we determined the transcriptome of MAFB-deficient M-MØ 
(Figure 19A). Defective MAFB expression revealed a significantly (adj p<0.05) altered 
expression of 284 probes (247 annotated genes) in M-MØ (Table VII). Specifically, 
MAFB knockdown led to downregulation of 147 genes and upregulation of 100 genes 
in M-MØ (Figure 19B and Table VII). These results were later confirmed by qRT-PCR 
of selected genes, which showed that MAFB silencing not only reduces the expression 
of M-MØ-specific genes (e.g., IL10, CCL2, EMR1, SLC40A1) but also increases the 
expression of genes associated to GM-CSF-driven pro-inflammatory polarization 
(e.g., CLEC5A) 79 as well as other cell surface receptor-encoding genes (e.g., FPR1, 
ALCAM) (Figure 19C,D). Gene Ontology analysis (ENRICHR, http://amp.pharm.mssm.
edu/Enrichr/) 154; 155 of the genes downregulated upon MAFB knock-down revealed a 
significant enrichment of genes upregulated by IL-10 (adj p=7.4x10-23) and IFNβ (adj 
p=9.8x10-32), but downregulated upon MYB overexpression (adj p=5.8x10-14), thus 
supporting the link between MAFB and the expression of anti-inflammatory genes, and 
in line with the type I IFN rheostat function of MAFB 117 and the competing activities 
of MAFB and MYB on myeloid cell differentiation 98 (Figure 20). Regarding the genes 
whose expression significantly increases after MAFB knock-down, ENRICHR analysis 
revealed a significant enrichment of genes with functional MYB-binding sites (adj 
p=5.1x10-16) as well as vitamin D3- or Retinoic acid-responsive genes (adj p=3.4x10-3 
and 5.4x10-3, respectively) (Figure 20), two compounds that control osteoclast 
proliferation and differentiation 156. Moreover, MAFB knock-down downregulated the 
expression of 69 genes whose mouse orthologous have been identified as MAFB 
targets by ChIP-seq 157 (Figure 21), further supporting the significance of the results.
 Finally, Gene Set Enrichment Analysis (GSEA) was done using the gene sets that 
best define pro-inflammatory GM-MØ- and anti-inflammatory M-MØ-specific signatures 
138; 151. The analysis revealed that MAFB knockdown significantly downregulates the 
expression of the genes within the “M-MØ-specific anti-inflammatory gene set” while 
increases the expression of the “GM-MØ-specific anti-inflammatory gene set” (Figure 
19E). In fact, 19.4% of the genes within the M-MØ-specific gene set (33 out of 170) 
were significantly downregulated upon MAFB knockdown, including genes with known 
anti-inflammatory ability like HTR2B and IGF1 (Figure 19F). Conversely, none of the 
GM-MØ-specific gene set (0 out of 182) were affected by MAFB silencing (Figure 19F). 
These results were validated at the protein level, as MAFB knockdown specifically 
reduced the basal production of both CCL2 (Figure 19G) and IL-10 (Figure 19H) 
from M-MØ. Altogether, the above results demonstrate that MAFB is a critical factor 
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Figure 20. Gene Ontology analysis of genes whose expression is significantly modulated upon 
MAFB knockdown in M-MØ. (A, B) Genes significantly affected by siMAFB knockdown in M-MØ (A, 
downregulated; B, upregulated) were analysed for significant enrichmet of GO terms using the online 
tool ENRICHR. From top to bottom, the following databases were queried: ChEA, Ligand Perturbations 
from GEO, Single Gene Perturbations from GEO and Drug Perturbations from GEO. Color gradient 
intensity illustrates more to less significant hits. As suggested by the ENRICHR website, results are 
represented as ‘Combined score’ (combined score = log(p-value) * z-score). All the GO terms shown 
exhibit adjusted p value<0.05. 
75
CHAPTER TWO
for the acquisition/maintenance of the anti-inflammatory transcriptome of human 
macrophages, as it positively controls the expression M-MØ-specific genes and 
impairs the expression of genes associated to the GM-CSF-directed pro-inflammatory 
polarization. Such a conclusion is also supported by GSEA of the microarray data, 
which revealed a significant enrichment of the “Hallmark-Inflammatory Response” and 
“Hallmark-Interferon gamma response”, “Hallmark-Interferon gamma response” and 
“Hallmark-Interferon alpha response” terms in the genes upregulated after siMAFB 
transfection (FDR q-val = 0) and a significant enrichment of the “Hallmark-Angiogenesis” 
term (FDR q-val=0.011) in the genes downregulated upon MAFB knock-down (data 
not shown). 
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Figure 21. The mouse ortologues of a significant 
number of MAFB-regulated genes cont in Mafb-
binding sites. (A) Comparison of the number of 
genes significantly affected by siMAFB knockdown 
(147 downregulated genes; 100 upregulated genes) 
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and the presence of Mafb-binding sites in the vicinity of their corresponding mouse ortologues, as 
determined by Chip-seq 115. (B) List of M-MØ MAFB-regulated genes whose corresponding mouse 
ortologues include an experimentally verified Mafb-binding site.
B
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RESULTS
The M-MØ-specific macrophage transcriptome is altered in macrophages derived 
from Multicentric Carpo Tarsal Osteolysis monocytes. 
 Addressing the role of MAFB in the adult organism has been hampered by the 
fact that Mafb KO mice die shortly after birth from apnea due to a defect in the neuronal 
development of the respiratory center of the brain 123. Recently, however, mutations 
clustering within the amino-terminal transcriptional activation domain of MAFB have 
been demonstrated to cause Multicentric carpotarsal osteolysis (MCTO, OMIM# 
166300), a very rare autosomal dominant disorder that causes degradation of the 
carpal and tarsal bones in early childhood and eventually evolves to end-stage renal 
failure 133-135; 137. To date, all reported MCTO mutations affect the GSK3 phosphorylation 
sites within MAFB 133-135; 137, and mutations of the homologous region of MAF and NRL 
result in the recently described Aymé-Gripp syndrome (OMIM #601088) and retinitis 
pigmentosa 104, respectively. Since impaired GSK3 phosphorylation of large MAF family 
members leads to extended half-life and weaker transactivation potency 96; 104; 105, we 
hypothesized that MCTO-causing MAFB mutations would modulate MAFB levels and 
activity in human macrophages, thus influencing the anti-inflammatory gene signature 
of M-MØ. To test this hypothesis, we first generated MAFB expression constructs 
with either the Ser54Leu (161C>T) mutation, which was identified in a case of MCTO 
previously characterized only from the clinical point of view (hereafter termed MCTO#1) 
(Figure 22A) 158, the Pro63Arg mutation (188C>G, MCTO#2) 133; 134 or the Pro71Ser 
mutation (211C>T, MCTO#3) 133 (Figure 22B). Transfection of the three MCTO-causing 
MAFB mutants in HEK293T cells revealed their extended half-life upon cycloheximide 
treatment (Figure 22E), with an apparent stronger effect of mutations affecting the 
more C-terminal residues of the GSK3 phosphorylation sequence. This effect is also 
observed in monocytes and M-MØ from MCTO#1 (Figure 22C,D) Besides, and in 
agreement with previous results on MAF and MAFA mutations 96; 105, MCTO MAFB 
mutants exhibited reduced transactivation activity on a MAFB reporter construct 
(Figure 22F). Therefore, MCTO-causing MAFB mutations affect both the stability and 
the transcriptional activity of MAFB. This result is in agreement with previous results 
on other members of the large MAF subfamily, and might explain the increase of 
MAFB protein in the absence of overt changes in MAFB mRNA levels during M-MØ 
differentiation (Figure 17C).
 Having demonstrated that MCTO-causing mutations increase MAFB protein 
stability, we next assessed the effect of enhanced MAFB levels on macrophage anti-
inflammatory polarization through the use of monocyte-derived macrophages from 
MCTO patients. To that end, M-MØ and GM-MØ were generated from the MCTO#1 
patient 158, and the transcriptomic profile of MCTO#1 M-MØ was determined. Comparison 
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Figure 22. Mutations responsible for Multicentric carpotarsal osteolysis affect the stability and 
transcriptional activity of MAFB. (A) Nucleotide sequence of the mutation hotspot in the MAFB gene 
in MCTO. Sequencing of a healthy donor (top) and the MCTO#1 patient (down) is shown. Red arrow 
marks the heterozygous mutation (161C>T) in MCTO#1. (B) Representation of the MAFB protein. Red 
dots indicate amino acids mutated in MCTO. Black arrows indicate the amino acids mutated in the 
MCTO MAFB expression vectors and the amino acids affected in the MCTO#1, MCTO#2 and MCTO#3 
patients. (C-D) MAFB mRNA and protein expression in monocytes (C) and M-MØ (D) from MCTO#1 
and three healthy controls, as determined by qRT-PCR and western blot. (E) MAFB protein levels were 
determined by western blot in HEK293T transfected with the indicated expression vectors after 1-5 
hours of cycloheximide (CHX) treatment. (F) MAFB-dependent MARE-specific transcriptional activity in 
HEK293T cells transfected with the indicated MAFB expression vectors. The MARE-specific luciferase 
activity was determined by expressing the luciferase activity produced by each MAFB construct on the 
3xMARE-Luc reporter relative to the luciferase activity produced by the same expression vector in the 
presence of the promoter-less TATA-pXP2 plasmid. In all cases, the MARE-specific activity of each 
MCTO-causing MAFB mutant is referred to the activity produced by pMAFBwt (arbitrarily set to 1) (n=3; 
*, p < 0.05; For pMAFB161T, p=0.12).  
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Figure 23. MCTO MAFB mutations significantly affect the M-MØ transcriptome. (A) Number of 
genes whose expression is higher (MCTO1>Control) or lower (MCTO1<Control) in MCTO#1 M-MØ 
than in control M-MØ (p < 0.005; adjusted p < 0.192; |log2 fold MCTO#1/Control| > 0.7), as determined 
by microarray analysis. (B) Gene ontology analysis of genes downregulated in MCTO#1, using the 
ENRICHR tool. The results extracted from the indicated databases are shown (combined score = log(p-
value) x z-score). (C) Validation of microarray results by qRT-PCR in M-MØ from the three MCTO 
patients. Results are indicated as mean ±SD of mRNA levels in MCTO M-MØ relative to control M-MØ 
(n=3; *, p < 0.05; **, p < 0.005; ***, p < 0.0005). (D) GSEA analysis of the “t statistic-ranked” list of genes 
obtained from the MCTO#1 M-MØ versus Control M-MØ limma analysis, using the proinflammatory 
(top) and anti-inflammatory (bottom) gene sets previously defined. (E) Data are indicated as mean ±SD 
of mRNA levels in MCTO M-MØ relative to control M-MØ as determined by qRT-PCR (n=3; *, p < 0.05). 
(F) Results from a single experiment are indicated as the mRNA levels in MCTO#1 GM-MØ relative 
to control GM-MØ as determined by qRT-PCR. (G) MCTO#1 and control osteoclasts, as determined 
by phase contrast microscopy on cells stained for TRAP. Two independent experiments were done on 
monocytes from the MCTO#1 patient, and one of them is shown. 
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of MCTO#1 and control M-MØ gene signatures revealed the differential expression 
(adj p<0.19 or p<0.005) of 321 annotated genes, with 231 genes downregulated and 
90 genes upregulated in MCTO#1 M-MØ (Figure 23A, Table VIII). Global analysis of 
the genes with lower expression in MCTO M-MØ revealed a significant enrichment of 
genes containing functional MYB- (adj p=4.5x10-9), MITF- (adj p=7.5x10-13) and JUN-
binding sites (adj p=6.5x10-8) (Figure 23B), a finding that fits with the known inhibitory 
actions of MAFB 99. Further supporting the presence of elevated MAFB levels in MCTO 
M-MØ, the set of genes with lower expression in MCTO M-MØ was also significantly 
enriched in genes whose expression is enhanced by RANKL (adj p=1.9x10-13), a major 
driver of osteoclast generation 99 (Figure 23B). Interestingly, the set of genes with higher 
expression in MCTO M-MØ was enriched in genes downregulated in systemic juvenile 
idiopathic arthritis (adj p=2.5x10-2), a pathology that mimics MCTO 159. Microarray data 
was further validated through qRT-PCR on independent preparations of MCTO#1 
M-MØ as well as in M-MØ generated from additional MCTO#2 and MCTO#3 patients. 
These experiments identified 14 genes whose expression is significantly different 
between control and MCTO-derived M-MØ (Figure 23C). 
The global effect of MCTO-causing MAFB mutations on the M-MØ transcriptome was 
also assessed by GSEA using the gene sets that best define GM-MØ- and M-MØ-
specific signatures 138; 151. As shown in Figure 23D, MCTO#1 M-MØ exhibited a 
significant reduction in the expression of pro-inflammatory (GM-MØ-specific) genes 
as well a significant increase in the expression of anti-inflammatory (M-MØ-specific) 
genes. Specifically, genes like IL10, HTR2B and CD209, whose expression is linked to 
M-MØ polarization, critically contributed to the global increase of the anti-inflammatory 
gene set in MCTO#1 M-MØ (Figure 23D). In fact, the expression of these M-MØ-
specific genes was also significantly enhanced in M-MØ derived from MCTO#2 and 
MCTO#3 (Figure 23E). In line with the GSEA results, the expression of genes that 
best define pro-inflammatory GM-MØ polarization (TNF, CCR2, INHBA, EGLN3) 
138; 152; 160 appeared reduced, while IL10 was enhanced, in GM-MØ from MCTO#1 
(Figure 23F). Moreover, in agreement with the inhibitory effect of the MCTO#1 MAFB 
mutation on the expression of RANKL-regulated genes (Figure 23B), MCTO#1 
monocytes exposed to M-CSF and RANKL exhibited an impaired ability to differentiate 
into multinucleated osteoclasts as shown by microscopy analysis (Figure 23G), the 
expression of osteoclast markers (Figure 24A) and collagen-degradation assays 
(Figure 24B). Altogether, these results indicate that macrophages from MCTO patients 
exhibit an enhanced anti-inflammatory profile and that heterozygous MCTO-causing 
MAFB mutations drive macrophages towards the upregulation of genes associated to 
anti-inflammatory macrophage polarization, thus reinforcing the contribution of MAFB 
to the acquisition and maintenance of the anti-inflammatory gene signature in human 
macrophages. 
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RESULTS
MAFB also influences the LPS responsiveness of human macrophages. 
Since MAFB controls the M-MØ transcriptome under basal conditions, the potential 
involvement of MAFB in the LPS-induced activation of M-MØ was also assessed. We 
have determined that M-MØ exhibit a unique transcriptional response to LPS, which 
is distinct from that of GM-MØ and includes the upregulation of CCL19, ARNT2, 
MAOA and PDGFA (Figure 12, Table III & IV). Knockdown of MAFB altered the LPS-
responsiveness of M-MØ, as it significantly reduced the LPS-dependent upregulation 
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Figure 24. MCTO#1 monocytes exhibit an impaired osteoclast differentiation potential. (A) 
mRNA expression of osteoclast markers of in vitro-generated osteoclasts derived from monocytes from 
MCTO#1. Results from a single experiment are indicated as the mRNA levels in MCTO#1 and two 
healthy control osteoclasts at the indicated times during differentiation relative to TBP mRNA levels as 
determined by qRT-PCR. (B) Human collagen-degradation assay. Results from a single experiment are 
indicated as the intensity of fluorescently-labeled collagen degradation products in MCTO#1 and two 
healthy control osteoclasts. 
81
CHAPTER TWO
of CCL19, ARNT2, PDGFA and MAOA (Figure 25A). In fact, MAFB knockdown 
significantly diminished the LPS-induced expression of IL10 (Figure 25B). By contrast, 
the LPS-mediated increase of these genes was higher in MCTO#1 M-MØ than in 
control M-MØ (Figure 25C), again illustrating the opposite consequences of MAFB 
silencing and MCTO-causing MAFB mutations. Therefore, MAFB also contributes to 
the acquisition of the gene expression profile of LPS-activated M-MØ. 
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Figure 25. MAFB impacts the LPS response of M-MØ. (A) mRNA expression levels in LPS-treated 
(10ng/ml, 4h) siMAFB M-MØ, as determined by qRT-PCR using custom-made microfluidic gene cards. 
Results are indicated as the mRNA levels of each gene in LPS-treated siMAFB M-MØ relative to LPS-
treated siControl M-MØ (n=3; *, p < 0.05; **, p < 0.005; ***, p < 0.0005). (B) IL10 mRNA expression in 
LPS-treated siMAFB M-MØ as determined by qRT-PCR. Results are shown relative to the IL10 mRNA 
level detected in siControl-transfected LPS-treated M-MØ (arbitrarily set to 1) (n=5; *, p < 0.05). (C) 
mRNA expression levels in LPS-treated MCTO#1 M-MØ, as determined by qRT-PCR. Results are 
indicated as the change in the expression of each gene in LPS-treated MCTO#1 M-MØ relative to the 
change of the same gene in LPS-treated control M-MØ. 
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RESULTS
Co-expression of MAFB and MAFB-regulated genes in human macrophages in 
vivo.
 To gain evidences for the pathophysiological significance of the MAFB-dependent 
transcriptome in human macrophages, we next determined whether a correlation 
existed between the expression of MAFB and proteins encoded by MAFB-dependent 
genes in human macrophages in vivo. To that end we performed immunofluorescence 
on melanoma, where accumulation of tumor-promoting and immunosuppressive 
macrophages associates with a poor clinical outcome 161, as well as in other tissues 
(e.g., gut) where macrophages display anti-inflammatory and homeostatic functions 
162. As shown in Figure 26A, co-expression of MAFB and CD163L1 was observed 
in CD163+ macrophages from colon and dermis, where MAFB expression had been 
previously found (see Figure 17F). Moreover, CD163+ tumor-associated macrophages 
from melanoma samples revealed the co-expression of MAFB and the proteins 
encoded by MAFB-dependent genes like HTR2B, CD163L1 and CXCL12 (Figure 
26B). The correlation between MAFB and CD163L1 expression is particularly relevant 
because CD163L1 expression marks anti-inflammatory IL-10 producing tissue-resident 
macrophages in healthy secondary lymphoid organs and gut, and also characterizes 
tumor-associated macrophages in melanoma 79. Therefore, MAFB is a primary driver 
of the anti-inflammatory gene profile of human M-CSF-dependent macrophages, 
and the presence of MAFB-regulated genes provides useful markers for the in vivo 
identification of anti-inflammatory macrophages. 
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Figure 26. Human tissue-resident macrophages co-express MAFB and MAFB-dependent genes. 
(A) Immunofluorescence of MAFB (green) and CD163L1 (L1, red) in tissues, as determined by confocal 
microscopy. Right panel: Correlation between MAFB and CD163L1 expression in CD163+ macrophages. 
Red and blue mark tissues with CD163+MAFB+ or CD163+MAFB- macrophages, respectively. (B) 
Expression of the indicated proteins in samples of primary melanoma (PMel #276). Yellow arrows mark 
CD163+ MAFB+ CD163L1+ HTR2B+ CXCL12+ macrophages, while white arrows mark CD163+ MAFB- 
CD163L1- HTR2B- CXCL12- macrophages. Bottom panels show the positive correlation between 
MAFB expression and the expression of CD163L1, HTR2B and CXCL12 in CD163+ tumor-associated 
macrophages from primary melanoma (Pmel #276), lymph node metastatic melanoma (MMel #274) and 
skin metastatic melanoma (MMel #255) samples.
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Probe log2FC Avg.Exp. t p value adj. p val Gene Symbol
A_23_P17345 -2.2267 14.2667 -20.875 0.0000 0.0051 MAFB
A_23_P202448 -2.4133 10.3833 -18.0454 0.0000 0.0051 CXCL12
A_33_P3215803 -1.89 8.8617 -16.9278 0.0000 0.0051 EMR1
A_33_P3220837 -1.9933 15.64 -16.7766 0.0000 0.0051 MAFB
A_23_P376557 -1.9 10.09 -16.5567 0.0000 0.0051 MMP25
A_33_P3236881 -1.87 11.705 -15.9739 0.0000 0.0053 MINOS1-NBL1
A_23_P25994 -2.61 11.8617 -14.8108 0.0000 0.0063 LGMN
A_23_P164047 -1.81 10.2817 -14.7345 0.0000 0.0063 MMD
A_23_P41217 -1.7067 6.63 -13.3588 0.0000 0.0081 CD200R1
A_23_P210482 -1.5033 14.2017 -12.7094 0.0000 0.0088 ADA
A_33_P3400273 -1.49 7.8783 -12.603 0.0000 0.0088 SELL
A_23_P33723 -1.3367 15.3517 -12.2681 0.0000 0.0088 CD163
A_23_P2431 -1.37 12.885 -12.1283 0.0000 0.0088 C3AR1
A_23_P78037 -1.8067 7.9167 -12.0801 0.0000 0.0088 CCL7
A_33_P3330264 -1.5533 6.71 -11.9528 0.0000 0.0088 CXCL1
A_24_P125335 -2.8967 7.075 -11.8415 0.0000 0.0088 CCL13
A_23_P200073 -1.53 8.9783 -11.841 0.0000 0.0088 PITHD1
A_24_P379750 -1.3733 10.93 -11.7523 0.0000 0.0088 MXD1
A_24_P183150 -1.6567 7.4883 -11.3972 0.0000 0.0102 CXCL3
A_23_P435521 -1.1667 7.3467 -10.8924 0.0000 0.0112 TMEM106A
A_33_P3235053 -1.2433 13.575 -10.6768 0.0000 0.0115 TRIM47
A_33_P3395605 -1.8633 10.3683 -10.6599 0.0000 0.0115 TMEM119
A_23_P152838 -1.67 10.155 -10.5402 0.0000 0.0117 CCL5
A_33_P3712341 -1.3833 6.7317 -10.2985 0.0000 0.0129 CXCL12
A_23_P374322 -1.34 9.66 -10.2836 0.0000 0.0129 LACC1
A_33_P3317580 -1.9167 10.225 -10.0243 0.0000 0.0141 GFRA2
A_23_P152605 -2.57 6.9083 -9.8334 0.0000 0.0149 GSDMA
A_23_P252962 -1.1167 8.195 -9.792 0.0000 0.0149 ITSN1
A_23_P30567 -1.43 6.825 -9.7494 0.0000 0.0149 CRHBP
A_24_P120934 -1.1067 9.15 -9.7161 0.0000 0.0149 GADD45G
A_24_P335305 -1.1367 9.7017 -9.5666 0.0001 0.0158 OAS3
A_23_P167328 -2.7133 9.34 -9.5492 0.0001 0.0158 CD38
A_23_P340848 -1.2333 10.62 -9.4147 0.0001 0.0165 PTGIR
A_23_P46351 -1.0033 6.4383 -9.376 0.0001 0.0166 TDRKH
A_33_P3423941 -1.3633 9.805 -9.2828 0.0001 0.0173 IFITM1
A_33_P3375859 -2.1533 5.9267 -9.0743 0.0001 0.019 CXCR2P1
A_33_P3225512 -1.0167 9.6217 -9.0176 0.0001 0.0194 OAS2
A_33_P3421626 -1.0167 9.7383 -8.8972 0.0001 0.0203 KIAA1147
A_23_P376449 -1.18 9.4433 -8.8294 0.0001 0.0204 XLOC_l2_002049
A_23_P151805 -1.2467 7.1233 -8.775 0.0001 0.0204 FBLN5
A_23_P321388 -1.0533 7.6633 -8.677 0.0001 0.0208 RNF19B
A_23_P204087 -0.9133 9.4933 -8.6385 0.0001 0.0208 OAS2
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A_23_P15146 -1.72 7.6367 -8.6378 0.0001 0.0208 IL32
A_24_P131522 -1.19 6.2783 -8.5918 0.0001 0.0208 ANTXR1
A_33_P3282489 -1.1767 8.205 -8.5298 0.0001 0.0208 GCNT1
A_23_P404821 -1.0433 8.7117 -8.5131 0.0001 0.0208 KIAA1147
A_23_P500381 -1.0933 10.8567 -8.4474 0.0001 0.021 HTR7
A_33_P3370305 -0.9733 7.6267 -8.437 0.0001 0.021 TMEM106A
A_23_P94533 -0.93 15.6817 -8.2637 0.0001 0.0222 CTSL
A_24_P257416 -1.3067 9.7567 -8.2259 0.0001 0.0223 CXCL2
A_23_P81441 -1.2033 12.555 -8.0955 0.0001 0.0236 C5orf20
A_32_P201979 -1.0533 7.6567 -8.0778 0.0001 0.0236 HECTD2
A_24_P173754 -0.86 8.63 -8.0121 0.0002 0.0245 C1orf21
A_33_P3258346 -0.8533 9.5067 -7.9963 0.0002 0.0245 XAF1
A_33_P3331511 -1.48 7.61 -7.9744 0.0002 0.0246 LINC00173
A_23_P143621 -1.35 7.105 -7.935 0.0002 0.0247 CRYBB1
A_33_P3252394 -0.9033 11.3017 -7.9054 0.0002 0.0247 GADD45G
A_23_P68031 -1.15 8.715 -7.8926 0.0002 0.0247 STAT4
A_23_P45871 -1.38 11.7467 -7.8643 0.0002 0.0247 IFI44L
A_33_P3401243 -1.56 10.3233 -7.654 0.0002 0.0278 OLFML2B
A_23_P129064 -1.01 11.1783 -7.4786 0.0002 0.0311 GATM
A_23_P126735 -1.5333 9.4967 -7.4646 0.0002 0.0311 IL10
A_23_P145631 -0.89 9.785 -7.45 0.0002 0.0312 GIMAP6
A_33_P3299898 -1.28 10.7967 -7.4115 0.0002 0.0314 CTSLP2
A_33_P3214586 -0.9333 6.4467 -7.3771 0.0002 0.0314 ARTN
A_23_P87545 -0.7833 14.1983 -7.3744 0.0002 0.0314 IFITM3
A_23_P116942 -0.8933 6.92 -7.3668 0.0002 0.0314 LAG3
A_23_P315364 -1.18 10.9533 -7.3649 0.0002 0.0314 CXCL2
A_24_P140788 -0.8667 8.5 -7.3546 0.0002 0.0314 FGD2
A_23_P205489 -1.0467 9.3933 -7.3179 0.0003 0.032 SLC7A8
A_33_P3348288 -1.24 9.2533 -7.3084 0.0003 0.032 RHOBTB1
A_33_P3317058 -0.7867 8.0867 -7.2914 0.0003 0.0322 STAG3
A_33_P3397840 -1.0133 8.5867 -7.2446 0.0003 0.0328 WIPF3
A_24_P366509 -0.9333 6.8133 -7.2179 0.0003 0.0329 PIK3R6
A_33_P3311863 -0.9267 6.27 -7.189 0.0003 0.0329 AP2A2
A_23_P61466 -1.8567 11.2817 -7.1821 0.0003 0.0329 CD163L1
A_23_P125680 -0.8633 7.915 -7.1501 0.0003 0.0329 TMEM255A
A_23_P167005 -0.8333 10.5 -7.1477 0.0003 0.0329 GPR160
A_33_P3371089 -1.0233 11.595 -7.1365 0.0003 0.0329 SGTB
A_33_P3292679 -0.7933 11.92 -7.0367 0.0003 0.034 SNX6
A_33_P3489737 -1.05 10.2583 -7.0362 0.0003 0.034 NLN
A_23_P35995 -0.8 6.78 -7.0303 0.0003 0.034 CLMP
A_33_P3262124 -1.1333 7.1067 -7.0034 0.0003 0.034 MMP25
A_33_P3234697 -0.8833 12.365 -7.0026 0.0003 0.034 LXN
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A_32_P140139 -1.4967 13.5283 -7.0019 0.0003 0.034 F13A1
A_33_P3411075 -0.8467 12.1833 -6.982 0.0003 0.034 FSCN1
A_24_P33982 -0.7733 11.1167 -6.9695 0.0003 0.034 MILR1
A_23_P89431 -2.5 11.5433 -6.9593 0.0003 0.034 CCL2
A_23_P75800 -0.9467 8.3167 -6.9084 0.0004 0.0346 RAB3IL1
A_33_P3327847 -0.7333 10.9333 -6.8909 0.0004 0.0349 SGPL1
A_24_P932418 -0.87 11.4583 -6.8705 0.0004 0.0352 AP2A2
A_24_P131222 -0.8867 8.7567 -6.8614 0.0004 0.0352 ATP13A2
A_23_P102391 -1.43 10.775 -6.7868 0.0004 0.0358 SLC40A1
A_23_P163567 -1.3167 8.5383 -6.7838 0.0004 0.0358 SMPD3
A_23_P64828 -0.8567 9.8817 -6.78 0.0004 0.0358 OAS1
A_23_P204850 -0.8433 12.1017 -6.7778 0.0004 0.0358 RB1
A_23_P54000 -0.7833 11.595 -6.7767 0.0004 0.0358 SNX6
A_32_P54553 -1.12 6.4433 -6.7711 0.0004 0.0358 USP41
A_33_P3298062 -0.7467 9.6167 -6.7292 0.0004 0.0362 ABCC5
A_23_P105794 -1.0467 9.4367 -6.7247 0.0004 0.0362 EPSTI1
A_23_P7144 -2.76 7.1767 -6.7161 0.0004 0.0362 CXCL1
A_23_P347632 -0.93 9.3317 -6.6999 0.0004 0.0362 MTSS1
A_23_P16953 -0.7967 11.7383 -6.6901 0.0004 0.0362 HTR2B
A_33_P3355230 -0.7567 10.5483 -6.6894 0.0004 0.0362 LAIR1
A_24_P287043 -0.7033 13.375 -6.6429 0.0004 0.037 IFITM2
A_33_P3400389 -0.72 10.47 -6.6239 0.0005 0.0372 SPATS2L
A_24_P15502 -0.7067 12.4867 -6.6007 0.0005 0.0377
A_23_P12554 -1.05 9.275 -6.5137 0.0005 0.0396 PKD2L1
A_33_P3332112 -1.2967 5.8317 -6.5107 0.0005 0.0396 FAS
A_33_P3222451 -1.43 6.6383 -6.5081 0.0005 0.0396 AKT1S1
A_23_P145657 -0.7633 10.125 -6.485 0.0005 0.0402 STAG3
A_33_P3228322 -0.7833 11.6083 -6.4597 0.0005 0.0402 IL18BP
A_33_P3264926 -0.7633 9.185 -6.4582 0.0005 0.0402 SAMD4A
A_23_P105465 -1.04 9.9433 -6.4014 0.0005 0.0418 CMKLR1
A_24_P354724 -0.6933 8.3367 -6.3635 0.0006 0.0423 TAGAP
A_23_P47777 -0.7633 10.215 -6.3425 0.0006 0.0429 9-Mar
A_33_P3346826 -1.2967 6.4883 -6.3164 0.0006 0.043 IL32
A_23_P75071 -0.6833 6.345 -6.3137 0.0006 0.043 KIF20B
A_23_P111583 -0.68 13.51 -6.3094 0.0006 0.043 CD36
A_32_P101860 -0.8833 11.1517 -6.2832 0.0006 0.0435 TMEM106A
A_33_P3380383 -1.4067 13.09 -6.2728 0.0006 0.0435 TIFAB
A_32_P163125 -0.92 10.8833 -6.2724 0.0006 0.0435 SGMS1
A_23_P18452 -2.4567 7.6617 -6.2638 0.0006 0.0436 CXCL9
A_33_P3393821 -0.8267 6.66 -6.2495 0.0006 0.0438 C1R
A_23_P97064 -0.6733 9.2767 -6.2297 0.0006 0.0439 FBXO6
A_23_P168951 -0.67 7.435 -6.2054 0.0006 0.0439 ZHX2
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A_32_P100109 -0.71 7.2983 -6.2043 0.0006 0.0439 REPS2
A_24_P16124 -0.6733 11.68 -6.1964 0.0007 0.0439 IFITM4P
A_24_P66027 -0.94 8.7767 -6.1863 0.0007 0.0439 APOBEC3B
A_23_P27332 -0.8033 12.7817 -6.1835 0.0007 0.0439 TCF4
A_23_P145024 -0.77 8.845 -6.1787 0.0007 0.0439 ADRB2
A_23_P66241 -0.8967 9.4217 -6.1687 0.0007 0.0439 MT1M
A_24_P11315 -0.7667 6.73 -6.1491 0.0007 0.0445 OLFML3
A_23_P150768 -0.8167 12.3683 -6.1083 0.0007 0.0452 SLCO2B1
A_24_P766716 -0.9967 13.8217 -6.0885 0.0007 0.0456 CMKLR1
A_23_P137689 -1.45 10.0083 -6.0599 0.0007 0.0456 OLFML2B
A_33_P3416097 -1.7267 7.0467 -6.0528 0.0007 0.0456 F13A1
A_23_P56734 -0.65 11.485 -6.0447 0.0008 0.0456 HNMT
A_33_P3281795 -0.6567 13.1183 -6.035 0.0008 0.0456 MGLL
A_32_P174572 -0.68 9.6033 -6.0348 0.0008 0.0456 HTR7P1
A_23_P17481 -1.3067 10.7467 -6.0345 0.0008 0.0456 SIGLEC1
A_33_P3232955 -1.5233 8.995 -6.0198 0.0008 0.0456 F2RL3
A_24_P212539 -0.6833 9.485 -6.0165 0.0008 0.0456 GALM
A_33_P3306973 -0.8333 7.79 -6.0161 0.0008 0.0456
A_23_P133868 -0.7233 7.795 -6.0123 0.0008 0.0456 ZKSCAN4
A_23_P7827 -1.4967 9.235 -6.0117 0.0008 0.0456 FAM26F
A_32_P4262 -1.15 6.4317 -5.9917 0.0008 0.0459 C20orf26
A_32_P46214 -0.8133 11.9933 -5.9824 0.0008 0.0459 SLC9A9
A_23_P55270 -0.7533 12.0433 -5.972 0.0008 0.0459 CCL18
A_33_P3253394 -0.7933 12.89 -5.9654 0.0008 0.0459 LAIR1
A_24_P393838 -0.6333 9.15 -5.9623 0.0008 0.0459 TOMM20
A_23_P214222 -0.89 14.7317 -5.9236 0.0008 0.0468 MARCKS
A_33_P3248967 -0.66 9.6733 -5.9163 0.0008 0.0468 MPP5
A_24_P304423 -0.8833 10.8817 -5.9091 0.0009 0.0469 IGF1
A_23_P119478 -1.92 8.92 -5.9052 0.0009 0.0469 EBI3
A_33_P3354607 -1.99 11.755 -5.8665 0.0009 0.048 CCL4
A_23_P29257 -0.8367 9.555 -5.8467 0.0009 0.0483 H1F0
A_24_P59667 -0.76 11.2967 -5.8433 0.0009 0.0483 JAK3
A_23_P100001 -0.9933 6.9367 -5.8266 0.0009 0.0484 FAM174B
A_24_P142118 -0.85 7.6083 -5.8207 0.0009 0.0484 THBS1
A_33_P3316323 -0.6533 12.4767 -5.819 0.0009 0.0484 RBMS1
A_23_P63896 -1.1933 8.5267 -5.8087 0.0009 0.0484 FAS
A_33_P3375368 -0.7067 7.5633 -5.7945 0.0009 0.0488 GPR35
A_32_P44394 -0.9733 6.1233 -5.7861 0.0010 0.0488 AIM2
A_24_P228130 -1.1467 10.95 -5.7759 0.0010 0.0488 CCL3L3
A_23_P67367 -0.8267 8.3833 -5.765 0.0010 0.0488 DHDH
A_23_P13907 -0.84 13.1267 -5.7494 0.0010 0.0492 IGF1
A_23_P252541 -0.6167 11.5083 -5.739 0.0010 0.0493 RAB7B
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A_24_P56194 -0.6233 9.8683 -5.7388 0.0010 0.0493 CREBL2
A_33_P3417452 0.6067 10.17 5.7219 0.0010 0.0498 ZGLP1
A_23_P99397 0.6233 8.155 5.7363 0.0010 0.0493 ZDHHC20
A_23_P152791 0.74 8.9333 5.756 0.0010 0.0491 SLC16A6
A_23_P82929 0.9233 8.7483 5.7661 0.0010 0.0488 NOV
A_24_P124624 0.7033 7.945 5.7671 0.0010 0.0488 OLR1
A_33_P3321657 0.79 9.6183 5.7672 0.0010 0.0488 HSPG2
A_33_P3540143 0.72 11.7933 5.7853 0.0010 0.0488 IL17RA
A_33_P3360942 0.6433 8.1083 5.793 0.0009 0.0488 SCAMP1
A_33_P3272390 0.7367 7.5183 5.8112 0.0009 0.0484 RANBP2
A_32_P180265 0.62 7.77 5.8134 0.0009 0.0484
A_23_P206310 0.7067 12.3733 5.8212 0.0009 0.0484 KIAA0513
A_23_P76823 0.92 7.56 5.8212 0.0009 0.0484 ADSSL1
A_24_P389491 0.67 8.7683 5.8548 0.0009 0.0482 COQ4
A_24_P192914 0.8933 14.5433 5.8588 0.0009 0.0482 AMICA1
A_23_P325690 0.71 6.9583 5.8661 0.0009 0.048 ANKRD35
A_23_P6413 0.85 9.735 5.8997 0.0009 0.0469 SELM
A_23_P154234 0.6333 11.0967 5.9184 0.0008 0.0468 POLE4
A_23_P501722 0.72 8.0767 5.9191 0.0008 0.0468 TSPAN32
A_33_P3394404 0.8067 8.1533 5.9333 0.0008 0.0468 TSPAN32
A_23_P26905 0.63 8.585 5.9401 0.0008 0.0467 POLG2
A_24_P322741 0.82 11.0233 5.9663 0.0008 0.0459 IL10RB
A_33_P3702055 0.7767 10.4317 5.9783 0.0008 0.0459 SLC11A1
A_24_P163237 0.81 7.3083 5.984 0.0008 0.0459 STOX2
A_24_P239811 0.7933 8.9467 5.9939 0.0008 0.0459 UBXN11
A_23_P211212 0.6633 7.355 6.009 0.0008 0.0456 COL18A1
A_32_P88905 0.6433 8.6317 6.0174 0.0008 0.0456
A_33_P3248265 0.66 7.3933 6.0398 0.0008 0.0456 LTB
A_33_P3316878 1.0133 8.8233 6.0475 0.0007 0.0456 CHPF
A_23_P365817 0.65 11.615 6.064 0.0007 0.0456 PPP1R14B
A_23_P38795 1.11 11.485 6.0779 0.0007 0.0456 FPR1
A_33_P3215676 1.06 6.3 6.1066 0.0007 0.0452 MANSC4
A_23_P61487 0.89 6.855 6.1082 0.0007 0.0452 LRRC20
A_23_P105862 0.7133 7.31 6.109 0.0007 0.0452 FRY
A_33_P3209960 0.7433 7.215 6.1298 0.0007 0.0451 RASGRP2
A_23_P97990 0.7967 12.4783 6.1688 0.0007 0.0439 HTRA1
A_23_P350574 0.66 9.1167 6.1799 0.0007 0.0439 FCRLB
A_23_P329152 0.72 8.6667 6.1956 0.0007 0.0439 ILF3
A_33_P3328426 0.8467 11.65 6.2152 0.0006 0.0439 ANO10
A_23_P406438 0.7033 8.485 6.2179 0.0006 0.0439 SRPK2
A_24_P551028 0.8267 8.7 6.2383 0.0006 0.0439 SPOPL
A_33_P3419691 0.6867 7.66 6.2473 0.0006 0.0438 GATS
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A_24_P365327 0.6633 10.665 6.2769 0.0006 0.0435 LSM14A
A_24_P941643 0.95 6.2717 6.323 0.0006 0.043 PLCB1
A_24_P71700 0.7267 10.0733 6.3314 0.0006 0.043 ZBTB47
A_23_P43326 0.8467 9.7367 6.3683 0.0006 0.0423 SPTLC1
A_23_P30275 0.83 9.505 6.3895 0.0006 0.0418 PCYOX1L
A_33_P3225843 0.7233 9.7883 6.3947 0.0005 0.0418 CCDC149
A_23_P97700 0.73 13.7883 6.3996 0.0005 0.0418 TXNIP
A_23_P64058 0.9633 7.2217 6.4595 0.0005 0.0402 RASGRP2
A_23_P166408 0.9233 9.575 6.4722 0.0005 0.0402 OSM
A_33_P3320212 0.7267 7.37 6.5545 0.0005 0.0388
A_33_P3423270 0.85 5.8483 6.5598 0.0005 0.0388 TMEM40
A_23_P90601 1.5067 11.0867 6.6362 0.0004 0.037 STEAP3
A_23_P143147 0.7233 7.6983 6.6624 0.0004 0.0366 TCFL5
A_32_P195401 0.7633 8.4017 6.6829 0.0004 0.0362 FAM117B
A_23_P94095 0.8233 8.045 6.7086 0.0004 0.0362 ANKRD46
A_23_P206733 1.49 8.5483 6.718 0.0004 0.0362 CES1
A_24_P645765 0.8233 7.035 6.7607 0.0004 0.0359 KLHL42
A_32_P56001 0.9667 7.3733 6.776 0.0004 0.0358 CD93
A_33_P3272209 0.8267 8.8 6.7977 0.0004 0.0358 MFSD6
A_33_P3334220 0.7367 7.3383 6.8096 0.0004 0.0358 ACACB
A_23_P28697 0.7433 8.3817 6.9147 0.0004 0.0346 HAAO
A_33_P3244122 0.75 12.2717 6.9463 0.0003 0.034 HAAO
A_24_P252996 0.86 7.29 6.9527 0.0003 0.034 FOLR3
A_23_P77048 0.7567 12.0583 6.9633 0.0003 0.034 SLC25A29
A_23_P133474 1.0367 9.9183 7.0076 0.0003 0.034 GPX3
A_23_P218456 0.81 10.1517 7.0444 0.0003 0.034 ILF3
A_32_P172864 0.7967 9.7917 7.0897 0.0003 0.0336 FAM102B
A_33_P3331451 0.89 6.7317 7.1271 0.0003 0.0329 TGFBR1
A_23_P167276 1.03 7.9417 7.1274 0.0003 0.0329 PAQR3
A_24_P200000 1.0833 7.305 7.1372 0.0003 0.0329 STEAP3
A_23_P34597 1.0533 10.6367 7.1913 0.0003 0.0329 CDA
A_23_P140384 1.65 6.7617 7.1956 0.0003 0.0329 CTSG
A_33_P3286041 1.03 7.5617 7.2714 0.0003 0.0324 POLR3E
A_23_P140668 0.7867 9.0867 7.4023 0.0002 0.0314 IDH3A
A_23_P6099 0.9667 7.0467 7.4804 0.0002 0.0311 PLCB1
A_33_P3222203 0.8933 10.59 7.6506 0.0002 0.0278 OXER1
A_33_P3330608 0.8233 13.3217 7.7763 0.0002 0.0258 PRAM1
A_23_P218549 1.08 6.88 7.8104 0.0002 0.0254 EMR3
A_33_P3394075 1.05 7.7017 7.8705 0.0002 0.0247 RIT1
A_23_P23171 0.9133 7.7733 7.9169 0.0002 0.0247 AGO4
A_23_P104692 0.8433 9.2917 7.9393 0.0002 0.0247 PELI3
A_23_P25503 1.02 12.4133 8.0869 0.0001 0.0236 FNDC3A
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A_23_P152181 0.9667 8.7633 8.1267 0.0001 0.0236 POLR3E
A_23_P304356 1.56 6.6667 8.245 0.0001 0.0222 CLEC5A
A_24_P248053 1.2667 8.7133 8.2627 0.0001 0.0222 TOP1MT
A_32_P19294 1.2967 7.505 8.2685 0.0001 0.0222 GLT1D1
A_24_P916614 0.93 11.6717 8.2947 0.0001 0.0222 PTBP3
A_23_P253791 1.09 7.0783 8.3214 0.0001 0.0222 CAMP
A_23_P62967 0.9633 9.6417 8.468 0.0001 0.021 DISC1
A_33_P3241269 1.7533 12.8 8.5092 0.0001 0.0208 CES1
A_32_P178966 1.0833 9.565 8.5683 0.0001 0.0208 TMEM170B
A_33_P3343210 1.08 6.5267 8.6082 0.0001 0.0208 SLC25A37
A_23_P429977 1.1367 10.965 8.6294 0.0001 0.0208 KCNQ1
A_23_P52676 1.2233 8.6383 8.7577 0.0001 0.0204 CATSPER1
A_24_P32085 0.97 7.4417 8.7619 0.0001 0.0204 MOB3B
A_33_P3713357 1.14 10.6933 8.8421 0.0001 0.0204 ALCAM
A_32_P161762 1.0767 6.485 8.9201 0.0001 0.0203 RUNX2
A_23_P56505 1.0133 7.5833 9.1325 0.0001 0.0187 ITGA4
A_33_P3353816 1.04 9.3233 9.4428 0.0001 0.0165 ITGA4
A_23_P92842 1.1 10.0867 9.8356 0.0000 0.0149 SAR1B
A_23_P122852 1.36 10.5833 10.0014 0.0000 0.0141 SMARCD3
A_24_P64100 1.1033 7.0817 10.1625 0.0000 0.0135 SLC25A37
A_23_P250245 1.5933 7.6767 10.6238 0.0000 0.0115 CD72
A_23_P144959 1.35 6.5817 10.7674 0.0000 0.0115 VCAN
A_24_P196851 1.2067 10.0933 10.8934 0.0000 0.0112 TLN1
A_23_P91390 1.36 10.6333 10.995 0.0000 0.0112 THBD
A_23_P101434 1.6533 6.4733 11.0705 0.0000 0.0112 NLRP12
A_23_P121956 1.2267 8.09 11.3288 0.0000 0.0102 THG1L
A_33_P3210561 1.4367 8.3683 11.9763 0.0000 0.0088
A_23_P304682 1.37 6.7983 12.5537 0.0000 0.0088 EMP2
A_23_P106682 1.51 8.7217 13.0495 0.0000 0.0086 EMP2
A_33_P3350863 1.4567 6.665 13.6752 0.0000 0.0076 RETN
A_24_P347378 1.4767 9.5383 13.8758 0.0000 0.0076 ALOX5AP
A_23_P21485 1.7233 8.0683 14.5693 0.0000 0.0063 PID1
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A_24_P213161 3.26 5.555 18.1618 0.0000 0.0161 NLRP2
A_23_P140384 2.72 5.76 16.5142 0.0000 0.0161 CTSG
A_23_P136683 5.77 12.83 16.31 0.0000 0.0161 HLA-DQB1
A_23_P26325 3.59 7.87 15.1319 0.0000 0.0161 CCL17
A_23_P164773 2.82 6.32 12.3875 0.0000 0.026 FCER2
A_33_P3250612 2.3 5.675 12.0732 0.0000 0.0283 MOCS1
A_23_P3911 2.03 9.505 10.562 0.0001 0.0437 PLXDC1
A_23_P94819 1.735 7.8475 10.3913 0.0001 0.0438 RPH3AL
A_24_P165864 1.69 6.34 10.335 0.0001 0.0438 P2RY14
A_24_P945113 1.87 8.695 9.8538 0.0001 0.048 ACVRL1
A_24_P245379 1.605 6.3775 9.8033 0.0001 0.048 SERPINB2
A_33_P3236881 1.685 13.0325 9.0084 0.0002 0.0554 MINOS1-NBL1
A_33_P3424222 2.235 14.5475 9.0045 0.0002 0.0554 HLA-DQB1
A_23_P119222 1.72 8.685 8.7898 0.0002 0.0573 RETN
A_33_P3350863 1.55 10.03 8.726 0.0002 0.0583 RETN
A_32_P4262 1.605 7.3525 8.6265 0.0002 0.0587 C20orf26
A_33_P3753757 1.445 8.7675 7.8466 0.0004 0.0763 LOC158402
A_24_P31235 1.295 10.1275 7.655 0.0004 0.0816 EIF5A
A_23_P109427 1.495 9.0425 7.4833 0.0005 0.0858 GSTT2
A_33_P3252695 1.22 8.895 7.4711 0.0005 0.0858 CYTL1
A_23_P142631 1.19 8.91 7.2773 0.0005 0.0882 FKBP1B
A_33_P3232557 1.2 7.44 7.2659 0.0006 0.0882 DLGAP3
A_24_P10657 1.28 7.025 7.2572 0.0006 0.0882 SLC44A2
A_23_P360209 1.28 14.385 7.2572 0.0006 0.0882 ND3
A_33_P3281567 1.365 8.7425 6.6268 0.0009 0.1092 CMAHP
A_23_P400378 1.215 11.4925 6.5977 0.0009 0.1094 GPBAR1
A_23_P74252 1.1 8.895 6.3907 0.0010 0.1186 LINC00339
A_23_P10647 1.205 8.6225 6.3718 0.0011 0.1186 CYTL1
A_33_P3316786 1.06 7.48 6.3203 0.0011 0.1186 DACH1
A_23_P30666 1.085 12.6675 6.2655 0.0011 0.1186 TNFRSF21
A_33_P3268472 1.05 13.205 6.2566 0.0012 0.1186 CTSC
A_23_P4160 1.045 6.2875 6.2546 0.0012 0.1186 NBR2
A_23_P43276 1.11 6.125 6.2361 0.0012 0.1186 GPR124
A_23_P76538 1.065 13.9625 6.2234 0.0012 0.1186 TESC
A_23_P351467 1.215 8.6675 6.1978 0.0012 0.1186 CMAHP
A_23_P330461 1.35 7.595 6.1707 0.0012 0.1186 TMC4
A_23_P3963 1.23 9.03 6.1165 0.0013 0.122 CDR2L
A_33_P3412087 1.085 9.9525 6.0145 0.0014 0.128 CCDC170
A_33_P3330549 1.28 7.08 5.9434 0.0015 0.128 SLC44A2
A_33_P3283601 1.155 8.5475 5.8636 0.0016 0.1337 LOC389033
A_33_P3318696 1.275 7.3925 5.8228 0.0016 0.1339 CCBL2
A_32_P224522 1.2 7.44 5.8162 0.0016 0.1339 SLC25A23
A_33_P3221748 1.03 14.035 5.7867 0.0017 0.1339 RUNX3
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A_33_P3392892 0.985 6.4525 5.7816 0.0017 0.1339 ULK4
A_24_P339858 3.2 5.855 5.7793 0.0017 0.1339 C21orf90
A_23_P218579 1.205 8.9475 5.7675 0.0017 0.1339 GLB1L
A_32_P36694 0.965 7.7925 5.7643 0.0017 0.1339 JAZF1
A_23_P19510 2.395 12.4725 5.7443 0.0017 0.1346 HLA-DQB2
A_24_P331560 1.62 6.59 5.7117 0.0018 0.1356 STS
A_23_P126735 0.985 9.5425 5.6532 0.0019 0.1369 IL10
A_33_P3281572 1.04 8.2 5.6359 0.0019 0.1374 CMAHP
A_23_P45871 0.905 8.4775 5.4937 0.0021 0.1422 IFI44L
A_23_P150549 1.315 7.2825 5.4787 0.0022 0.1422 PGA3
A_24_P379820 0.905 7.0175 5.4713 0.0022 0.1424 ITM2C
A_23_P160849 0.875 15.0525 5.4007 0.0023 0.1464 FCER1G
A_23_P44684 0.9 7.37 5.3734 0.0024 0.1486 ECT2
A_23_P127663 0.935 6.7925 5.3565 0.0024 0.1501 PRRG4
A_23_P205489 1.065 10.5925 5.3383 0.0024 0.1503 SLC7A8
A_33_P3289045 1.9 7.265 5.2628 0.0026 0.154 GSTT2B
A_24_P402690 0.88 10.32 5.2436 0.0027 0.1558 ITM2C
A_23_P165989 0.865 6.8375 5.2119 0.0027 0.1566 NEURL2
A_23_P29303 0.915 6.7225 5.2072 0.0027 0.1566 RRP7A
A_23_P140563 1.235 7.6975 5.2026 0.0028 0.1566 TTC23
A_33_P3255677 0.97 6.685 5.2003 0.0028 0.1566
A_33_P3260053 1.28 6.385 5.1752 0.0028 0.1581 AIF1L
A_23_P326893 0.985 6.0975 5.1269 0.0029 0.1593 CCDC151
A_23_P74088 1.715 6.2375 5.1102 0.0030 0.1607 MMP23B
A_24_P397294 0.935 11.5475 5.1052 0.0030 0.1607 LTC4S
A_33_P3387696 1.21 11.065 5.1044 0.0030 0.1607 TMBIM4
A_23_P217917 0.98 9.435 5.0824 0.0031 0.1621 GSTM4
A_33_P3214943 0.92 7.85 5.0804 0.0031 0.1621 SPOCK2
A_24_P243749 0.905 8.2625 5.0748 0.0031 0.1621 PDK4
A_24_P287043 0.86 13.105 5.0535 0.0032 0.1638 IFITM2
A_23_P119196 0.83 10.545 4.9885 0.0033 0.1705 KLF2
A_23_P252193 1.02 8.125 4.9731 0.0034 0.1705 ITGA9
A_23_P423309 1.355 7.8275 4.8863 0.0037 0.1762 PCDH12
A_23_P254842 1.055 9.9175 4.8768 0.0037 0.1765 HDHD1
A_23_P347632 0.865 11.3025 4.8364 0.0038 0.1784 MTSS1
A_24_P354724 0.915 7.9975 4.8259 0.0039 0.1784 TAGAP
A_33_P3276207 1 7.78 4.8155 0.0039 0.1784 NXPE3
A_23_P55356 0.8 8.98 4.8049 0.0040 0.1796 VMO1
A_23_P12733 0.78 7.38 4.8017 0.0040 0.1796 H2AFY2
A_33_P3395081 0.86 6.77 4.787 0.0040 0.1797 ACSM5
A_23_P217269 0.785 16.1425 4.7652 0.0041 0.1806 VSIG4
A_23_P101093 1.005 7.2725 4.7601 0.0041 0.1806 COPZ2
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A_23_P318284 0.845 10.1525 4.7578 0.0041 0.1806 GPD1L
A_24_P382187 0.995 8.2075 4.7107 0.0043 0.1836 IGFBP4
A_23_P357760 1.3 7.095 4.6663 0.0045 0.1881 ARSD
A_24_P129588 0.95 7.3 4.6441 0.0046 0.1902 FFAR4
A_33_P3423570 0.77 10.98 4.6387 0.0046 0.1902 METRN
A_23_P256561 0.77 8.16 4.6263 0.0047 0.1902 TLR6
A_23_P371765 0.98 6.655 4.6258 0.0047 0.1902 SPATC1L
A_24_P373768 0.95 7.29 4.6236 0.0047 0.1902 GIPR
A_23_P94754 0.83 6.595 4.6042 0.0048 0.1909 TNFSF15
A_33_P3358957 0.81 6.365 4.5993 0.0048 0.1909 PAPL
A_23_P41217 1.65 9.09 4.5992 0.0048 0.1909 CD200R1
A_33_P3287611 0.855 7.7025 4.5954 0.0048 0.191 KRT3
A_23_P35444 1.165 6.4575 4.5847 0.0049 0.1912 INA
A_33_P3405068 -0.79 6.625 -4.5768 0.0049 0.1912 NAV1
A_23_P46928 -0.835 8.8475 -4.5769 0.0049 0.1912 PFKP
A_33_P3283828 -0.755 9.5325 -4.5769 0.0049 0.1912 CCDC154
A_23_P393401 -0.78 9.005 -4.5776 0.0049 0.1912 PDXDC2P
A_24_P96961 -0.745 8.4175 -4.5822 0.0049 0.1912 SPSB1
A_23_P254271 -0.87 11.145 -4.6034 0.0048 0.1909 TUBB6
A_33_P3214105 -0.915 6.8975 -4.6123 0.0048 0.1907 ATF3
A_24_P39639 -0.81 7.195 -4.6131 0.0048 0.1907 EXOSC6
A_33_P3223660 -0.865 7.2375 -4.6147 0.0047 0.1907 LINC00476
A_23_P161076 -0.975 6.5525 -4.6295 0.0047 0.1902 CD2
A_23_P106362 -0.88 9.385 -4.6335 0.0047 0.1902 AQP9
A_23_P25674 -0.785 6.6825 -4.6343 0.0047 0.1902 CKB
A_23_P213102 -0.92 7.51 -4.6359 0.0047 0.1902 PALLD
A_33_P3321781 -1.025 9.7025 -4.6418 0.0046 0.1902 FLJ44342
A_24_P673063 -1.21 10.68 -4.679 0.0045 0.1864 FABP5
A_23_P133133 -0.95 8.945 -4.6825 0.0044 0.1863 ALPK1
A_23_P30805 -0.78 10 -4.688 0.0044 0.186 HIST1H4J
A_23_P133293 -1.16 9.36 -4.695 0.0044 0.1853 MCTP1
A_24_P241183 -0.78 7.88 -4.6974 0.0044 0.1853 CLEC2D
A_33_P3362891 -0.795 10.5925 -4.7116 0.0043 0.1836 HNRNPA2B1
A_23_P40956 -1.475 8.2125 -4.7143 0.0043 0.1836 GHRL
A_33_P3245539 -0.855 6.8525 -4.7288 0.0043 0.1822 PNMA1
A_24_P145316 -0.795 7.9875 -4.7301 0.0043 0.1822 DTNBP1
A_23_P212497 -1.005 6.2075 -4.7404 0.0042 0.1813 ACAD11
A_24_P401870 -0.805 9.1975 -4.7463 0.0042 0.1809 C9orf139
A_23_P137665 -0.8 13.355 -4.7498 0.0042 0.1809 CHI3L1
A_33_P3268564 -1.04 8.77 -4.7537 0.0042 0.1807 NCK2
A_23_P157875 -0.885 14.1625 -4.7592 0.0041 0.1806 FCN1
A_23_P143374 -0.8 9.05 -4.77 0.0041 0.1806 NINL
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A_33_P3279708 -0.795 9.7575 -4.7709 0.0041 0.1806 RNU2-1
A_33_P3216890 -1.165 7.0675 -4.7717 0.0041 0.1806 PAG1
A_33_P3718269 -1.07 8.495 -4.7883 0.0040 0.1797 MIR146A
A_33_P3296707 -0.935 6.9375 -4.7903 0.0040 0.1797 FAM127C
A_23_P200728 -0.875 12.9425 -4.7908 0.0040 0.1797 FCGR3A
A_33_P3298024 -0.795 10.1375 -4.8161 0.0039 0.1784 ABCC3
A_33_P3235330 -0.815 6.7075 -4.8176 0.0039 0.1784 MTMR3
A_33_P3645805 -0.845 12.0025 -4.8233 0.0039 0.1784
A_33_P3390107 -1.695 9.9475 -4.8309 0.0039 0.1784 RNA18S5
A_23_P126486 -1.26 9.455 -4.8324 0.0039 0.1784 CROCCP2
A_32_P108655 -1.28 7.04 -4.834 0.0039 0.1784 AK4
A_33_P3324884 -0.845 8.1275 -4.8497 0.0038 0.1781 MICAL1
A_23_P394064 -0.945 6.9775 -4.8557 0.0038 0.1777 PTRF
A_33_P3269069 -1.12 7.49 -4.8629 0.0038 0.1771 HS2ST1
A_23_P102000 -0.825 13.1275 -4.8642 0.0037 0.1771 CXCR4
A_33_P3531828 -0.915 8.9375 -4.8738 0.0037 0.1765 LARS
A_33_P3254380 -0.95 7.26 -4.8832 0.0037 0.1762 SLC9A7
A_23_P14515 -0.86 6.93 -4.8832 0.0037 0.1762 ACOT4
A_23_P12554 -0.795 9.1375 -4.8863 0.0037 0.1762 PKD2L1
A_33_P3308481 -1 6.465 -4.8885 0.0037 0.1762 HYMAI
A_32_P83465 -0.84 15.04 -4.9032 0.0036 0.176 NBPF10
A_33_P3225983 -0.865 7.5725 -4.905 0.0036 0.176
A_24_P67898 -0.95 7.8 -4.9366 0.0035 0.1719 MGEA5
A_32_P86763 -0.92 6.165 -4.9415 0.0035 0.1718 TGM2
A_33_P3338440 -0.95 6.885 -4.9428 0.0035 0.1718
A_33_P3226542 -1.015 9.3775 -4.9471 0.0035 0.1718 SNORD3B-1
A_33_P3255290 -1.34 8.655 -4.9563 0.0034 0.1713 JAKMIP2
A_23_P15146 -1.73 7.56 -4.9581 0.0034 0.1713 IL32
A_33_P3372526 -0.835 6.2625 -4.9681 0.0034 0.1706 MDH1B
A_23_P98350 -1.18 8.455 -4.9737 0.0034 0.1705 BIRC3
A_33_P3336760 -0.84 6.775 -4.9743 0.0034 0.1705 ABCB4
A_23_P125748 -1.025 8.1725 -4.9848 0.0034 0.1705 ZMAT1
A_23_P427760 -0.995 7.8275 -5.0085 0.0033 0.1681 PIWIL4
A_23_P54918 -0.84 8.62 -5.0151 0.0033 0.1677 LDHD
A_33_P3567967 -1.22 10.825 -5.0374 0.0032 0.165 FLJ11292
A_23_P321703 -1.275 9.1625 -5.0451 0.0032 0.1644 BCL2A1
A_33_P3264612 -0.94 9.01 -5.0692 0.0031 0.1621 TPCN2
A_33_P3219572 -0.885 7.1225 -5.0731 0.0031 0.1621
A_33_P3713357 -1.06 9.165 -5.0925 0.0030 0.1618 ALCAM
A_23_P138137 -1.195 8.7075 -5.1311 0.0029 0.1593 OMA1
A_33_P3393766 -1.485 8.6475 -5.1348 0.0029 0.1593 C17orf96
A_23_P47682 -0.88 7.58 -5.1367 0.0029 0.1593 NRIP3
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A_33_P3397795 -0.86 8.3 -5.1516 0.0029 0.1583 PCNXL4
A_23_P210131 -0.965 7.0725 -5.1564 0.0029 0.1583
A_33_P3381943 -1.4 7.095 -5.16 0.0029 0.1583 DMTF1
A_33_P3413962 -0.945 6.3775 -5.1655 0.0028 0.1583 PFKP
A_33_P3228102 -0.97 8.34 -5.1715 0.0028 0.1581 NPHP3
A_23_P56590 -0.855 9.3575 -5.1726 0.0028 0.1581 C1D
A_23_P500271 -0.965 13.9075 -5.1922 0.0028 0.1571 IRF5
A_23_P345942 -0.955 9.0825 -5.2115 0.0027 0.1566 NDUFAF2
A_23_P206806 -0.87 9.09 -5.2132 0.0027 0.1566 ITGAL
A_23_P392942 -0.92 9.47 -5.2239 0.0027 0.1566 MSR1
A_33_P3357580 -0.855 6.6025 -5.2332 0.0027 0.1566 MRTO4
A_24_P152649 -0.89 6.195 -5.2618 0.0026 0.154 LOC644189
A_24_P283341 -0.895 10.4025 -5.2667 0.0026 0.154 MICAL1
A_33_P3325558 -0.935 8.5175 -5.2894 0.0026 0.1523 RABGAP1L
A_24_P68908 -1.075 8.0775 -5.2957 0.0025 0.1521 LOC344887
A_23_P211680 -0.89 7.745 -5.3032 0.0025 0.1518 MLC1
A_23_P203475 -1.43 9.845 -5.3115 0.0025 0.1513 PRKCDBP
A_23_P63209 -1.495 8.3475 -5.3124 0.0025 0.1513 HSD11B1
A_33_P3413701 -1.21 10.16 -5.3142 0.0025 0.1513 ERAP1
A_23_P398491 -1.29 6.395 -5.334 0.0025 0.1503 C15orf57
A_33_P3327956 -0.9 7.9 -5.3348 0.0025 0.1503 ZNF605
A_23_P35066 -0.93 6.345 -5.3482 0.0024 0.1503 SNX7
A_23_P132956 -1.14 9.03 -5.38 0.0024 0.1484 UCHL1
A_23_P103672 -0.95 7.185 -5.4202 0.0023 0.1447 NES
A_23_P97141 -1.06 7.03 -5.4209 0.0023 0.1447 RGS1
A_32_P128258 -1.14 6.615 -5.4443 0.0022 0.143 SIGLEC17P
A_23_P22352 -1.2 9.865 -5.4525 0.0022 0.1427 FRMD4A
A_33_P3399571 -1.635 10.2725 -5.4577 0.0022 0.1427 VNN1
A_33_P3233906 -1.055 6.5925 -5.4612 0.0022 0.1427 RAMP1
A_24_P136551 -0.91 7.135 -5.484 0.0022 0.1422 NPLOC4
A_23_P85693 -0.995 8.8375 -5.4845 0.0022 0.1422 GBP2
A_33_P3368750 -1.36 6.155 -5.512 0.0021 0.1409 PAQR5
A_23_P414913 -0.915 12.3075 -5.5132 0.0021 0.1409 GLIPR2
A_33_P3265956 -1.02 9.3 -5.5275 0.0021 0.1404 CBFA2T2
A_23_P146456 -0.94 7.845 -5.5307 0.0021 0.1404 CTSV
A_33_P3336527 -1.51 7.86 -5.5349 0.0021 0.1404 PDXDC1
A_23_P414958 -0.945 9.1225 -5.5468 0.0020 0.1402 PLXNC1
A_33_P3275255 -0.95 7.58 -5.547 0.0020 0.1402
A_24_P366509 -0.925 6.4325 -5.5511 0.0020 0.1402 PIK3R6
A_24_P351283 -0.925 6.4225 -5.5622 0.0020 0.1402 MREG
A_24_P238143 -0.915 8.2375 -5.5696 0.0020 0.1402 LRRC37A2
A_23_P108948 -1.2 8.26 -5.572 0.0020 0.1402 MREG
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A_23_P75430 -0.94 10.99 -5.6048 0.0019 0.1376 SMCO4
A_33_P3287388 -1.215 9.1225 -5.6098 0.0019 0.1376
A_23_P52207 -1.71 6.48 -5.6113 0.0019 0.1376 BAMBI
A_24_P416997 -0.915 7.4875 -5.6239 0.0019 0.1375 APOL3
A_33_P3361422 -1.03 14.355 -5.6309 0.0019 0.1374 CYP27A1
A_33_P3244931 -0.92 14.67 -5.6477 0.0019 0.1369 DBI
A_33_P3338121 -1.055 7.7875 -5.6553 0.0019 0.1369 LAMB3
A_33_P3514859 -1.8 6.98 -5.664 0.0019 0.1369 LOC100506342
A_23_P34915 -1.255 10.2675 -5.6684 0.0018 0.1369 ATF3
A_23_P99253 -1.31 6.625 -5.6799 0.0018 0.1369 LIN7A
A_23_P50508 -0.995 10.7975 -5.6829 0.0018 0.1369 PLA2G4C
A_33_P3345036 -0.92 6.82 -5.6835 0.0018 0.1369 POMC
A_23_P90626 -1.165 9.7025 -5.7109 0.0018 0.1356 CYTIP
A_23_P44724 -1.12 6.78 -5.7277 0.0018 0.1353 CSRP2
A_23_P129903 -1.185 7.5575 -5.7404 0.0017 0.1346 TRIM16L
A_24_P161293 -0.98 14.05 -5.7605 0.0017 0.1339
A_23_P201808 -1.54 9.405 -5.7636 0.0017 0.1339 PPAP2B
A_33_P3273584 -0.965 7.5475 -5.7758 0.0017 0.1339 SCARNA2
A_33_P3404097 -1.25 12.955 -5.7834 0.0017 0.1339 PGM5P2
A_24_P931443 -0.95 10.195 -5.7876 0.0017 0.1339 GPR68
A_23_P384044 -1.06 6.795 -5.8191 0.0016 0.1339 CNIH3
A_23_P103110 -1.04 6.92 -5.8497 0.0016 0.1339 MAFF
A_32_P168464 -1.04 7.575 -5.8965 0.0015 0.131 CASK
A_23_P111804 -1.02 9.455 -5.9333 0.0015 0.128 PARP12
A_23_P76488 -0.995 11.6925 -5.9357 0.0015 0.128 EMP1
A_23_P210690 -1.005 10.7825 -5.9446 0.0015 0.128 TRIB3
A_33_P3382105 -1.085 9.3925 -5.9472 0.0015 0.128
A_33_P3290443 -1.065 12.5575 -5.9547 0.0015 0.128 SCARNA9
A_23_P59877 -1.26 11.42 -5.9586 0.0015 0.128 FABP5
A_24_P248240 -1.075 6.7875 -5.9795 0.0014 0.128 SYT11
A_23_P426021 -1.025 7.3875 -5.9859 0.0014 0.128 SEL1L3
A_33_P3272231 -0.99 6.955 -5.9944 0.0014 0.128 MFSD2A
A_23_P408094 -1.015 9.0175 -5.9999 0.0014 0.128 MXD1
A_33_P3246833 -1.01 13.88 -6.0281 0.0014 0.128 IL1RN
A_33_P3244998 -1.035 14.1225 -6.075 0.0013 0.1244 ODF2L
A_24_P173754 -0.985 6.6925 -6.0797 0.0013 0.1244 C1orf21
A_23_P78037 -1.005 6.0125 -6.1301 0.0013 0.1216 CCL7
A_23_P50946 -1.205 8.8425 -6.1736 0.0012 0.1186 RAMP1
A_32_P356316 -1.155 13.0675 -6.1814 0.0012 0.1186 HLA-DOA
A_23_P125078 -1.075 11.7075 -6.1924 0.0012 0.1186 SLC26A11
A_33_P3333982 -2.345 13.2925 -6.1958 0.0012 0.1186 PDE4DIP
A_23_P146325 -1.565 7.4025 -6.2344 0.0012 0.1186 ASAP1-IT1
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A_33_P3267263 -1.105 9.9775 -6.2511 0.0012 0.1186 RNVU1-18
A_23_P62764 -1.12 6.57 -6.274 0.0011 0.1186 CCDC28B
A_33_P3289865 -1.075 7.0475 -6.2818 0.0011 0.1186 PLCL1
A_23_P206501 -1.025 7.2225 -6.2824 0.0011 0.1186 CLEC18B
A_33_P3371305 -1.585 7.3025 -6.2882 0.0011 0.1186 LOC644090
A_23_P315364 -1.045 10.4025 -6.3049 0.0011 0.1186 CXCL2
A_33_P3454679 -1.395 7.1125 -6.3246 0.0011 0.1186
A_23_P103932 -1.23 12.65 -6.3287 0.0011 0.1186 FGR
A_33_P3366120 -1.18 11.155 -6.3312 0.0011 0.1186 FLNA
A_23_P46936 -1.45 9.625 -6.3491 0.0011 0.1186 EGR2
A_33_P3342443 -1.205 9.5975 -6.3586 0.0011 0.1186 RASA4B
A_33_P3394140 -1.255 8.4225 -6.4173 0.0010 0.1186 ZMIZ1-AS1
A_23_P50678 -1.235 7.2075 -6.4217 0.0010 0.1186 MATK
A_23_P342131 -1.075 12.1825 -6.5435 0.0009 0.111 CYB561A3
A_33_P3432961 -1.215 6.1525 -6.5549 0.0009 0.111 LOC401320
A_33_P3354604 -2.245 6.6175 -6.5665 0.0009 0.111 CCL4L2
A_33_P3231414 -1.23 10.35 -6.5995 0.0009 0.1094 LILRB1
A_23_P326142 -1.18 6.13 -6.6255 0.0009 0.1092 SND1-IT1
A_23_P82929 -1.705 5.9875 -6.6267 0.0009 0.1092 NOV
A_24_P807031 -1.09 6.895 -6.6405 0.0009 0.1092 ATP6AP1L
A_24_P228130 -1.635 9.8475 -6.6616 0.0008 0.1092 CCL3L3
A_33_P3415191 -2.135 6.0525 -6.7043 0.0008 0.1079 ATP8B1
A_24_P59667 -1.185 10.7425 -6.7196 0.0008 0.1078 JAK3
A_24_P370472 -1.225 15.0225 -6.779 0.0008 0.1042 HLA-DRB4
A_33_P3269803 -1.36 6.195 -6.8258 0.0008 0.1017 CLSTN3
A_23_P420610 -1.19 9.11 -6.8371 0.0007 0.1017 FCHO2
A_33_P3363091 -1.19 7.325 -6.8644 0.0007 0.1009 VAC14
A_23_P55270 -2.295 8.8025 -6.8656 0.0007 0.1009 CCL18
A_23_P17914 -2.09 6.18 -6.8886 0.0007 0.1009 PNPLA3
A_24_P286114 -1.2 11.625 -6.9285 0.0007 0.0994 SLC1A3
A_23_P123853 -1.245 6.6775 -6.945 0.0007 0.0993 CCL19
A_23_P40847 -1.13 6.83 -6.9784 0.0007 0.098 CHST2
A_23_P398566 -1.41 7.105 -7.0751 0.0006 0.0925 NR4A3
A_23_P26024 -1.395 10.1325 -7.1126 0.0006 0.0911 C15orf48
A_23_P376557 -1.49 9.695 -7.1476 0.0006 0.0899 MMP25
A_23_P354805 -1.17 7.33 -7.1849 0.0006 0.0885 KLF12
A_23_P48056 -1.65 6.945 -7.2044 0.0006 0.0883 CKAP4
A_23_P79518 -1.205 7.6475 -7.2122 0.0006 0.0883 IL1B
A_33_P3364869 -1.355 7.4175 -7.2289 0.0006 0.0883 NAMPT
A_23_P146233 -1.275 11.0075 -7.2559 0.0006 0.0882 LPL
A_23_P74609 -1.31 6.315 -7.2711 0.0006 0.0882 G0S2
A_33_P3337896 -1.74 8.63 -7.2852 0.0005 0.0882
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A_33_P3342111 -2.415 6.4425 -7.3272 0.0005 0.0882 ZNF169
A_23_P165598 -1.85 5.9 -7.3605 0.0005 0.0882 DAPL1
A_23_P104464 -1.285 10.6025 -7.4573 0.0005 0.0858 ALOX5
A_33_P3286774 -1.245 6.4725 -7.4915 0.0005 0.0858
A_33_P3474859 -1.405 7.8575 -7.4956 0.0005 0.0858 LINC00537
A_23_P8640 -1.265 6.3975 -7.5265 0.0005 0.0858 GPER1
A_33_P3267799 -1.25 12.87 -7.6762 0.0004 0.0816 LILRB4
A_33_P3323298 -1.84 8.55 -7.6815 0.0004 0.0816 JUN
A_33_P3280502 -1.735 7.1125 -7.7923 0.0004 0.0779
A_33_P3412900 -1.38 7.48 -7.8736 0.0004 0.0761 CBLN3
A_24_P166663 -1.65 8.695 -7.9151 0.0004 0.0753 CDK6
A_23_P150693 -1.725 6.0975 -7.9271 0.0004 0.0753 FJX1
A_32_P61684 -1.475 7.4525 -7.9619 0.0004 0.0753 PAG1
A_33_P3296181 -1.66 8.615 -8.1221 0.0003 0.0692 CCL3L3
A_23_P209954 -1.6 6.11 -8.1237 0.0003 0.0692 GNLY
A_33_P3242543 -1.435 6.8425 -8.2866 0.0003 0.0646 MAOA
A_23_P42718 -3.455 7.3125 -8.2964 0.0003 0.0646 NFE2L3
A_33_P3234697 -1.39 10.675 -8.3486 0.0003 0.0643 LXN
A_33_P3405424 -1.965 13.0125 -8.4373 0.0003 0.062 IL4I1
A_23_P208182 -2.05 6.56 -8.4805 0.0003 0.0615 SIGLEC10
A_23_P57667 -1.425 11.2175 -8.5177 0.0002 0.0612 PLXNA1
A_33_P3233645 -1.755 9.5225 -8.6184 0.0002 0.0587 MT1G
A_33_P3376821 -1.64 5.85 -8.6776 0.0002 0.0587 GZMA
A_23_P211561 -1.435 8.5275 -8.8385 0.0002 0.0568 MEI1
A_23_P134176 -1.635 13.2025 -8.9076 0.0002 0.0557 SOD2
A_33_P3265016 -1.53 7.625 -8.9534 0.0002 0.0554 PEX6
A_23_P165624 -1.63 7.405 -8.991 0.0002 0.0554 TNF-αIP6
A_24_P299685 -2.045 6.3025 -9.1168 0.0002 0.0551 PDPN
A_33_P3342628 -1.57 6.555 -9.1412 0.0002 0.0551 HES4
A_23_P42144 -1.86 8.635 -9.344 0.0002 0.0509 PEX6
A_33_P3229918 -1.625 7.9125 -9.4481 0.0001 0.0493 PTCRA
A_33_P3367850 -2.235 7.0575 -9.5189 0.0001 0.0486 CHRM4
A_23_P138541 -2.115 7.1525 -9.5419 0.0001 0.0486 AKR1C3
A_33_P3368313 -1.94 8.445 -9.6121 0.0001 0.0486 MT1H
A_23_P44421 -1.77 7.535 -9.6871 0.0001 0.048 HTRA4
A_33_P3398912 -1.68 11.1 -9.6909 0.0001 0.048 SLC2A6
A_32_P187617 -2.28 7.28 -9.7278 0.0001 0.048 TDRD3
A_24_P355145 -1.84 6.66 -9.7714 0.0001 0.048 DNAJC5B
A_33_P3316273 -1.84 12.945 -9.8202 0.0001 0.048 CCL3
A_23_P116694 -1.88 16.005 -10.241 0.0001 0.0444 RPS26
A_33_P3242623 -3.005 7.9875 -10.3906 0.0001 0.0438 SLC7A11
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A_32_P206839 -2.035 7.9875 -10.6618 0.0001 0.0433 LOC100288911
A_23_P122724 -2.13 11.995 -10.7029 0.0001 0.0433 VNN2
A_24_P233786 -1.995 9.7525 -11.3534 0.0001 0.0339 FAM129A
A_33_P3280157 -2.065 6.0675 -11.566 0.0001 0.0322 SNORD116-19
A_32_P105083 -2.135 7.2775 -11.7948 0.0000 0.0304 FTCDNL1
A_33_P3286157 -2.22 10.475 -12.7549 0.0000 0.0236 TNFRSF4
A_24_P353638 -2.125 11.3025 -12.8211 0.0000 0.0236 SLAMF7
A_23_P140290 -2.65 8.375 -13.4742 0.0000 0.0199 RTN1
A_24_P289404 -2.195 13.3825 -13.5291 0.0000 0.0199 RPS26
A_33_P3401902 -3.835 5.4775 -13.7896 0.0000 0.0199 ANKRD20A2
A_24_P49597 -2.29 9.03 -13.8329 0.0000 0.0199
A_23_P252082 -2.315 12.5025 -13.9486 0.0000 0.0199 TMEM176A
A_33_P3351180 -2.63 5.99 -15.0554 0.0000 0.0161
A_33_P3346327 -2.525 6.3825 -15.1127 0.0000 0.0161 KGFLP1
A_23_P23639 -2.635 7.1775 -15.123 0.0000 0.0161 MCOLN2
A_23_P157007 -2.68 12.96 -15.4975 0.0000 0.0161 TMEM176B
A_24_P852756 -3.5 10.265 -20.5929 0.0000 0.0111 HLA-DQA2
A_24_P281395 -3.62 7.675 -21.0311 0.0000 0.0111
A_23_P152605 -5.43 6.58 -21.4537 0.0000 0.0111 GSDMA
Table VIII. Probes and annotated genes with altered expression in MCTO#1 M-MØ
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 Macrophages exhibit a huge phenotypic and functional heterogeneity (Figure 1, 
Table I). The macrophage ability to regulate development, homeostasis and repair is 
tissue-specific, a feature that reflects the existence of tissue-specific transcriptional 
signatures shaped by the local microenvironment 21; 25; 49; 63; 163. This functional 
heterogeneity of macrophages is also evidenced by their capability to both initiating 
and resolving inflammation 28; 30; 32; 33. Deregulation of macrophage functions leads 
to the onset of pathology 74 and, therefore, the determination of the molecular basis 
of macrophage functional heterogeneity should pave the way for the development 
of tissue-specific therapies for chronic inflammatory disorders 164. In fact, numerous 
current clinical trials target either macrophages or the factors that directly regulate their 
polarization state 51; 164. Further refinement and improvement of these trials require a 
detailed knowledge of the molecular mechanisms underlying macrophage polarization 
and function. 
 This PhD thesis addresses the study of the transcriptional profile of human 
macrophages that have been primed with M-CSF under homeostatic, pathologic 
and activating conditions. We have determined the transcriptome of M-MØ after a 
short-term exposure to activating agents (TLR ligands), and describe a novel gene 
set that exclusively identifies human IL-10-producing activated macrophages both in 
vitro and in vivo. The activated-M-MØ gene set includes growth factors (e.g., BMP6, 
PDGFA), signaling molecules (e.g., SOCS2) and chemokines (e.g., CCL19), whose 
co-expression is observed in vivo and depends on stimulus-induced phosphorylation 
of ERK and p38MAPK. Furthermore, we have described the whole range of MAFB-
dependent genes in IL-10-producing anti-inflammatory M-MØ. The analysis of the 
MAFB-dependent gene set, combined with the gene signature of macrophages derived 
from MCTO patients, has allowed us to demonstrate that the MAFB transcription factor 
controls the acquisition of the transcriptional signature and effector functions that 
characterize anti-inflammatory human macrophages both in vivo and in vitro. 
 Human M-MØ activation
 Several recent reports have demonstrated the validity of the “spectrum model” 
of macrophage polarization 28; 72, which implies that macrophages in tissues (tissue-
resident and incoming) can display a wide array of activation states whose acquisition 
is ultimately driven by the integration of signals from surrounding extracellular stimuli, 
cytokines and factors controlling macrophage differentiation 74; 77. However, the 
analysis of the transcriptional macrophage heterogeneity and the various macrophage 
activation states 72; 75; 95; 165 have been mainly adressed on mouse tissue-resident cells 
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and on macrophages primed towards the pro-inflammatory side, mostly after long-term 
exposure to activating stimuli 72. Therefore, it is of utmost importance to determine 
the factors that underlie human macrophage heterogeneity under homeostatic and 
pathological conditions and to define the transcriptional basis of other alternative 
modes of human macrophage activation. 
 Nevi are very common bening tumors of melanocytes 166-168. Nevi and mostly 
diplastic nevi are risk factors for the development of melanoma, as well as familial 
history and ultra-violet radiation 167. Even though nevi are considered as risk factors, 
the development of melanoma from a diplastic nevus rarely occurs 167. The diagnosis of 
melanocytic lesions depends on semiquantitative observations of five different features: 
assymetry, border irregularity, color, diameter and evolution. Indeed, according to 
these parameters, benign diplastic nevi usually exhibit melanoma features and may 
lead to misdiagnosis 166-168, what calls for additional studies to establish clearer criteria 
for recognizing high-risk lesions. Expression of proteins encoded by the activated-M-
MØ gene set has been found in macrophages in gut (colon submucosa), skin, nevus 
and melanoma. The expression of the activated-M-MØ gene set in colon and skin 
CD163+ macrophages might be related to the fact that, unlike other tissues, resident 
macrophages in colon and skin are replenished by monocyte-derived macrophages 
7; 74; 169. In the case of nevi, the co-expression of the four proteins CCL19, SOCS2, 
BMP6 and PDGFA suggests that, like TAM 161; 170, macrophages in nevi might exhibit 
an anti-inflammatory (trophic and immune-regulatory) profile. Although no detailed 
phenotypic characterization of macrophages within nevi has yet been reported, it is 
posible that the population of proliferating melanocytes in nevi might also skew the 
polarization of surrounding macrophages towards the anti-inflammatory/trophic side. 
Alternatively, melanocytic nevi display several properties of senescent cells (activated 
BRAF expression, proliferative arrest, and expression of p16INK4A and senescence-
associated acidic β-galactosidase) 171, whose clearance is executed by macrophages 
both during development 172; 173 and within tumors 174; 175. Since senescent cells release the 
alarmin HMGB1 176, a ligand for TLR2, TLR4 and TLR9 177; 178, it is tempting to speculate 
that the expression of the activated M-MØ gene signature in CD163+ macrophages 
in nevi is driven by senescent melanocyte-derived HMGB1. This hypothesis is in line 
with the recent demonstration that HMGB1 drives IL-10 production in M-CSF+IL-4-
polarized mouse macrophages and that low HMGB1 expression correlates with low 
levels of CD163+ cells and absent IL-10 expression in human nevi 179. 
 The presence of the CCL19 and SOCS2 genes within the activated-M-MØ 
gene set, and their exclusive expression in IL-10-producing human macrophages, is 
specially worth noting as they might significantly contribute to the immunosuppressive 
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and anti-inflammatory actions of activated M-MØ. CCL19 encodes a ligand for CCR7 
180, the chemokine receptor that determines T lymphocyte recirculation and dendritic 
cell migration into lymph nodes 181. Although the two known CCR7 ligands (CCL19 and 
CCL21) are equally capable of promoting intracellular signaling, only CCL19 binding 
to CCR7 leads to receptor desensitization 182-185. Therefore, CCL19 produced by 
activated M-CSF-primed macrophages might impair emigration of dendritic cells and 
T lymphocytes from tissues towards the lymph nodes, thus inhibiting the generation 
of immune responses. This activity would be compatible with the immunoregulatory 
(IL-10-producing) ability of activated M-CSF-dependent macrophages. Besides, since 
both GM-MØ and M-MØ upregulate CCR7 upon LPS stimulation but CCL19 is only 
produced by LPS-stimulated M-MØ, this differential expression might constitute an 
autocrine mechanism for preventing CCR7-dependent anti-inflammatory macrophage 
motility and emigration from inflamed tissues.  
 Regarding SOCS2, which encodes the Suppressor of Cytokine Signalling 2 
(SOCS2) protein 186, its differential regulation in GM-MØ and M-MØ might contribute 
to the distinct cytokine and gene profile of both macrophage subtypes under resting 
and activated conditions. In agreement with its STAT5-mediated GM-CSF inducibility 
186, SOCS2 mRNA levels are higher in GM-MØ than in M-MØ (Table III). However, 
although SOCS2 is upregulated after TLR activation in human monocyte-derived 
dendritic cells 147, its expression is greatly upregulated by LPS only in M-MØ. In fact, 
LPS-activated M-MØ exhibit significantly much higher levels of SOCS2 than GM-MØ 
or LPS-activated GM-MØ (Table III). This is particularly relevant because SOCS2 acts 
as an anti-inflammatory factor that promotes TRAF6 degradation 187, inhibits TLR4 
signaling in macrophages 146, mediates the anti-inflammatory actions of lipoxins 188; 
189 and Interferon type I 145, and its levels are diminished in inflammatory pathologies 
190. Therefore, the higher levels of SOCS2 in GM-MØ (compared to M-MØ) might 
promote a stronger TRAF6 degradation and, consequently, the weaker LPS-induced 
phosphorylation of the three MAPK we have observed in GM-MØ (Figure 9). Along the 
same line, and if the same mechanism holds true after LPS treatment, the elevated 
levels of SOCS2 could favor the attainment of a state of refractoriness to TLR stimulation 
in LPS-activated M-MØ.
 The induction of growth factors like BMP6 and PDGFA in activated M-MØ 
highlights a different functional aspect of M-CSF-primed macrophages. Tissue 
resident macrophages are known for their critical homeostatic and trophic roles during 
tissue development as well as tissue maintenance and repair after injury in the adult 
organism. Besides, the trophic roles of macrophages are known to promote tumor 
growth and metastasis 191. In this regard, PDGFA is expressed in neural, lung and 
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intestinal tissues during development where it regulates proliferation, migration and 
tissue remodeling 192. Moreover, the PDGF family has long been recognized as having 
a critical role in tumorigenesis. In fact, several PDGF signaling antagonists have been 
developed to treat a variety of malignant diseases 193 and recent reports show success 
in the use of sunitinib, a PDGFR kinase inhibitor, in the treatment of melanoma 193; 
194. Therefore, the production of PDGFA by in vivo nevus-associated macrophages 
might contribute to the progression of skin proliferative diseases. Indeed, PDGFA from 
melanoma conditioned-media is responsible for the activation of fibroblasts that leads 
to hyaluronan deposition and metalloproteinase secretion, which promote melanoma 
cell growth and metastasis 195; 196.  
 BMP6 regulated systemic iron homeostasis by inducing the hormone hepcidin, 
which leads to increased intracellular iron in cells by binding and driving the degradation 
of the iron exporter SLC40A1 (ferroportin) 197; 198. Iron is essential for electron 
exchanges in core biological cellular processes, such as the electron transport chain 
to produce ATP in mithochondria or the production of ROS in inflammation 199. Thus, 
iron availability affects cell growth and inflammatory responses 200; 201. Tumor cells are 
especially dependent on iron to maintain their high proliferation levels and are able to 
reprogram iron metabolism to favor iron influx 202. Therefore, the presence of BMP6 in 
nevus and melanoma macrophages might reflect a mechanism whereby proliferative 
cells promote BMP6 production by macrophages in order to favor tumor growth. This 
is further supported by the elevated levels of BMP6 found in serum from breast cancer 
patients 203. Moreover, increased intracellular iron has an anti-inflammatory effect on 
macrophages 201; 204 from which tumor cells also benefit. In fact, in vitro activated M-MØ 
not only upregulate BMP6, but also downregulate SLC40A1 and, contrarily, GM-MØ 
upregulate SLC40A1 upon LPS stimulation (Figure 11D and Table III). Altogether, 
redirecting iron metabolism by inducing BMP6 expression in macrophages might be an 
advantageous strategy of malignant cells to sustain tumor development. 
 ARNT2 (aryl hydrocarbon receptor nuclear translocator 2) is a member of the 
bHLH-PAS family that includes AHR, HIF and SIM transcription factors 205. ARNT2 is a 
close homolog of ARNT, however, their expression patterns differ greatly 205; 206. ARNT 
is ubiquitously expressed whereas ARNT2 is only expressed in neurons and kidney 
and its functions remain nowadays mostly unknown 205; 206. In the nervous system 
ARNT2 has been described to dimerize with SIM1 and NPAS4 to regulate appetite and 
neuronal firing and Arnt2 ablation in mice results in perinatal death, similar to mice with 
a targeted mutation in SIM1 205; 206. HIF1A has also been shown to form active dimers with 
ARNT2 and likely affect hypoxia responses in neurons 206; 207. In vitro assays originally 
showed a similar capacity of ARNT and ARNT2 to bind to AHR and induce transcription 
107
DISCUSSION
of CYP1A1 after TCDD activation of AHR 208. However, later studies carried out in cell 
lines revealed that ARNT2 is not able to induce AHR-dependent transcription 209. It has 
been suggested that different AHR ligands might induce different AHR conformations 
that in turn affect its affinity to bind ARNT and ARNT2 210. Thus, different cellular contexts 
could modulate AHR dimerization to different partners. Nonetheless, this issue has not 
been further addressed. Surprisingly, unlike ARNT, ARNT2 is expressed at low levels 
in steady state M-MØ and is greatly induced upon activation of M-MØ, whereas its 
expression in GM-MØ is very low (TableIII, Table IV, Figure12A). Besides, HIF1A is 
more highly expressed (2-fold) in M-MØ than GM-MØ, both under steady state and 
LPS-stimulating conditions (see Table III). We previously reported that an increase in 
HIF1A in M-MØ exposed to hypoxia primes M-MØ to increase the production of pro-
inflammatory cytokines after a successive activation with LPS 211. Regarding AHR, 
its expression is slightly higher in M-MØ, but is downregulated upon LPS stimulation, 
and our preliminary results show that AHR has different roles in the regulation of the 
polarization and LPS response of GM-MØ and M-MØ (data not shown). All things 
considered, this is the first time, to our knowledge, that ARNT2 expression has been 
reported in leukocytes and we hypothesize that ARNT2 might have an unexpected 
role in macrophage polarization and activation through regulation of HIF1A and AHR 
function. 
 Altogether, the definition of the transcriptomic profile of activated M-MØ after a 
short exposure to LPS has allowed us to expand our knowledge on the regulation of 
the characteristic anti-inflammatory response of M-MØ.
 MAFB-directed human macrophage anti-inflammatory polarization
 The importance of the transcription factor MAFB in development and homeostasis 
is widely accepted. MAFB is critical for the development of the hindbrain, pancreas, 
kidneys, cartilage and lymphatic vessels (see Figure 4) 101; 108-110; 112; 113. Moreover, 
maintenance of kidney and pancreas functions are dependent on MAFB 110; 114, and 
its function as an oncogene in multiple myeloma has been described 212-214. In murine 
monocytes and macrophages, MAFB has been established as a master regulator of 
their differentiation 121; 125. Nonetheless, the available knowledge about the genes and 
functions in macrophages that are regulated by MAFB is surprisingly limited. This might 
be mostly due by the fact that MAFB deficient mice die shortly after birth 123, making 
the work with murine models very cumbersome. All things considered, and knowing 
that MAFB was preferentially expressed in M-MØ compared to GM-MØ (Figure 17), 
we decided to determine the genes and functions regulated by MAFB in human anti-
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inflammatory macrophages under steady-state and activating conditions. Moreover, 
we validated our results with macrophages derived from MCTO patients that carry 
mutations in the transactivation domain of MAFB, what constitutes an excellent genetic 
tool to further study the role of MAFB in human macrophage biology. 
 In addition to reported genes regulated by MAFB in mouse myeloid cells, like 
CCL2 100, and in line with the preferential expression of MAFB in IL-10-producing 
macrophages, the MAFB-dependent transcriptome of human M-MØ under resting 
conditions includes genes with known anti-inflammatory effects as well as genes 
whose expression is associated with the acquisition of anti-inflammatory activity by 
human macrophages (Table VII). Among the first group it is worth mentioning IL-
10, the paradigmatic anti-inflammatory cytokine 215, CCL2, that recruits monocytes 
towards inflamed tissues and impairs the production of inflammatory cytokines 152; 216; 
217, and HTR2B, whose ligation skews macrophage differentiation towards the anti-
inflammatory side 150. The presence of CD163L1 within the MAFB-dependent gene set 
is especially relevant because CD163L1 expression primarily marks tissue-resident 
macrophages with IL-10-producing ability 79. In fact, the presence of CD163L1 on 
macrophages appears to be concomitant with that of the CD209 lectin, a receptor 
whose ligation also potentiates IL-10 production from macrophages 38. Along the same 
line, MAFB also positively regulates the expression of the EMR1 gene, whose mouse 
ortologue (the F4/80 receptor-encoding Emr1 gene) is required for the induction of 
regulatory T cells in peripheral tolerance 218 and whose expression depends on the 
Mafb-heterodimerizing factor c-Maf 113; 219. Conversely, MAFB negatively regulates 
the expression of genes associated to pro-inflammatory polarization like CLEC5A, 
which codes for a lectin preferentially expressed in TNF-α-producing macrophages 
in secondary lymphoid organs and in lamina propria macrophages from inflammatory 
bowel disease patients 79. The gene ontology analysis of the transcriptome of MCTO 
and siMAFB-transfected M-MØ has lent further support to the link between MAFB 
expression and macrophage anti-inflammatory polarization. GSEA revealed that 
MAFB knockdown leads to a global downregulation of genes preferentially expressed 
in anti-inflammatory macrophages (“anti-inflammatory gene set”) and to a significant 
upregulation of the “pro-inflammatory gene set”. Furthermore, and in agreement with 
the higher half-life of MCTO-causing MAFB mutants, the MCTO M-MØ gene signature 
shows the opposite effect, with a global upregulation of the “anti-inflammatory gene 
set”. Besides, the set of genes positively regulated by MAFB is significantly enriched 
in genes upregulated by IL-10 and downregulated upon IL10 gene ablation (Figure 
20). All the above findings indicate that MAFB controls the expression of a large set of 
molecules that either contribute, or are associated to, the anti-inflammatory ability of 
IL-10-producing human macrophages (IL-10, CCL2, HTR2B, CD163L1, EMR1), thus 
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identifying MAFB as a critical determinant for the acquisition of the anti-inflammatory 
profile of steady-state human macrophages.
 Moreover, MAFB confers anti-inflammatory ability to M-MØ also under activating 
conditions, such as LPS stimulation (Figure 25). MAFB-deficient M-MØ exhibit a 
decreased expression of IL10 after LPS treatment. Furthermore, MAFB positively 
regulates the induction of the activated-M-MØ gene set described in Figure 12. 
Specifically, LPS-mediated induction of CCL19 and PDGFA, which are expressed 
in nevus-associated macrophages, is dependent on MAFB whereas MCTO-derived 
M-MØ have an increased induction of CCL19 and PDGFA as compared to controls. 
Together, these results hint at a role for MAFB in the regulation of the response to an 
inflammatory challenge by macrophages and highlight the increased anti-inflammatory 
potential of MCTO-derived M-MØ. However, whether MCTO patients show an impaired 
ability to deal with infectious diseases or alergies has not yet been addressed.
 Recently, fate-mapping studies on the murine macrophage ontogeny concluded 
that tissue-resident macrophages in the brain, epidermis, liver and lungs have 
an embryonic origin and are not replenished by monocytes in the steady state 7-12, 
whereas tissue-resident macrophages in the intestine, dermis, heart, pancreas 
and peritoneum are monocyte-derived 2-6. These observations lead to questioning 
whether macrophages from various origins would have specific functions dictated by 
particular differentiating factors. In this regard, and as shown in Figure 26, we have 
seen expression of MAFB in human tissue-resident macrophages from the colon and 
dermis, whereas macrophages from placenta and liver samples don’t have detectable 
levels of MAFB. This observation is intriguing since all of the above macrophage 
populations are tissue-resident, homeostatic macrophages and dependent on CSF1R 
ligands for their differentiation 51; 54. However, only macrophages from tissues where 
continuous replenishment by monocytes occurs (colon and dermis) are MAFB-
positive, as opposed to tissues where resident macrophages have been described 
to be of embryonic origin (placenta and liver). We therefore surmise that MAFB might 
not only define anti-inflammatory macrophages, but it might specifically mark anti-
inflammatory/homeostatic macrophages that derive from monocytes in humans in vivo. 
This hypothesis would also be in agreement with the known ability of MAFB to restrict 
myeloid cell proliferation 121 and the fact that murine tissue-resident macrophages that 
have an embryonic origin are known to self-renew 9; 13-15. 
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 Pathological relevance of MAFB-driven macrophage polarization
 Although we have used MCTO-derived macrophages mainly as a genetic tool 
to unravel the role of MAFB in anti-inflammatory human macrophage polarization, the 
information we have gathered on macrophages derived from MCTO monocytes might 
shed light on the pathogenic mechanisms operating in MCTO and other diseases that 
share either similar etiologies, such as diseases caused by mutations in MAFB or other 
MAF familiy members, or similar symptoms, namely diseases where osteolysis is a 
defining pathological feature. Duane retraction syndrome 126, Aymé-Gripp syndrome 
104, and retinitis pigmentosa 220 are caused by MAFB loss of function, MAF and NRL 
mutations, respectively. Specifically, mutations that cause Aymé-Gripp syndrome and 
retinitis pigmentosa cluster in the same homologous region as MCTO mutations, which 
is necessary for GSK3 phosphorylation of MAF family members. Thus, the study of 
MCTO-derived macrophages may allow us to unravel the pathological consequences 
of a deffective GSK3 function. Alternatively, other rare osteolytic syndromes exist that, 
despite extensive efforts, have yet unknown causes, namely, Multicentric osteolysis, 
nodulosis and arthropathy (MONA, OMIM #259600), Winchester syndrome (OMIM 
#277950) and Gorham-Stout disease (OMIM #123880). The osteolysis observed in 
these diseases and in MCTO might be due to common misregulated mechanisms 
for which the study of MCTO-derived macrophages and osteoclasts may be of great 
value. 
 In the case of MCTO, we have identified a number of genes whose expression 
is altered not only in MCTO-derived macrophages but also in peripheral blood 
monocytes from the three analyzed MCTO patients (data not shown). Although 
analysis of additional patients is still required to propose their use as potential MCTO 
diagnostic markers, a disease commonly misdiagnosed 159, our results suggest that 
MCTO-causing mutations impact on the generation of monocytes and affect their later 
differentiation into fully functional tissue-resident macrophages, as exemplified by their 
inability to differentiate into functional osteoclasts in response to M-CSF and RANKL 
in vitro. Whether the profound anti-inflammatory skewing of MCTO-derived M-MØ is 
responsible for their inability to generate osteoclasts in vitro is an issue that we are 
currently pursuing. Along the same line, the genes downregulated in MCTO-derived 
M-MØ include a significant proportion of MYB- and ZXDC-regulated genes, two factors 
that participate in monocyte-to-macrophage differentiation, M-CSF-driven macrophage 
polarization 221; 222 and even positive regulation of CCL2 gene expression 221. 
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 MMP25 expression is downregulated in siMAFB-transfected M-MØ and in MCTO 
M-MØ. This feature resembles the ability of mouse Mafb to control the expression of 
MMP-9 and -12 in alveolar macrophages 131, and MMP-13 in neonatal chondrocytes 
112. The MAFB-MMP-25 link might also have pathological relevance because MMP-
25 directly activates MMP-2 223, a metalloproteinase whose mutation is responsible 
for MONA, a rare autosomal recessive disorder also characterized by multicentric 
osteolysis 224; 225. Moreover, mutations in the MT1-MMP-encoding MMP14 gene are 
now known to be responsible for Winchester syndrome, a pathology similar to MONA 
and whose clinical symptoms include severe osteolysis in the hands and feet and 
generalized osteoporosis and bone thinning 224. Since MMP14 also activates MMP-2 
226-228, it is tempting to speculate that the altered expression of MMP-25 that we have 
observed in MCTO monocyte-derived macrophages might be relevant to the pathology 
in MCTO. The finding that MMP-14 and MMP-2 are responsible for the fibroblast-
mediated contraction in Dupuytren’s disease 229, a disease where MAFB is significantly 
upregulated 128 further supports the validity of this hypothesis. Gorham-Stout disease, 
also known as vanishing bone disease, is characterized by massive localized 
osteolysis that can arise in any bone and that is preceded by an enormous increase 
in lymphatic vascularization of the bone 230. Although the precise etiology of Gorham-
Stout disease remains unclear, it is believed that the increase of lymphangiogenesis is 
related to the lysis of the bone. In this regard, a recent report has described MAFB as 
an important transcription factor in the generation of lymphatic vessels 101. Thus, one 
could hypothesize that a deregulation of MAFB function, as occurs in MCTO, might be 
responsible for the increase in lymphatic vessel formation and an abnormal osteoclast 
function in Gorham-Stout disease. 
 Our results on in vitro monocyte-derived macrophages clearly points to a 
link between M-CSF-driven differentiation and MAFB expression: M-CSF-driven 
macrophage differentiation results in high levels of MAFB, while the presence of GM-
CSF lowers the basal levels of MAFB found in human monocytes. This result agrees 
with the ability of murine MafB to antagonize the phenotypic alteration of microglia 
induced by GM-CSF 231. Whether the MAFB/GM-CSF antagonism operates in all types 
of macrophages is still unknown. However, we have observed that MCTO mutations 
limit the acquisition of GM-CSF-inducible genes in GM-MØ, a finding that might be 
relevant in the case of macrophage whose development is critically dependent on 
GM-CSF (lung alveolar macrophages) 61. Although no lung-associated pathology has 
been so far reported in MCTO patients, it is worth noting that a significant number of 
genes aberrantly expressed in pulmonary diseases (pulmonary sarcoidosis, asthma 
and tuberculosis) exhibit an altered expression in MCTO M-MØ (Figure 23B), a 
finding that might be related to the fact that mature alveolar macrophages, identified as 
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intermediate positive for the Emr1-encoded F4/80, are reduced in the bronchoalveolar 
lavage of mice expressing a dominant-negative MafB in macrophages 131. Given these 
antecedents, the analysis of further MCTO patients it is certainly worthy as a means to 
get a deeper knowledge of the molecular mechanisms operating in this and other MAF 
family- and osteolytic-related syndromes as well as to more clearly delineate the role 
of MAFB in the acquisition of the human macrophage anti-inflammatory profile. 


CONCLUSSIONS
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1. The response of GM-MØ and M-MØ to LPS and other TLR ligands differs in terms of 
intracellular signaling, with a higher activation of MAPK, STAT3 and CREB in M-MØ, and a 
more robust phosphorylation of IRF3 in GM-MØ. 
2. The preferential production of IL-10 by activated M-MØ, the defining feature of this 
macrophage subtype, is in line with the existence of an M-MØ-specific gene expression 
program characterized by a strong anti-inflammatory component that can be triggered by LPS 
and other TLR ligands.
3. ERK, p38MAPK and JNK directly contribute to the M-MØ-specific LPS-induced 
transcriptomic and cytokine profile, supporting that differences in LPS-triggered intracellular 
signals lie at the basis of the distinct transcriptomic responses of activated GM-MØ and M-MØ.
4. The co-expression of CCL19, PDGFA, BMP6 and SOCS2 observed in LPS-activated 
M-MØ is also found in macrophages in melanoma and nevi, thus reinforcing the existence 
of a co-regulated set of genes that are specifically expressed upon activation of human anti-
inflammatory/homeostatic macrophages.
5. The expression of MAFB characterizes human macrophages with homeostatic/anti-
inflammatory functions both in vitro and in vivo.
6. MAFB is a critical factor for the acquisition/maintenance of the anti-inflammatory 
transcriptome of human macrophages, as it positively controls the expression M-MØ-
specific genes and impairs the expression of genes associated to the GM-CSF-directed pro-
inflammatory polarization.
7. MCTO-causing MAFB mutations affect both the stability and the transcriptional activity 
of MAFB and drive MCTO macrophages towards the upregulation of genes associated to anti-
inflammatory macrophage polarization leading to a global increase of the expression of anti-
inflammatory M-MØ-specific genes, thus reinforcing the contribution of MAFB to the acquisition 
and maintenance of the anti-inflammatory gene signature in human macrophages.
8. MCTO-causing MAFB mutations impact on the generation of monocytes and affect their 
later differentiation into fully functional tissue-resident macrophages, as exemplified by their 
inability to differentiate into functional osteoclasts in response to M-CSF and RANKL in vitro. 
9. MAFB also contributes to the acquisition of the specific gene expression profile of LPS-
activated M-MØ. 
10. MAFB is a primary driver of the anti-inflammatory gene profile of human M-CSF-dependent 
macrophages, and the presence of MAFB-regulated genes provides useful markers for the in 
vivo identification of anti-inflammatory macrophages.

EXPERIMENTAL 
PROCEDURES
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 Generation of monocyte-derived macrophages. 
 Human Peripheral Blood Mononuclear Cells (PBMC) were isolated from buffy 
coats from normal donors over a Lymphoprep (Nycomed Pharma, Oslo, Norway) 
gradient according to standard procedures. Monocytes were purified from PBMC by 
magnetic cell sorting using anti-CD14 microbeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) (>95% CD14+ cells). Monocytes (0.5 x 106 cells/ml, >95% CD14+ cells) were 
cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) for 7 days in the 
presence of 1000 U/ml GM-CSF, 10 ng/ml M-CSF (ImmunoTools, Friesoythe, Germany) 
or 10 ng/ml IL-34 (Biolegend, CA, USA) to generate GM-CSF-polarized macrophages 
(GM-MØ) or M-CSF-polarized macrophages (M-MØ), or IL-34-polarized macrophages 
(IL34-MØ), respectively. Cytokines were added every two days. Cells were cultured 
in 21% O2 and 5% CO2. Monocyte-derived osteoclasts were generated by culturing 
monocytes for 12 days on glass coverslips or in an Osteolyse Assay Kit (Lonza, MD, 
USA) in the presence of M-CSF (25 ng/ml) and RANKL (30 ng/ml). After fixing, osteoclast 
generation was verified by staining for tartrate-resistant acid phosphatase (TRAP) using 
the Leukocyte Acid Phophatase kit (Sigma Aldrich). Generation of monocyte-derived 
macrophages from Multicentric carpotarsal osteolysis (MCTO) patients was done using 
a similar procedure and following the Medical Ethics committee procedures of Hospital 
Clínico Universitario, Santiago de Compostela (patient MCTO#1) and of Hôpital Necker 
Enfants Malades, Paris (patients MCTO#2 and MCTO#3). MCTO#1 patient was found 
to contain a Ser54Leu (161C>T) mutation, whereas patients MCTO#2 and MCTO#3 
contain a Pro63Leu (188C>T) mutation 134. For MAFB and STAT3 knockdown, M-MØ 
(106 cell/ml) were transfected with a MAFB- or STAT3-specific small interfering RNA 
(siMAFB and siSTAT3, 50 nM) (Thermo Fisher Scientific) using Hiperfect (Qiagen). 
As a control, cells were transfected with a non-specific siRNA (siControl, Thermo 
Fisher Scientific). After transfection, cells were cultured for the indicated times in RPMI 
1640 supplemented with 10% FBS. For macrophage activation, cells were treated 
with 10 ng/ml E. coli 055:B5 lipopolysaccharide (LPS, Sigma-Aldrich, MO, USA) or 
10μg/ml N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-
lysyl-[S]-lysyl-[S]-lysyl-[S]-lysine (PAM3CSK4, Invivogen, CA, USA). For intracellular 
signaling inhibition, macrophages were exposed to p38MAPK inhibitor BIRB0796 (0.1 
μM) 143, MEK inhibitor U0126 (2.5 μM) 141 or JNK inhibitor SP600125 (30 μM) 142 for 
60 min before treatment with LPS. Macrophage supernatants were assayed for the 
presence of cytokines using commercial ELISA kits for human TNF-α, IL12p40, CCL2 
(BD Biosciences, CA, USA), IL-6 (Sigma-Aldrich, Steinheim, Germany), CCL19 (PBL 
Assay Science, NJ, USA) and IL-10 (Biolegend, CA, USA) according to the protocols 
supplied by the manufacturers. Where indicated, monocytes were exposed to tumor 
ascitic fluids of different origins 38 that were kindly provided by Dr. Mª Isabel Palomero 
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(Oncology Department, Hospital General Universitario Gregorio Marañón). Mouse 
bone marrow-derived macrophages were generated using human M-CSF (10 ng/mL; 
ImmunoTools).
 Quantitative real-time RT-PCR. 
 Total RNA was extracted using the NucleoSpin RNA/Protein kit (Macherey-
Nagel, Düren, Germany), retrotranscribed, and amplified using the Universal Human 
Probe library (Roche Diagnostics, Mannheim, Germany). Oligonucleotides for selected 
genes were designed according to the Roche software for quantitative real-time PCR 
(Roche Diagnostics, Mannheim, Germany). Assays were made in triplicate and results 
normalized according to the expression levels of TBP or 18S for macrophage or monocyte 
samples, respectively. Custom-made microfluidic gene cards (Roche Diagnostics) 
were designed to analyze the expression of genes whose expression is differentially 
modulated by LPS in GM-MØ and M-MØ. Specifically, the gene cards included 10 
genes upregulated by LPS in both GM-MØ and M-MØ, 16 genes upregulated by LPS 
exclusively in GM-MØ, 37 genes upregulated by LPS exclusively in M-MØ, 3 genes 
downregulated by LPS exclusively in GM-MØ, and 20 genes downregulated by LPS 
exclusively in M-MØ. Assays were made in duplicate on three independent samples of 
each type, and the results normalized according to the mean of the expression level of 
endogenous reference genes HPRT1, TBP and RPLP0. In all cases the results were 
expressed using the ΔΔCT method for quantitation.
 Western blot. 
 Cell lysates were obtained in RIPA buffer (10 mM Tris-HCl pH 8, 150 mM NaCl, 
1% NP-40, 2 mM Pefabloc, 2 mg/ml aprotinin/antipain/leupeptin/pepstatin, 10 mM NaF, 
and 1 mM Na3VO4). 10 µg of cell lysate was subjected to SDS-PAGE and transferred 
onto an Immobilon polyvinylidene difluoride membrane (Millipore). Protein detection 
was carried out using antibodies against phosphorylated and total ERK1/2, p38MAPK 
and JNK (Cell Signaling, MA, USA), phosphorylated and total STAT1 and STAT3 (BD 
Biosciences, CA, USA), and IκBα, phosphorylated IRF3 and phosphorylated CREB 
(Cell Signaling), MAFB (sc-10022, Santa Cruz, CA, USA), CLEC5A (MAB2384, R&D 
Systems, MN, USA). Samples for CLEC5A detection were assayed under non-reducing 
conditions. Protein loading was normalized using a monoclonal antibody against 
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GAPDH (sc-32233, Santa Cruz, CA, USA), α-actin (Sigma-Aldrich), or β-tubulin (sc-
58667, Santa Cruz, CA, USA). 
 Microarray analysis. 
 Global gene expression analysis was performed on RNA obtained from three 
independent samples of untreated (M-MØ or GM-MØ) or LPS-treated human monocyte-
derived macrophages (4h, M-MØ+LPS or GM-MØ+LPS). For siMAFB and MCTO 
microarrays, RNA was obtained from siControl-transfected M-MØ, siMAFB-transfected 
M-MØ (three independent samples), and M-MØ generated from either MCTO#1 or 
from two healthy individuals. In the case of M-MØ from MCTO#1, two RNA aliquots 
were analyzed in parallel. RNA was isolated using the NucleoSpin RNA/Protein kit 
(Macherey-Nagel, Düren, Germany) and analyzed with a whole human genome 
microarray from Agilent Technologies (Palo Alto, CA). Only probes with signal intensity 
values >60% quantile in at least one condition were considered for the differential 
expression and statistical analysis. Statistical analysis for differential gene expression 
was carried out using empirical Bayes moderated t test implemented in the limma 
package (http://www.bioconductor.org). The p values were further adjusted for multiple 
hypotheses testing using the Benjamini-Hochberg method to control the false discovery 
rate 232. All the above procedures were coded in R (http://www.r-project.org). Data from 
siMAFB and MCTO microarrays were deposited in the Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) under accession no. GSE84622. The differentially 
expressed genes were analysed for annotated gene sets enrichment using the online 
tool ENRICHR (http://amp.pharm.mssm.edu/Enrichr/) 154; 155. Enrichment terms were 
considered significant when they had a Benjamini-Hochberg-adjusted p value <0.05. 
For gene set enrichment analysis (GSEA) 233, the previously defined “Pro-inflammatory 
gene set” and “Anti-inflammatory gene set” 151, which contain the top and bottom 
150 probes from the GM-MØ versus M-MØ limma analysis of the microarray data in 
GSE68061 (ranked on the basis of the value of the t statistic) were used.
 MAFB expression vectors, site-directed mutagenesis and reporter assays. 
 The coding sequence of MAFB was amplified by PCR from reverse-transcribed 
cDNA from a healthy donor and was sequenced to confirm the absence of mutations. The 
oligonucleotides used for amplification of the MAFB coding region were 5’-CGGAATTC-
CGATGGCCGCGGAGCTGAGC-3’ and 5’- GCTCTAGAGCTCACAGAAAGAACTCG-
GGAGAG-3’, which include EcoRI and XbaI restriction sites for subsequent cloning 
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into EcoRI- and XbaI-cut pCDNA3.1(+) expression vector (pMAFBwt). Site-directed 
mutagenesis was carried out using the QuikChange site-directed mutagenesis kit 
(Stratagene, CA, USA) to generate MAFB expression constructs with the Ser54Leu 
mutation (161C>T, found in MCTO#1 patient) (pMAFB161T), the Pro63Arg mutation 
(188C>G) (pMAFB188G) 134 or the Pro71Ser mutation (211C>T) (pMAFB211T) 133. The 
oligonucleotides used for mutagenesis were S54LF (5’-CACGCCTGCAGCCAGCCG-
GCTTGGTGTCCTCCAC-3’), S54LR (5’-GTGGAGGACACCAAGCCGGCTGGCT-
GCAGGCGTG-3’), P63RF (5’-CCGCTCAGCACTCGGTGTAGCTCCGTGCCCTC-
GTC-3’), P63RR (5’-GACGAGGGCACGGAGCTACACCGAGTGCTGAGCGG-3’), 
P71SF (5’-GTAGCTCCGTGCCCTCGTCGTCCAGCTTCAGCCCGACCGAAC-3’) and 
P71SR (5’-GTTCGGTCGGGCTGAAGCTGGACGACGAGGGCACGGAGCTAC-3’). 
The resulting plasmids were verified by sequencing. 
 To check the transcriptional activity of MAFB MCTO-causing mutations, HEK293T 
cells were seeded in 24-well plates at 4 x 104 cells/well and transfected with SuperFect 
(Qiagen) with 200 ng of each expression vector and 1 µg of the 3xMARE-Luc reporter 
vector. Each transfection also included 25 ng of a construct expressing the Renilla 
luciferase for normalization of transfection efficiency. After 24 hours, firefly and Renilla 
luciferase activities were determined by using the Dual-Luciferase Reporter Assay Sys-
tem (Promega). The 3xMARE-Luc reporter construct was generated by inserting three 
multimerized MAF-Recognition Element (MARE) 97 into HindIII- and XhoI-cut pXP2-TA-
TA plasmid. The sequences of the oligonucleotides used to generate the 3xMARE-Luc 
construct were 5’-agctttcgacccgaaaggTGCTGAcgTCAGCAgctagccctcgacccgaaag-
gTGCTGAcgTCAGCAgctagccctcgacccgaaaggTGCTGAcgTCAGCAgctagcccc-3’ 
and 5’-tcgaggggctagcTGCTGAcgTCAGCAcctttcgggtcgagggctagcTGCTGAcgTCAG-
CAcctttcgggtcgagggctagcTGCTGAcgTCAGCAcctttcgggtcgaa-3’, where capital letters 
indicate the MAFB-binfding sites.  
 To assess the protein stability of MAFB MCTO-causing mutants, HEK293T cells 
were transfected with 1 µg of pMAFBwt, pMAFB161T, pMAFB188G or pMAFB211T 
plasmids using SuperFect (Qiagen). After 24h cells were treated with 10 µg/ml 
cycloheximide and cell lysates generated at the indicated times using RIPA buffer.
 Fluorescence confocal microscopy. 
 Human biopsied samples were obtained from patients undergoing surgical 
treatment and following the Medical Ethics committee procedures of Hospital General 
Universitario Gregorio Marañón. Frozen samples were cryosectioned (5 µm), fixed with 
acetone, blocked with human immunoglobulins and simultaneously stained with different 
primary antibodies at 1-5 μg/ml. Imaging was performed with the glycerol ACS APO 
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20x NA 0.60 immersion objective of a confocal fluorescence microscope (SPE, Leica 
Mycrosystems). For quantification of in vivo protein expression, mean fluorescence 
intensities of the proteins of interest (SOCS2, BMP6, CCL19, PDGFA, MAFB, CD163L1, 
HTR2B and CXCL12) were quantified at segmented CD163+ macrophages using the 
FIJI software (National Institute of Health, USA), and background subtracted data from 
at least three different fields displayed as scatter plots (GraphPad). The antibodies 
used were the following: mouse monoclonal anti-CD163 (K0147-4, MBL, MA, USA), 
rabbit polyclonal anti-PDGFA and rabbit polyclonal anti-SOCS2 (sc-127 and sc-9022, 
Santa Cruz, CA, USA), goat polyclonal anti-BMP6 (AF507, R&D Systems, MN, USA), 
rabbit polyclonal anti-CCL19 (13397-1-AP, Proteintech, IL, USA), goat polyclonal anti-
MAFB (sc-10022, Santa Cruz, CA, USA), rabbit polyclonal anti-CD163L1 (HPA015663, 
Sigma-Aldrich, MO, USA), rabbit polyclonal anti-CXCL12 (P87B, Peprotech, NJ, USA) 
and rabbit polyclonal anti-HTR2B (sc-25647, Santa Cruz, CA, USA).
 Statistical analysis. 
 For comparison of means, and unless otherwise indicated, statistical significance 
of the generated data was evaluated using the Student t test. In all cases, p<0.05 was 
considered as statistically significant.
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